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Abstract 
 
Epizootic Hemorrhagic Disease Virus (EHDV) is an insect-transmitted pathogen of 
ruminants, causing periodic and significant losses in wild and captive deer 
populations and less frequently, a bluetongue-like disease in cattle. The serogroup of 
EHDV within the Orbivirus genus of the Reoviridae family consists of seven 
serotypes, in which emerging serotypes pose an increasing risk either regionally or 
globally, due to the insect vectors. To date, no vaccine against EHDV is 
commercially available, apart from the live-attenuated vaccine for EHDV-2 (IBAV). In 
this study, Virus-Like Particles (VLPs) of EHDV-1 and heterologous VLPs of EHDV-2 
were generated using baculovirus multigene expression system for the synthesis of 
the two outer and two inner capsid proteins, essential for the formation of VLPs. The 
assembly of EHDV-1 recombinant structural proteins into Core-Like particles (CLPs, 
two proteins) and (VLPs, four proteins) was confirmed by EM analysis. The biological 
activity of the raised antisera to neutralise EHDV-1 was efficiently confirmed by 
neutralisation assay at 1:64 dilution. Cross neutralising activities were also detected 
against EHDV-2 and EHDV-6 serotypes at 1:8 dilution. Results presented in this 
study validate the potential efficacy of the VLP as a neutralising vaccine and strongly 
suggest its use as vaccine candidate.  
Additionally, an alternative approach was also initiated in this research to develop a 
rational vaccine against EHDV-2 using the reverse genetics system (RG). Towards 
this, it was first established that in vitro synthesised transcripts from purified EHDV-2 
cores could generate infectious virus upon cell transfection. Note that both the 
generation of core transcripts and recovery of infectious virus of EHDV were not 
demonstrated previously. Subsequently a complete set of 10 T7 transcripts was 
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synthesised, however, it was not possible to recover any infectious virus, likely to be 
some unwarranted mutations. Nevertheless, these transcripts will be further 
investigated for future RG studies.  
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1.1. Reoviridae Family 
The Reoviridae is the largest of the double-stranded RNA (dsRNA) families and the 
most diverse with respect to host range including vertebrates, plants and insects 
(Table 1) (Hill et al., 1999). Genera of this family are distinguished by their genome 
organisation, particle structures as well as host range. As a group III viruses their 
genome is comprised of dsRNA as indicated by physiochemical properties and 
nuclease insensitivity. However, isolation of such genomic dsRNA demonstrates a 
segmented nature which is consistent across family members (Gomatos and Tamm, 
1963, Langridge and Gomatos, 1963). The number of dsRNA segments is variable 
across species, falling between 10 and 12. This was initially confirmed for 
Bluetongue Virus (BTV) by early results from electronic microscopy (EM) (Vasquez 
and Kleinschmidt, 1968), followed by evidence from polyacrylamide gel 
electrophoresis (PAGE) which showed that the dsRNA genome is released from 
disrupted particles as 10 discrete segments, which can be divided into large (L), 
medium (M) and small (S) sizes (Shatkin et al., 1968, Watanabe et al., 1968). 
Initially, studies using sequence analysis of the full-length cDNA of the genome 
segments and in vitro translation indicated that each segment encodes for a single 
protein, on only one of the complementary RNA strands; however it was later 
demonstrated that some segments may encode for up to three proteins due to the 
presence of more than one in-frame initiation codon (Lee and Roy, 1986, Mertens et 
al., 1984). More recently, the presence of a frame shifted internal coding sequence 
has been observed for the NS4 protein of BTV which is translated from within the 
VP6 coding region (Ratinier et al., 2011).  
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Morphologically, the mature virion sizes ranges from 60 to 85 nm with no capsid 
envelope. The structural proteins are arranged in two concentric layers of 
icosahedral symmetry, an inner capsid or “core” and outer capsid.  
Using cyro-electron micrographic (Cryo-EM) reconstruction and EM studies have 
shown that members of Reoviridae family can be further divided into two distinct 
subfamilies, turreted and non-turreted, based on the structures of their core particles 
(Hill et al., 1999). The Sedoreovirinae subfamily includes genera containing non-
turreted (smooth) core particles that are almost spherical in appearance, including 
Cardoreovirus, Mimoreovirus, Orbivirus, Phytoreovirus, Rotavirus and 
Seadornavirus. The Spinareovirinae subfamily includes genera containing viruses 
with large spikes or turrets at the 12 icosahedral vertices of the virus or core particles 
including Aquareovirus, Coltivirus, Cypovirus, Dinovernavirus, Fijivirus, Idnoreovirus, 
Mycoreovirus, Orthoreovirus and Oryzavirus (Table 2) (Roy, 2013) . Such grouping 
of Reoviridae family members is supported partially by the similarities of enzyme 
motifs between the turreted and non-turreted groups (Nibert and Kim, 2004, Attoui et 
al., 2005). Despite these structural differences, all Reoviridae members distinctively 
synthesize viral messenger RNAs (mRNAs) within an enclosed capsid, setting the 
mechanistic details of their replication cycle apart from other virus families.  
Table 1.  
Taxonomic classification of dsRNA viruses. Adapted from (Hill et al., 1999).  
Family Genera Hosts 
Reoviridae 15 Mammals, Birds, Reptiles, Fish, Insects, Plants, Fungi  
Birnaviridae 3  Birds, Fish, Insects 
Totiviridae 3 Fungi, Protozoa 
Partitiviridae 3 Fungi, Plants 
Chrysoviridae 1 Fungi, Plants 
Hypoviridae 1 Fungi 
Cystoviridae  1 Bacteria  
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Table 2. 
Virus genera and orbivirus serogroups. Adapted from Fields Virology, Sixth Edition (Roy, 
2013).  
Reoviridae viruses 
Genus 
Genome  
segments   
Hosts  
Subfamily Sedoreovirinae 
Cardoreovirus 12 Crustaceans 
Mimoreovirus 11 Marine protists 
Orbivirus 10 Mammals, Birds, Arthropods 
Phytoreovirus 12 Plants, Insects 
Rotavirus 11 Mammals, Birds 
Seadornavirus 12 Humans, Insects 
Subfamily Spinareovirinae 
Aquareovirus 11 Fish, Molluscs 
Coltivirus 12 Mammals, Arthropods 
Cypovirus 10 Insects 
Dinovernavirus 9 Insects 
Fijivirus 10 Plants, Insects 
Idnoreovirus 10 Insects  
Mycoreovirus 11-12 Fungi 
Oryzavirus 10 Plants, Insects 
Orthoreovirus 10 Mammals, Birds, Reptiles 
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1.2. Orbiviruses  
 
The Orbivirus genus is one of 15 genera within the Reoviridae family, which includes 
vertebrate, arthropod, and plant pathogens. In Latin, Orbis means ring shape 
referring to the surface of the core particles which can be observed by negative 
staining under EM. Unlike the reoviruses and rotaviruses, orbiviruses are arthropod-
borne viruses causing serious diseases in domestic and wild animals. Additionally, 
orbivirus particles are fairly fragile and lose their infectivity in low acidic conditions 
(pH= 6), while they are relatively resistant to solvents and detergents (Borden et al., 
1971). Based on serologic reactivities, 21 serogroups of orbiviruses are 
distinguished, and within each group many serotypes are differentiated by 
neutralization tests (Table 3) (MacLachlan, 1994, Mertens et al., 2004, Maan et al., 
2007).  
These viruses are morphologically identical and transmitted to vertebrates primarily 
by arthropod vectors which, depending on the individual virus, can be certain species 
of Culicoides midges (Fig. 1), mosquitoes, black flies, sandflies or ticks (Tabachnick, 
2004, Wilson et al., 2008, Purse et al., 2005). Although orbiviruses do not have the 
ability to transfer directly between vertebrates, they can replicate in both vertebrates 
and arthropods. The global and seasonal distribution of individual virus species is 
limited to the distribution of competent biological vectors and appropriate climate 
changes (Shope et al., 1960, Purse et al., 2005).  
Economically, the most important viruses within this genus are BTV and African 
horse sickness virus (AHSV), which are responsible for Bluetongue disease (BT) in 
sheep and cattle and African horse sickness disease (AHS) in horses (Maclachlan 
and Guthrie, 2010). However, several others including EHDV pose an increasing risk 
either regionally or globally, due to the insect vectors.  
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Table 3. 
Orbiviruses serogroups and serotypes. Adapted from (Mertens et al., 2004).  
Serogroups Serotypes 
African Horse Sickness 9 
Bluetongue  26 
Changuinola 13 
Chenuda 8 
Chobar Gorge 2 
Corriparta 6 
Epizootic Hemorrhagic Disease virus  7 
Equine encephalosis  7 
Eubenangee 4 
Ieri 3 
Great Island 37 
Lebombo 1 
St. Croix River 1 
Palyam 11 
Peruvian Horse Sickness 1 
Orungo 4 
Umatilla  4 
Wallal 3 
Warrego 3 
Wongorr  8 
Wad Medani  2 
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Fig. 1. Blood-Feeding Culicoides Midges (Wilson et al., 2008).  
 
1.3. Epizootic Hemorrhagic Disease Virus  
 
EHDV belongs to the Orbivirus genus and shares many morphological and genetic 
characteristics with other members of the genus, particularly BTV and AHSV 
(Verwoerd et al., 1979, Roy and Gorman, 1990, Knudson and Monath, 1990). EHDV 
is an insect-transmitted pathogen of ruminants, causing periodic and significant 
losses in wild and captive deer populations and less frequently, a bluetongue-like 
disease in cattle (Omori et al., 1969). The current report by the International 
Committee on the Taxonomy of Viruses (ICTV) designates that there are ten 
predicted serotypes/strains of EHDV (Mertens et al., 2005). However, based on the 
recent molecular and serological analysis of the outer capsid proteins VP2 and VP5, 
seven serotypes of EHDV have been recognised, wherein the EHDV serotype 3 (Ib 
Ar 22619) and serotype 1 were similar and could be considered as one serotype, 
and EHDV-318 was serologically identical to EHDV-6 and Ibaraki virus (IBAV) is 
similar to EHDV-2 (Anthony et al., 2009b).  
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Recently, genomic studies and phylogenetic analysis comparing the whole genome 
of EHDV strains showed that the core proteins can be used to group EHDV into 
“eastern” (i.e. Asia and Australia) and “western” (i.e. America, Africa and Middle 
East) strains (Anthony et al., 2009b, Anthony et al., 2010). Depending on these 
studies, strain designation would depend on serological and molecular analysis of 
the genetic variations within the serotypes 
1.4. Epidemiology and susceptible hosts 
Historically, EHDV has been associated with disease in wild cervids, particularly 
white-tailed deer. Clinical signs of Epizootic Hemorrhagic Disease (EHD) have been 
observed in North America, Australia, Asia and more recently in the countries 
surrounding the Mediterranean Basin (Fig. 2). Two serotypes; EHDV-1 (New Jersey 
strain), first described in North America in 1955 when a large number of white-tailed 
deer died and EHDV-2 (IBAV), originally isolated in southern Alberta Canada in 
1962, are known to be endemic (Shope, 1955). 
In 2006, a virus was recovered from dead white-tailed deer in Indiana and Illinois, 
which was later confirmed as EHDV serotype 6 by serological and genetic tests 
(Allison et al., 2010). In 2007, additional isolates of EHDV-6 were detected in 
Missouri (in white-tailed deer) followed by detection in Kansas and Texas in 2008 
(Allison et al., 2010), and Missouri and Michigan in 2009. Such spreading of the virus 
suggested that a reassortment strain EHDV-6 had appeared with higher 
pathogenicity and was geographicallly endemic in a widespread region of the United 
States. 
Until 2006, it was believed that EHDV does not cause significant clinical signs in 
cattle with the exception of IBAV strain, which has been observed to infect cattle 
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causing severe disease (Omori et al., 1969). Several outbreaks of which occurred in 
Japan 1959, Korea and Taiwan, wherein thousands of herd of cattle were affected 
(Omori et al., 1969). However, in conjunction with this American outbreak, in 2006 
and 2007, EHDV-6 and EHDV-7 seroprevelance was documented in the 
Mediterranean Basin by Algeria, Tunisia, Morocco, Israel, Jordan as well as the 
Island of Reunion (Breard et al., 2004, Gibbs and Lawman, 1977, Temizel et al., 
2009). Each of the above strains was pathogenic and caused diseases in cattle. 
EHDV prevelance in the Mediterranean Basin can be traced back to 1951 in Israel, 
where a disease similar to BTV was described in cattle and sheep (Komarov and 
Goldsmith, 1951). 
Although no cases of EHDV infection have been reported in Europe, the recent 
outbreaks “wherein cattle were the main host” in the countries bordering Europe 
signifcantly increases the risk of its invasion into central and northern Europe. The 
scenario for EHDV can be thought of as similar to that of BTVs emergence in Europe  
which occurred in the late 1990s wherein some BTV serotypes were circulating in 
Algeria, Tunisia, Turkey and Israel. The virus then crossed the Mediterranean basin 
and entered Europe.  
Animal hosts of EHDV are prevelant in Europe allowing for potential emergence. 
European sheep breeds were found to be susceptible to EHDV infection. However, 
though the viraemia could been detected, the infection was subclinical, allowing 
sheep to potentially act as reservoirs in outbreaks (Gibbs and Lawman, 1977, 
Moore, 1974). The role of goats as a host for EHDV is uncertain although antibodies 
could be detected in goats in the regions where EHDV is found (al-Busaidy and 
Mellor, 1991). Pigs are not susceptible to EHDV and little is known about the 
susceptibility of dogs (Gibbs and Lawman, 1977, Howerth et al., 1995).  
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1.5. Pathogenicity  
EHDV pathogenicity is similar to that of BTV which has been extensively studied and 
thoroughly reviewed by MacLachlan (McLaughlin et al., 2003). During blood feeding 
of the hematophagous Culicoides species, animals are innoculated with infectious 
particles which bind to the red blood cells (RBC) using glycophorin A as a receptor 
causing primary viraemia (Eaton and Crameri, 1989). The virus is then disseminated 
through the blood stream to other sites of replication such as the lymph nodes 
(McLaughlin et al., 2003). As EHDV has tropism towards the endothelial cells of the 
lymphatic vessels (Tsai and Karstad, 1970), the virus replicates there causing 
secondary viraemia, reaching the reticulum endothelia system comprising of liver, 
spleen and lymph node. The virus then undergoes another cycle of replication before 
spreading to the whole body via blood stream (Gibbs and Lawman, 1977, Aradaib et 
al., 1997).  
During viraemia, the virus is cell-associated particularly to RBCs where the virus is 
present in higher titres and for longer period of time (Gibbs and Lawman, 1977, 
Aradaib et al., 1997). The duration of viraemia has been studied in deer, cattle and 
calves naturally and experimentally infected with EHDV. Gamma interferons were 
detected in the infected animals from 4 days post infection (dpi) until the appearance 
of detectable antibodies at 10 dpi, while neutralizing antibodies were detected 
between 10-14 dpi (Gibbs and Lawman, 1977).  
EHD disease has several clinical forms depending on the host type and immunity. 
The disease can be presented subclinically, wherein the animal shows no symptoms 
in spite of viremic load. This mainly occurs in sheep or goats (Thompson et al., 
1988).  However, in cattle infected with EHDV-2 (IBAV) or EHDV-6, the disease is 
characterised with fever, anorexia and difficulties in swallowing leading to emaciation 
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(Inaba, 1975). Oedema haemorrhages, erosion and ulceration in the mouth and lips 
can also be seen (Fig. 3 and Fig. 4) (Temizel et al., 2009).  
In white-tailed deer, there are three phases of the disease; pre-acute, acute and 
chronic. In the first phase, animals exhibit clinical signs similar to those observed in 
cattle, accompanied by severe and rapid oedema of the head and neck (Fig. 5). 
During this stage of disease, deer death is rapid, mostly within 8-36 hours (h) and at 
times without clinical symptoms (Omori et al., 1969). As the virus disseminates 
throughout the body, the disease progresses to the acute phase. In the acute phase, 
the clinical signs of pre-acute might be accompanied by haemorrhages in many 
tissues including skin, heart and the gastrointestinal tract.  
Generally, animals in the acute phase develop ulcers or erosions of the tongue and 
dental pad. At this stage, the virus can be fatal and the animal could die within 72 h. 
The morbidity rate in the white-tailed deer is higher, up to 29% and a mortality rate of 
20% (Gaydos et al., 2004), while in cattle the morbidity varies from 1-18% but the 
mortality is usually low, around 2.2% (Yadin et al., 2008).  
In the chronic stage, deer are usually in poor health for several weeks but gradually 
recover. Post recovery, the individual might become lame or develop rings on 
hooves, ulcers scars, or erosions in the rumen, mainly due to the growth 
interruptions (Fig. 5) (Work et al., 1992). 
 
 
33 
 
 
Fig. 3. Erosive lesion on pulvinus dentalis of cow seropositive for EHDV (Temizel et al., 2009).  
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2662652/figure/F1/ 
  
                           
 
Fig. 4. Swollen conjunctiva of cow seropositive for EHDV (Temizel et al., 2009).  
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2662652/figure/F1/ 
 
 
                                 
 
Fig. 5. Lesions of white-tailed deer infected with EHDV during all forms of disease (Medical 
and veterinary entomology). http://vet.uga.edu/population_health_files/HD-brochure-web.pdf 
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1.6. Economic impact 
 
It is important to determine the economic impact of an infection as this influences the 
way in which the control strategies are selected. For a long time, EHD disease was 
considered as a disease of minor importance due to its non-agricultural host range. 
Recent outbreaks, however, in the Reunion Island, North Africa, Turkey and Israel 
wherein cattle were the main host have led to its consideration as an important 
emerging pathogen. Post these outbreaks, the economic losses in the industry of 
dairy cattle have become a significant concern especially for the USA and Europe.  
During these epidemics, the economic impact of the EHD in cattle was characterized 
by a significant reduction in milk production and increased mortality (Kedmi et al., 
2010). In total, a loss of $95 per cow could be attributed to EHDV infection, which 
equates 2% of the total annual production of these cows. This was a notable loss 
even when compared to the most costly production diseases in the dairy herd 
(Kedmi et al., 2010). In addition, economic losses were recorded due to abortion, 
infertility and inferior milk quality. Regarding morbidity and mortality, the highest 
morbidity rates of cattle infected with EHDV-6 occurred in Morocco (18%), while the 
rate of fatality cases was about 2.2% (OIE and WAHID, 2004). In comparison, 
EHDV-2 infected cattle in Japan scored the lowest percentage of both morbidity and 
mortality with up to 1.16% and 0.06%, respectively (Table 4) (Omori et al., 1969).  
As for wildlife, it is difficult to determine the morbidity and mortality rates. Generally, 
in areas of outbreaks, studies showed that white-tailed deer were the most severely 
affected animal with the disease, wherein the estimated number of infection was 
29% while mortality rate was 20% (Gaydos et al., 2004). However, the survival rate 
was considerably higher in mule deer, black-tailed deer and pronghorn antelope 
(Work et al., 1992).  
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Conversely, the economic impact might not only be due to the direct effect. For 
instance, the international movement of livestock and/or their germplasm is restricted 
from EHDV prevalent to EHDV free countries; unless the animals are certified to be 
clear of EHDV infection by serology or virus isolation (Aradaib et al., 1994). Such 
restrictions could lead to economic losses for EHDV-endemic countries that rely on 
the sale of livestock for foreign exchange (Abdy et al., 1999).  
Table 4.  
Morbidity and mortality of EHDV infection in cattle. Adapted from European Food Safety 
Authority (EFSA) Journal 2009;7(12):1418.  
 
Serotype Location Apparent 
morbidity 
Apparent 
mortality 
Reference 
IBAV (EHDV-2) Japan 1.96% 0% (Omori et al., 1969) 
IBAV (EHDV-2) Japan 1.16% 0.06% (Omori et al., 1969) 
EHDV-2 USA - - (House et al., 1998) 
NK Reunion 
Island 
3.23% 0% (Breard et al., 2004) 
EHDV-7 Israel - - (Yadin et al., 2008) 
EHDV-6 Turkey - - (Temizel et al., 2009) 
EHDV-6  Morocco 18% 2.2% (OIE and WAHID, 2004) 
EHDV-6 Algeria 8% 0.5% (OIE and WAHID, 2004) 
NK Not known 
 
1.7. Monitoring and control measures 
 
Control and prevention of the disease caused by viral infection should be based on 
two possibilities; the countries are free of the disease and want to prevent it from 
entering their territory, or they already have the infection but want to avoid its 
spreading. However, it is more difficult to manage and eradicate a viral vector-borne 
disease due to uncontrollable factors such as vector, climate and geographic 
features. Generally, controlling the disease using insecticides is expensive and not a 
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viable option in large areas, particularly when the reintroduction of the vector via 
wind is likely to occur. Another option is the use of insect secure tents to reduce the 
contact between the vector and vulnerable hosts.   
For EHDV, no official monitoring or control programmes were established initially. 
This was because no significant economic losses on dairy cattle were reported from 
the infection with EHDV. The only losses reports were on farmed and wild deer as 
EHD of deer is considered a compulsory notifiable disease according to Annex I of 
Council Directive 92/119/EEC. This scenario changed after the recent outbreaks 
caused by exotic serotypes EHDV-6 and EHDV-7 in Mediterranean basin countries, 
Morocco, Algeria, Tunisia, Turkey and Israel, wherein cattle were the main host. To 
control the invasion of EHDV, the EHDV outbreak countries have applied measures, 
such as monitoring of wild reservoirs, quarantine, vector control in infected premises 
and increasing the awareness of veterinarians and farmers.  
 
1.7.1. Vaccination 
To control EHDV infection, vaccination is the primary strategy along with the control 
of arthropod vectors. Several vaccines for BTV have been developed and used in 
endemic regions for the prevention of virus infection (Roy et al., 1994, Matsuo et al., 
2011). The development of a vaccine against EHDV is an urgent concern particularly 
for EHDV strains which are responsible for severe clinical indications in domestic 
ruminants in the USA or Turkey, which might be imported into Europe. Autogenous 
inactivated vaccines were prepared in North America from EHDV-1 and EHDV-2 
isolates originated from infected or dead animals. However, the use of this vaccine 
was limited to the original and adjacent herds. Such vaccines have to be tested for 
safety and purity but not for efficacy; additionally, their application should be 
approved by The United State National Deer Farmers Association.  
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No vaccine for EHDV is commercially available, with the exception of the live- 
attenuated and inactivated vaccines to control Ibaraki disease caused by IBAV 
(Aradaib et al., 2009). This vaccine was used following the outbreaks in Japan in the 
1980s and proved to be safe and effective, at least up to the 1997 epidemic, during 
which abortion, stillbirths and other new clinical signs never observed in the previous 
outbreak were documented (Ohashi et al., 1999).  
One of the major challenges for Orbivirus vaccine researchers is the development of 
vaccines that can afford a wider protective immune response against many 
serotypes of each virus, and to develop diagnostic method to distinguish between 
vaccinated and infected animals (DIVA). However, it should be taken into 
consideration that the attenuated virus could revert to virulence and spread 
accidentally to animals via the Culicoides vectors (Aradaib et al., 2009), such as the 
insufficient attenuation of BTV-16 which allowed it to circulate in Corsica. In addition, 
the use of a modified vaccine, containing two or more serotypes may enable these 
viruses to reassort in nature, giving rise to virulence reversion. Furthermore, the 
genome reassortment can occur with circulating pathogen virus.   
1.8. Virion morphology 
 
Genetic studies and phylogenetic analysis have revealed that the members of 
Orbivirus genus in the Reoviridae family are closely related to each other particularly 
for BTV and EHDV (Mecham and Dean, 1988). BTV, as a prototype of the 
orbiviruses, has been extensively studied genetically, structurally and at the 
molecular level. Thus, it can act as a model for EHDV and other orbiviruses.  
BTV particles are complex structures, non-enveloped and composed of seven 
proteins organised in two concentric shells that enclose 10 dsRNA viral genome 
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segments (Fig. 6) (Roy et al., 2009). EM studies of the negatively stained and 
purified particles indicated an icosahedral double capsid structure of the mature 
virion and the cores with the absence of the outer layer (Fig. 7A and C) (French et 
al., 1990). The outer shell of the mature BTV-1 virion is composed of VP2 (112 kDa) 
(Urakawa et al., 1994) and VP5 (59 kDa) (Loudon et al., 1991) that enclose a 
transcriptionally active core (Verwoerd et al., 1972). The outermost layer of the core 
is formed by VP7 (38 kDa) (Wade-Evans, 1990), which interacts with the underlying 
sub-core capsid shell composed of VP3 (103 kDa) (Gould, 1987). The VP3 shell 
interacts with both the viral RNA genome and the transcription complex (TC) 
composing of minor proteins VP1, VP4 and VP6.  
The process of BTV assembly was previously investigated using baculovirus system 
that accommodated the expression of the entire size range of the structural proteins. 
Moreover, using baculovirus multiple expression system, the function of the 
structural proteins in the formation of specific virion structures was delineated. In 
insect cells, the production of CLPs was achieved by dual expression of the core 
proteins VP3 and VP7 (Fig. 7D) (French and Roy, 1990). Further expression studies 
enabling production of double-shelled VLPs (French et al., 1990) by coinfection of 
insect cells with two baculoviruses, one expressing CLP proteins VP3 and VP7 and 
the other expressing VP5 and VP2 outer capsid proteins (Fig. 7B). These data 
indicated that the outer and inner capsid proteins had the ability to form VLPs lacking 
the viral genome and TC.  
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Fig. 6. BTV cartoon based on Cryo-EM study. The BTV particle is composed of an outer layer of 
(VP2 and VP5) proteins, an outer core layer of VP7 proteins and inner core layer of the VP3 proteins. 
Along with VP3 are the VP1, VP4 and VP6 proteins. The 10 segments of the virus dsRNA are 
enclosed within the capsid. Adapted from (Roy et al., 2009).  
 
                                            
Fig. 7. Electron micrographs of baculovirus-expressed particles. (A) Authentic BTV particles. 
(B) Empty BTV double-shelled VLPs. (C) BTV core particles and (D) CLPs formed by VP7 and VP3. 
Adapted from French et al (French et al., 1990).  
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1.9. The outer capsid proteins 
The outer layer consists of 60 triskelion trimers, made up of 180 molecules per 
particle of VP2 and a total of 360 molecules of VP5 exist per particle, forming 120 
globular structures. VP2 represents the “sail-shaped” spikes which are located above 
of VP5 trimers and it is the most exposed protein (Fig. 8) that mainly interacts with 
the environment and mediates the initial attachment of the virus to the host cell 
receptors, thereby facilitating the entry (Hassan and Roy, 1999, Hassan et al., 2001, 
Huismans et al., 1987). Sequencing data and immunological analysis has 
demonstrated that VP2 is the most variable protein attributing to the serotype 
specificity (Maan et al., 2007, Maan et al., 2011). Moreover, sequence alignments of 
VP2 from several serotypes showed specific regions of higher variation suggesting 
that these regions might serve as epitope(s) targeted by neutralizing antibodies 
(Ghiasi et al., 1987). Studies show that VP2 has a strong affinity to the glycophorin A 
of RBCs, explaining its role in virus transmission by Culicoides species in vertebrates 
during blood feeding (Hassan and Roy, 1999). Furthermore, virion particles lacking 
VP2 but retaining VP5 lose the ability to bind to vertebrate cells and erythrocytes 
(Huismans et al., 1983).  
VP5, the globular and the second capsid protein, has an essential role in the host 
cell membrane penetration by the virus. Both the structural features and the location 
of VP5 in the virion shell supports its involvement in the permeabilization activity of 
the membrane.  VP5 has the characteristics of fusion proteins of enveloped viruses. 
This has been demonstrated by its ability to induce cell-to-cell syncytium formation, 
like other enveloped viruses when it is expressed as a membrane anchored protein 
(Forzan et al., 2004). Each VP2 and VP5 proteins make separate contact with the 
41 
 
underlying VP7 protein layer, suggesting that VP2 and VP5 proteins were 
independently assembled on the surface of the newly generated core particles. 
 
Fig. 8. Cryo-EM picture showing the structure of BTV-10 virion. (A) Triskelion shaped trimers of 
VP2 (red) are exposed on the outer surface. VP5 trimers (yellow) sit under VP2 trimers between the 
triskelion arms. (B) High magnification picture shows the position of VP2 and VP5 in the outer capsid 
(Nason et al., 2004). 
 
 
1.10. The inner core proteins 
 
The structure of purified core particles derived from virus via proteolytic treatment 
has been extensively studied by Cryo-EM and X-ray crystallography due to their 
stability (Fig. 9 and 10) (Prasad et al., 1992, Hewat et al., 1992, Grimes et al., 1998, 
Grimes et al., 1995). The core surface has a diameter of 73 nm with icosahedral 
symmetry, wherein the outer layer is made up of 780 molecules of VP7 protein 
forming 260 trimers that appear as knobbly projection on the surface of the core. 
Studies show that VP7 is the main immuno-dominant viral protein which could be 
involved in cell entry for insect cells for which BTV cores have a high specific 
infectivity (Prasad et al., 1992). As VP7 is antigenically specific to each of the 
Orbivirus species, it represents a suitable target for the design of group-specific 
diagnostic assays.  
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The underlying layer of the core is made up of 120 copies of VP3 protein, arranged 
in 60 dimers, in contrast to the VP7 layer, has a spherical structure with an angular 
appearance due to the variation in the thickness of the protein shells. The maximal 
diameter of VP3 shell is 59 nm with a central space of 38 nm internal diameter. VP3 
dimers serves as a scaffold for the deposition of the VP7 layer (Grimes et al., 1998).   
 
Fig. 9. BTV-10 core structure. Reconstitution of the core obtained by Cryo-EM showing VP7 (blue) 
and VP3 (Shapiro et al.) (Nason et al., 2004) 
 
 
Fig. 10. X-ray crystallography of the core particle of BTV-1 showing the VP3 scaffold. The 
inner layer of VP3 (T2) molecules is coloured red and green (Grimes et al., 1998).  
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1.11. Minor proteins and genome structure 
The Cryo-EM reconstructions and X-ray structures of both virion and core revealed a 
significant density internal to the VP3 layer. This density was occupied by the minor 
proteins (VP1, VP4 and VP6) that form the TC as well as layers of dsRNA which are 
organized in a highly ordered structure (Gouet et al., 1999). The genome segments 
are numbered from 1 to 10 according to their migration on SDS-PAGE (Fig. 11). Full 
details about each segment, encoded proteins and function of each protein are 
summarized in (Table 5) Fields Virology, Fifth edition, Orbiviruses chapter (Roy, 
2007).  
Table 5.  
BTV-10 and EHDV-1 coding assignments. Adapted from Fields Virology, Fifth edition, 
Orbiviruses chapter (Roy, 2007, Anthony et al., 2009a).  
 
Segment 
No. 
Protein No. of 
Amino 
Acids  
of BTV-10 
 
  No. of 
  Amino 
  Acids 
  of EHDV-1 
Location in 
Virion 
Particle 
Function 
1 VP1 1,302   1,302 Inner core  RNA polymerase  
2 VP2 956   971 Outer shell 
(spike)    
 Receptor binding 
 Virus entry  
 Hemagglutinin 
 specific neutralisation 
3 VP3 901   899 Subcore layer 
(scaffold)  
 Scafolld for VP7 trimers 
 Interacts with TC and genomic 
RNA 
4 VP4 654   644 Inner core  Capping enzyme 
guanylytransferase, 
methyltransferases 1 and 2, 
RNA5‘ triphosphatase 
 Inorganic pyrophosphatase 
NTPase 
5 VP5 526   527 Outer shell 
(globular)  
 Virus penetration 
 Fusogenic  
6 NS1 552   551 Nonstructural   Protein synthesis enhancer 
 Involved in virus maturation  
and trafficking 
 Forms tubules  
7 VP7 349   349 Core surface 
layer 
 Forms surface of core.  
 Responsible for core entry into 
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insect cells 
8 NS2 357   373 Nonstructural  Phosphorylated 
 Recruits BTV single-stranded 
RNA (ssRNA) 
 Forms cytoplasmic inclusion 
bodies 
 Site for core assembly 
9 VP6 
 
328 
 
  360 Inner core 
 
 Viral helicase 
 Adenosine triphosphatase 
(ATPse) 
 Form hexamer in presence of 
BTV RNA, RNA packaging  
NS4 77-79       - Inner core  Virus-host interaction 
 Counteract the antiviral 
response of the host (Ratinier 
et al., 2011) 
10 NS3  
NS3A 
 
 
 
229 
216 
  228 
    - 
Nonstructural  Glycoproteins 
 Membrane proteins 
 Interact with host membrane 
proteins calpactin and Tsg 101 
 Aids virus trafficking and 
release  
 
 
 
Fig. 11. BTV virion constituents. The 10 segments of dsRNA profile of purified core particles. 
(Sizes are calculated based on molecular weight for BTV serotype 10). Adapted from Fields Virology, 
Fifth edition, Orbiviruses Chapter (Roy, 2007).  
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1.12. Comparison of expression systems 
 
The study of viruses, virion structures and viral vaccine production has been 
frequently impeded by difficulties in the large-scale production of virus particles, 
recovery and purification. Several protein expression systems are available for 
recombinant proteins expression for the development of viral vaccines. The most 
commonly described protein expression systems are bacterial, Escherichia coli 
(E.coli) (Hunt, 2005, Terpe, 2006), Saccharomyces cerevisiae (Holz et al., 2002), 
Pichia pastoris (Macauley-Patrick et al., 2005), baculovirus/insect cells (Brondyk, 
2009, Jarvis, 2009), mammalian cell lines (Almo and Love, 2014) and cell-free 
systems (Jackson et al., 2004). Each of which has advantages and disadvantages. 
Such differentiation depends on the yield, speed of expression and complexity of the 
target recombinant protein/s.  
Both the bacterial (E.coli) and eukaryotic (yeast) expression systems remain the 
preferred systems for the expression of heterologous proteins due to the rapid 
expression and the ease of scaling up.  However, the disadvantage of these systems 
is that they do not effectively support the expression of complex proteins, such as 
those which are post-translationally modified or large complex protein folds (Baneyx, 
1999, Mattanovich et al., 2012). On the other hand, mammalian cells can provide 
expression of the targeted proteins with correct glycosylation and native post-
translational modification; but they are expensive at larger scale (Wurm, 2004).  
However, since 1983, when baculovirus expression technology was introduced, the 
system has become one of the most versatile and powerful eukaryotic vector 
systems for recombinant protein expression for several reasons (Pennock et al., 
1984, Smith et al., 1983). Firstly, substantial amounts of correctly folded recombinant 
proteins can be produced in high-density suspension culture (Bishop, 1990, Marek et 
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al., 2011). Secondly, as the insect cells do not need supplements derived from 
mammalian cells, the threat of opportunistic pathogens is minimized. Finally, 
baculovirus infects only a few species of lepidopteran, making it safe for vaccine 
applications. Such characteristics of baculovirus expression vector system (BEVS) 
have proven to be very useful for the correct expression and generation of VLPs. 
Therefore, several studies have been carried out to develop BEVS for simultaneous 
expression of multiple foreign proteins from a single recombinant baculovirus (Noad 
et al., 2009).  
 
1.13. Baculovirus expression technology and its modifications 
 
Baculoviruses belong to the Baculoviridae family that contains over 1000 members, 
most of which infect arthropods. These viruses have a large, double stranded, 
covalently-closed, circular DNA genome between 80 Kbp and 180 Kbp in size (van 
Oers and Vlak, 2007). The Autographa californica multicapsid nucleopolyhedrosis 
virus (AcMNPV) and Bombyx mori nucleopolyhedrosis virus (BmNPV), are the two 
mainly used species for recombinant protein expression, in which lepidopterans is 
the biological host (Blissard and Rohrmann, 1990).  
There are two forms of the virus, unoccluded and an occluded forms. In the 
unoccluded form, virions are membrane-bound and exist singly, while in the 
occluded form, multiple virus particles or virions are occluded within a crystalline 
matrix or polyhedron, termed as inclusion body (Blissard and Rohrmann, 1990). 
Polyhedrin protein constitutes the main component of the matrix, allows for the 
survival of the virus under extreme environmental conditions (Smith et al., 1983, van 
der Beek et al., 1980). This protein matrix dissolves in the alkaline environment of 
the larvae midgut releasing the un-occluded virions that fuse to the epithelial cell 
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membranes (Volkman and Summers, 1977). These are taken up by the cell through 
endosomes, trafficked to the nucleus wherein the virus transcription and translation 
occur (Volkman and Summers, 1977). Upon infection, the virus spreads 
systemically, causing liquefaction of the host by the viral enzyme protease (Hawtin et 
al., 1997). This allows the dissemination of viral inclusion bodies into the 
environment where the virus thrives until another host uptake it.  
Molecular studies have shown that the most abundantly expressed protein near the 
end of baculovirus infectious cycle is polyhedrin (Smith et al., 1983). Polyhedrin 
protein typically represents over half of the total protein found in the AcMNPV 
infected cells at this time (Miller et al., 1983). Furthermore, the polyhedrin gene is not 
essential for virus replication in culture and can be replaced with a foreign gene 
wherein the polyherin (polyh) promoter would drive its high expression (Smith et al., 
1983). Therefore, such ability of baculovirus to produce high level of polyhedrin 
protein (or foreign proteins) has been exploited by researchers to express specific 
proteins of interest to the biomedical sector.  
 
1.14. Baculovirus expression vector system for the production of VLPs 
 
The expression of a single protein can be easily achieved for the viruses that consist 
of one structural protein such as the commercially available VLP-based human 
vaccines against human papillomavirus (HPV) (Koutsky et al., 2002, Harper et al., 
2004, Harper et al., 2006). However, several viral capsids consist of more than one 
structural protein could be problematic. In the initial studies to produce VLPs of multi-
complex proteins using BEVS, a dual baculovirus expression vector was constructed 
which contains two polyh promoters placed in opposite orientations to minimize the 
homologous sequence recombination (Emery and Bishop, 1987), which allowed the 
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expression of the two recombinant proteins (French and Roy, 1990). Although 
successful, this process of VLPs formation suffers from several drawbacks. Firstly, 
the efficiency of coinfection is generally low and needs accurate determination of 
multiplicity of infections (MOI) of both recombinant baculoviruses, in order to get a 
correct expression of all proteins (Bertolotti-Ciarlet et al., 2003). Consequently, any 
problem in the expression of one of the proteins may stop the whole process of 
assembly. Secondly, due to recombination, the stability of DNA elements within 
baculoviruses is low and thereby making the simultaneous expression of the proteins 
from two dual recombinant baculoviruses very inefficient (French and Roy, 1990, 
French et al., 1990).  
To solve the instability and inefficiency problems of the dual vectors, further studies 
identified another strong promoter of the very late genes in the p10 locus wherein 
high expression levels of recombinant genes can be obtained (Vlak et al., 1990). The 
combination of both p10 and polyh, led to a more stable dual expressing vectors 
(Weyer and Possee, 1991). With this combinatorial method, triple and quadruple 
transfer vectors were generated (Belyaev et al., 1995, Belyaev and Roy, 1993); but 
were difficult to be manipulated by molecular techniques.  
More recent studies have shown that the genomic baculoviral DNA is easier to 
manipulate as a bacterial artificial chromosome (Bacmid) that can then be 
propagated in the E. coli strain (Oppenheim et al., 2004, Copeland et al., 2001). This 
has permitted researchers to generate viruses that can express up to 8 subunits 
using the multi-loci expression recombinant vector. One of the molecular 
mechanisms of manipulation is the use of the recET system for the introduction of 
multiple expression cassettes into the  baculovirus genome at different loci (Noad et 
al., 2009). This approach ensured that every cell in the cell culture would be infected 
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with the recombinant baculovirus, expressing specific genes at the same ratio, 
leading to sustainable levels of proteins expression at larger passages (Noad et al., 
2009).  
1.15. Immunological value of VLPs 
To control microorganism invasion, viral pathogens are recognised by pattern 
recognition receptors (PRRs) of the immune system and protective defences against 
them are induced. Several studies demonstrated that a specific recombinant viral 
capsid protein contains epitopes ‘which are targeted of broadly neutralising 
antibodies’ has the ability to protect hosts from infection. For example, gp350/220, is 
the predominant virion envelope protein of Epstein-Bar virus (EBV) (Cohen et al., 
2011), the HIV-1 envelope proteins (gp120 and gp41) (Pancera et al., 2010) and 
VP2 protein the major serotype determining antigen of BTV (Inumaru and Roy, 1987, 
Hassan and Roy, 1999, Huismans et al., 1987). Therefore, considerable efforts have 
been devoted to generate soluble forms of these proteins for vaccination purpose. 
Although promising, the variable success of the soluble protein trials showed that 
soluble protein vaccines are generally limited in immunogenicity and do not elicit 
long-lasting protection (Kingsman and Kingsman, 1988, Link et al., 2012, Roy et al., 
1990). According to Roy et al studies with BTV, partial protection was afforded in 
vaccinated animals with 100 µg of BTV-10 VP2 at least for 75 days (Roy et al., 
1990), while only 50 µg of VP2 in combination with 25 µg of VP5 was sufficient to 
protect animals against virulent virus challenge indicating that lower doses of VP2 
could achieve similar level of protection when the both outer capsid proteins were 
presented in the vaccination cocktail (Roy et al., 1990). In contrast to these subunit 
antigens, only 10 µg of VLPs were sufficient to afford complete protection for up to 
14 months post-vaccination challenge (Roy et al., 1992, Roy et al., 1994). This is 
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due to the particulate structure of the VLPs, organisation of multivalent epitopes and 
the correct antigen conformation (Deml et al., 1997, Grgacic and Anderson, 2006, 
Chackerian 2007, Noad and Roy, 2003). The presence of such regular array 
structure mimicking those of infectious viruses increases the recognition of VLPs as 
safe and effective vaccines due to their ability to stimulate innate and adaptive 
immune response against pathogens, leading to specific B cells activation inducing 
rapid and robust antibody response (Spohn et al., 2007, Rohn et al., 2006, Da Silva 
et al., 2007, Stewart et al., 2013). 
1.16. BTV and other successful VLPs vaccines 
For most viral infections, vaccines are the most cost efficient long standing protection 
against the disease and the spread of the infectious viruses. Generally, the main 
purpose of vaccination is to produce suitable immune responses against antigens 
present on the virus surface or the virus-infected cells by eliciting innate and humoral 
immunities.  
At present, many vaccines against various viral diseases have been developed and 
commercially approved. These vaccines are mainly based on live attenuated viruses 
(such as measles, mumps, rubella, oral polio, smallpox, varicella and yellow fever) 
(Dhillon and Curran, 2008, Martin and Minor, 2002, Saijo et al., 2006) or inactivated 
viruses (like influenza, polio, rabies and hepatitis A) (Dumas et al., 1997, Centers for 
Disease and Prevention, 2013) or subunit vaccines (for instance hepatitis B) (Purcell 
and Gerin, 1975); however each of these vaccines has disadvantages regarding 
safety, efficiency and low levels of immunogenicity. The recombinant DNA 
technology has enabled the engineering of VLPs based safer vaccines in yeasts (like 
papillomavirus VLPs), insect or mammalian cells via specific expression vectors; 
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though insect cells in combination with the baculovirus expression system have 
proven to be one of the most effective technologies for the development of VLPs.  
VLPs are highly efficient subunit vaccines that mimic the organization and 
conformation of native viruses but lack the viral genome. The possibility of 
developing VLPs has originated from the ability of capsid proteins of the virion to 
self-assemble into structures that are morphologically identical to the infectious 
particles. So far, several baculovirus derived VLPs have been generated for human 
and animal enveloped or non-enveloped, DNA or RNA viruses in which their 
structure ranges from single to multiple capsid proteins (Table 6).  
VLPs for some members of the Reoviridae family, particularly BTV the prototype of 
orbiviruses, comprising the four structural proteins (VP2, VP3, VP5 and VP7) have 
been successfully produced using a baculovirus expression system (French et al., 
1990). In 1990, French and Roy were able to generate the first VLPs for BTV-10 by 
coinfection of insect cells with dual baculoviruses, one expressing the outer capsid 
proteins VP2 and VP5 and another expressing the CLP proteins VP7 and VP3 
(French et al., 1990). The BTV-10 VLPs elicited strong neutralizing antibody titres in 
vaccinated guinea pigs (French et al., 1990). Due to this success, VLPs were 
developed for the four serotypes of BTV-1, -2, -13 and 17. The purified VLPs 
particles were tested singly (BTV-10, -17) and in combination (BTV-1, -2, -10, -13 
and 17). Vaccinated sheep were challenged with homologous (BTV-10, -13 and 17) 
or specific heterologous virulent viruses (BTV-4, -11 and 16) (Stewart et al., 2010, 
Stewart et al., 2012). A complete protection was obtained in vaccinated animals 
against the vaccine serotypes, while heterologously challenged sheep were partially 
protected (Roy et al., 1994).  
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Studies showed that the multi-layered capsid of VLPs is made up of highly 
conserved cores and variable outer capsids which specify the serotype (Yamaguchi 
et al., 1988). This has been utilized to rapidly produce VLPs with the outer capsid 
proteins from different serotypes by coating the conserved inner layers. Based on 
this fact, vaccines against each of the BTV serotypes 2, 4 and 9 were generated, in 
which protection at low dose was shown (Stewart et al., 2010). Likewise, the 
developed VLPs could be rapidly applied for emerging viruses i.e. BTV-8 which was 
responsible for the outbreak in Europe (Stewart et al., 2013).  
Table 6.  
Baculovirus derived VLPs that have been tested as vaccines. Adapted from Roy and Noad 
(Roy and Noad, 2009).  
Family VLPs Proteins 
Expressed 
Vaccine Tested In 
Papillomaviridae Papillomavirus 1 Humans (licensed) 
Caliciviridae Norwalk and Norwalk-like 
viruses, Feline calicivirus 
1 Mice, Cats, 
Humans 
Hepeviridae Hepatitis E virus 1 Mice, 
Cynomologous 
Monkeys 
Parvoviridae Porcine parvovirus, mink 
enteritis parvovirus, Canine 
parvovirus, B19, Adeno-
associated virus 
1 Pigs, Dogs, Mink 
Circoviridae Chicken anemia virus, porcin 
circovirus  
1, 2 (Chicken 
anaemia virus) 
Chickens 
Polyomaviridae SV40,JC virus, murine, 
polyomavirus  
1 Mice, Rabbits (in 
vitro) 
Picornaviridae Polio virus 1 (polyprotein) - 
Reoviridae Bluetongue virus 
Rota virus  
4 (Bluetongue) 
2-3 (Rota) 
Sheep 
(Bluetongue), 
Mice, Pigs (Rota) 
Flaviviridae Hepatitis C virus 3 Mice, Baboons 
Retroviridae HIV, SIV, FIV, Visna virus, 
FeLV, BLV, Rous Sarcoma 
virus 
2 Mice, Guinea Pigs 
Paramyxoviridae Newcastle disease virus 1 Chickens 
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Coronaviridae SARS coronavirus  3 Mice (in vitro) 
Bunyaviridae Hantavirus 3 Mice 
Orthomyxoviridae Influenza A virus 2-4 Mice 
Birnaviridae Infectious Bursal Disease virus  1 Chickens 
 
 
1.17. Aims of the studies 
 
EHDV, the causative agent of EHD disease, belongs to the Orbivirus genus, 
Reoviridae family. As already outlined, EHDV imposes an emerging agricultural 
threat due to recent outbreaks in large number of domestic cattle. Currently No 
vaccine is available to control the viral infection, except the live-attenuated vaccine 
developed and used in Japan. Since VLPs have been shown to be highly 
immunogenic and safe vaccines, this study aimed to develop VLPs for EHDV 
serotypes. Baculovirus multiple genes expression system was used for the 
simultaneous expression of the four structural proteins, responsible for VLPs 
formation. To achieve this target, several steps were undertaken.  
Single gene expression in AcMNPV 
Due to the lack of published literature regarding the synthesis of EHDV structural 
proteins, initially the individual expression of the outer and inner capsid proteins of 
EHDV serotypes 1, 2 and 7 was investigated. DNA clones were produced and 
verified to assess the ability of utilising baculovirus multi-loci expression system.  
Development of EHDV-1 VLPs 
The advantages of VLPs as vaccines have been demonstrated for several types of 
enveloped and nonenveloped viruses, in particular, VLPs of BTV have been 
produced efficiently and shown to be highly efficacious (Stewart et al., 2012, Stewart 
et al., 2013). In contrast, VLPs of EHDV have not been reported to date, however 
this aim seems plausible given the very close phylogenetic relationship between BTV 
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and EHDV both at structural and genetic levels. This project examined the possibility 
of generating EHDV-1 VLPs using baculovirus multi-genes expression system for 
simultaneous expression of the recombinant targeted proteins. The possibility of 
generating conserved CLPs proteins as a platform for the formation of VLPs of 
heterologous serotypes was also examined.  
Development of heterologous VLPs against EHDV serotypes 
The recent epidemics caused by the emergent serotypes of EHDV that were more 
virulent to cattle, highlighted the need for a rapid generation of a safe vaccine. 
Previous research for BTV has demonstrated the ability to construct heterologous 
VLPs utilising the conserved CLP proteins VP7 and VP3 as a background, and 
exchanging the outer layer proteins related to the pathogenic strain (Belyaev and 
Roy, 1993, Stewart et al., 2010). Since no previous studies have addressed this 
issue for EHDV, here, the generation of heterologous VLPs of EHDV serotypes was 
undertaken using the conserved proteins of EHDV-1 CLP as a structural scaffold.  
Generation of EHDV-2 vaccine using RG system 
A RG system has been established and proved to be efficient for the development of 
defective virus vaccines, particularly, for BTV. EHDV-2 has been considered to be 
highly pathogenic for both wild and domestic animals. Therefore, as an initial 
attempt, in this work, an alternative strategy towards the development of a highly 
attenuated vaccine against EHDV-2 based on a RG system was carried out.  
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2.1. Baculovirus expression system 
2.1.1. Polymerase Chain Reaction (PCR) amplification  
Standard procedures were used for PCR according to Sambrook and Russell 
(Sambrook and Russell, 2001). To express EHDV structural proteins in baculovirus 
vector, the coding regions of EHDV-1 S2, S5 and S7, EHDV-2 S2 and S5, EHDV-7 
S2 were amplified using specific primers (Table 7). Primers were designed with 
appropriate restriction enzymes according to the published gene sequence 
(Genbank accession numbers Table 8).   
Melting temperature of each primer was calculated using the Sigma-Aldrich software 
http://www.sigmaaldrich.com/configurator/servlet/DesignTool?prod_type=STANDAR
D. Prior to amplification and to increase the efficiency of ligation of S2 into 
baculovirus transfer vector pAcYM1, primers were phosphorylated using T4 
Polynucleotide Kinase (T4 PNK) (Thermo Scientific) in a total volume of 10 µl 
containing: 0.5 µl forward (F) or reverse (R) primers; 1.0 µl 10X Buffer A; 10 mM 
ATP and 0.5 µl PNK enzyme (10U/µl). The mixture was incubated at 37°C for 20 
minutes (min) followed by incubation at 75°C for 10 min to inactivate the enzyme. 
Standard PCR reactions were carried out using KOD Hot Start DNA polymerase 
(Novagen) in a total volume of 50 µl containing: 30 µl PCR nuclease free water 
(nfH2O), 5 µl 10X PCR buffer, 5 µl dNTPs (final concentration 0.2 mM), and 2 µl 
MgSO4 (final concentration 1 mM), up to 100 ng template DNA, 3 μl of each (F and 
R) primers (5 pmol/μl, final concentration 0.3 μM) and 1 μl KOD Hot Start DNA 
Polymerase (1 U/μl). The PCR cycle conditions were carried out according to the 
manufacturer’s recommendations which are presented in (Table 9). PCR products 
were excised and purified from 1% agarose gel using Wizard® SV Gel and PCR 
Clean-Up System (Promega, UK). Briefly, the excised DNA band from gel was 
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transferred into a 1.5 ml microcentrifuge tube and 10 µl of membrane binding 
solution per 10 mg of gel slice was added. The mixture was incubated at 50-65°C 
until complete dissolve. The dissolved DNA mixture was transferred into the 
minicolumn, incubated at room temperature for 1 min and centrifuge at 16,000 x g for 
1 min. After centrifugation, 700 µl membrane wash solution were added and 
centrifuged using the same previous conditions. To elute the DNA, 25 µl nfH2O were 
used and the eluted PCR product was kept at -20°C for further experiments.  
Table 7.  
Primers used for cloning relevant inserts into pAcYM1 vector. 
Oligonucleotide 
name 
Sequence (5’-3’) Competent 
EHDV-1 primers 
BglII-S2 (F)a CTAAGATCTCATAAATATGGAGGACATTAACCTA 
BglII 
PH enhancer 
Start codon 
BglII-S2 (R)b CTAAGATCTTCAGTTCATTAATTTTG 
BglII 
 
BamHI-S5 (F)a CTAGGATCCATAAATATGGGCAAGTTCATT AAAC 
BamHI 
PH enhancer 
Start codon 
BamHI-S5 (R)b CTAGGATCCTCACGCGTATCGCATAAATTCG 
BamHI 
 
BamHI-S7 (F)a GTTGGATCCCATAAATATGGACACGATTGCTGCGGAG 
BamHI 
Start codon 
BamHI-S7 (R)b CTAGGATCCTCAGTTCATTAATTTTG 
BamHI 
 
pRN306-BamHI-S3 
(F)a 
GCTCGGTACCCGGGATCCCAAAATGGCAGATCCACCAGAT 
pRN306 
BamHI 
PH enhancer 
Start codon 
pRN306-XbaI-S3 
(R)a 
CTGCAGGTCGACTCTAGAATTACTAGGTATAGATATCGGT 
pRN306 
XbaI 
PH enhancer 
 
EHDV-2 primers 
SmaI-S2 (F)a CTACCCGGGTAAATATGGAGGAGATTTTCTTTA 
SmaI 
PH enhancer 
Start codon 
SmaI-S2 (R)b CTACCCGGGTCACTAGTGATTGTAA 
 
SmaI 
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BamHI-S5 (F)a 
CTAGGATCCATAAAT ATGGGCAAGATTATCAAGAAATT 
 
BamHI 
PH enhancer 
Start codon 
BamHI-S5 (R)b 
 
TCAGGATCCCGCGTAACGCATAAACT 
 
BamHI 
 
EHDV-7 primers 
NruI-S2 (F)a 
CTATCGCGACATAAATATGGAGGAGATTTTCTTTAGCGTAATT
GA 
NruI 
PH enhancer 
Start codon 
NruI-S2 (R)b 
 
CTATCGCGATCATTAGTTTTGAGATTATCT 
NruI 
 
BamHI-S5 (F)a CTAGGGATCCATAAATATGGGCAAGATTATCAAGAGATTGA 
BamHI 
PH enhancer 
Start codon 
BamHI-S5 (R) b 
CTAGGATCCCTCAATCTCTCTCCAATTAAGCTTA 
 
BamHI 
 
Primers used to clone EHDV-7 S5 into pRN296 transfer vector 
pRN296-BamHI-S5 
(F)a 
GCTCGGTACCCGGGATCCCAAAATGGCGGCCGCGGGAATTC
GAT 
pRN296 
BamHI 
PH enhancer 
Start codon 
pRN296-BamHI-S5 
(R)b 
CTGCAGGTCGACGGATCCATTATCATGATTTAAGGAGTT 
pRN296 
BamHI 
PH enhancer 
 
(F)a: Forward 
(R)b: Reverse 
 
Table 8.  
EHDV-1, EHDV-2 and EHDV-7 Genbank accession numbers. 
EHDV Gene Accession number Size (bps) 
EHDV-1 S2 NC_013397 2968 
EHDV-1 S5 NC_013400 1803 
EHDV-1 S7 NC_013402 1162 
EHDV-1 S3 NC_013398 2768 
EHDV-2 S1 AM744997 3942 
EHDV-2 S2 AM744998 3002 
EHDV-2 S3 AM744999 2768 
EHDV-2 S4 AM745000 1983 
EHDV-2 S5 AM745001 1803 
EHDV-2 S6 AM745002 1641 
EHDV-2 S7 AM745003 1162 
EHDV-2 S8 AM745004 1186 
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EHDV-2 S9 AM745005 1143 
EHDV-2 S10 AM745006 810 
EHDV-7 S2 AM745048 3002 
EHDV-7 S5 AM745051 1769 
 
Table 9.  
Cycling conditions used for PCR reactions. 
Stage Stage name Temperature °C Duration (min:sec) Cycles 
First Initial denaturation 95 2:00 1 
Second Denaturation 95 0:20 30 
Annealing 50-60 0:30 
Extension 70 0:20/kbp 
Third Final extension 70 7:00 1 
Forth Final extension 4 10:00 1 
 
2.1.2. The preparation of plasmid and Bacmid DNA 
To purify high-copy plasmids and Bacmid DNA from the bacterial culture, Invitrogen 
PureLinkTM HiPure Plasmid DNA Purification Kit was used following the 
manufacturer’s procedure (InvitrogenTM, UK). Briefly, the overnight culture resulted 
from the inoculation of a freshly streaked single bacterial colony in 50 ml Luria 
Bertani (LB) supplemented with 100 µg/ml ampicillin or (50 µg/ml kanamycin and 15 
µg/ml chloramphenicol) for Bacmid DNA, was centrifuged at 4,000 x g for 10 min at 
4°C. The supernatant was discarded and the bacterial pellet was resuspended in 4 
ml of buffer P1 (50 mM Tris-HCl, pH 8.0; 10 mM EDTA; 100 µl/ml RNase A). After 
complete resuspension, 4 ml of buffer P2 (200 mM NaOH; 1% SDS) were added to 
lyse the cell and the mixture was incubated at room temperature for 5-10 min. After 
incubation, 4 ml of chilled buffer P3 (3 M potassium acetate, pH 5.5) were added and 
incubated on ice for 10 min to enhance the precipitation of genomic DNA. At this 
stage, the precipitation material also contained proteins and cell debris. To separate 
the plasmid DNA, the mixture was centrifuged at 4,500 x g for 25 min at 4°C and the 
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clear supernatant was collected and applied onto a pre-equilibrated column to which 
the plasmid DNA binds. After washing, 5 ml of the elution buffer (1.25 M NaCl, 100 
mM Tris-HCl, pH 8.5) were used to elute the bound DNA followed by 1 volume of 
isopropanol precipitation. After centrifugation, the pellet was washed with 70% 
ethanol and allowed to air dry. The DNA pellet was resuspended in 200 µl of TE 
buffer (10 mM Tris-HCl, pH 8.0; 0.1 mM EDTA) and quantified by NanoDrop®ND-
1000 Spectophotometer (NanoDrop Techlonogies, Inc, USA).  
2.1.3. Construction of transfer vectors for baculovirus system  
 
To construct recombinant baculovirus single gene expression vectors, the coding 
regions of EHDV-1 S2, S5 and S7, EHDV-2 S2 and S5, and EHDV-7 S2 and S5 
were cloned into a baculovirus transfer vector pAcYM1 previously linearised by 
BamHI or SmaI (Thermo Scientific) restriction digestion.  
For the generation of baculovirus multigene expression vectors, a previously 
developed system was used (Noad et al., 2009). In this method, lambda red and 
bacteriophage PI Cre recombinase systems were combined to generate a 
recombinant AcMNPV in which foreign genes were inserted into different loci. Three 
transfer vectors; pRN296, pRN260 and pRN306 were used with a polyh promoter, 
Cre recombinase gene (Loxp71 and Loxp66), LacZα gene and baculovirus sequence 
specific to each locus. A specific baculovirus sequence in each vector is required for 
locus-specific homologous recombination. These vectors also contain BamHI or 
BamHI-XbaI cloning sites for the insertion of the foreign gene. For instance, 
pRN296-BamHI was used to clone the coding region of EHDV-1 S5, EHDV-2 S5 and 
EHDV-7 S5, while EHDV-1 S7 coding region was ligated into pRN260-BamH1 and 
EHDV-1 S3 was inserted into pRN306-BamHI-XbaI.  
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As shown in diagram 12 (Fig. 12), a linear DNA containing both cassettes was 
amplified by PCR (Fig. 12B) and inserted into Bacmid1629 already incorporated into 
the competent E. coli cells (E3K2) chromosome (Fig. 12C). Bacmid1629 is a modified 
baculovirus DNA by Kitts and Possee (Kitts and Possee, 1993). The key feature of 
the parental genome is the presence of a novel sequence in the polyhedrin locus 
that contributes a unique Bsu36I site. The linearised viral DNA cannot be replicated 
until it is mixed with a transfer vector which then used to cotransfect insect cells. In 
addition, Bsu36I digestion allows the deletion of a portion of orf1629, which is an 
essential viral gene located downstream of polyhedrin (Vialard and Richardson, 
1993). Recent studies using recombinatorial cloning methodology that utilises RecE 
and RecT genes products (Muyrers et al., 1999), orf1629 knockout has performed in 
a bacmid version of the baculovirus genome held in E.coli (Zhao et al., 2003). Such 
modification of the viral genome has increased the efficiency of recombinant 
baculovirus vector production in large volumes without the need for further isolation 
of the virus through large-scale DNA transfection. For the integration of the next 
gene, the selectable marker should be flipped out by activating Cre recombinase 
expression (Fig. 12D).   
Table 10.  
Primers used for generating appropriate gene inserts for the development of multiple genes 
Bacmid by homologous recombination. Adapted from (Kanai et al., 2013).  
Primers to amplify baculovirus sequence specific to each locus 
Plasmid Locus Promoter Forward Reverse 
pRN260 egt  polyh ATATGCGGAACGTACAAA
CG 
TACATGTAGTAATTTGAATACG
G 
pRN296 odv-ec56 polyh 
 
TCGAGGGGCCGTTGTTGG CATGACGCCGCTGCCGTG 
pRN306 39K polyh GCAAGGGCGCATTCACA
GCAACCG 
GACTGTGGTGCTTACCAACGC 
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Fig. 12. Schematics showing the generation of baculovirus multi-gene expression vector. (A) 
Transfer vector map containing specific AcMNPV sequence, expression cassette (p10 or polyh 
promoter and foreign gene) and selectable cassette (LacZα, ZeoR flanked by Cre recombinase gene 
Loxp71 and Loxp66). (B) Upper panel, PCR amplification of the insertion and selectable cassettes 
flanked by AcMNPV sequence. Bottom panel, competent cells (E3K2) containing Bacmid1629 genome. 
(C) Insertion of the PCR fragment in Bacmid1629 by homologous recombination. (D) The removal of 
selectable marker by activation of Cre recombinase genes. Adapted from (Kanai et al., 2013). 
 
Prior to ligation, the complete digestion of the vectors was verified by electrophoresis 
on 1% agarose gel (Sigma-Aldrich Ltd, UK). The linearised vectors were then 
dephosphorylated by incubation with Shrimp Alkaline Phosphatase enzyme (SAP) 
(Thermo Scientific). Briefly, 2-4 µg of the linear plasmid was mixed with 2 µl 10X 
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reaction buffer, 1 µl (1 U) SAP enzyme and nfH2O up to the total volume of 20 µl. 
The reaction mixture was incubated at 37°C for 1 h followed by incubation for 15 min 
at 65°C to stop the reaction. Ligation reactions were carried out using (TAKARA) 
ligation mix. The amount of the insert required for ligation of (50-100) ng of vector 
was calculated according to the following equation: 
 
 
The ligation mixtures were incubated at room temperature for 1-3 h and then 
transformed into the chemically competent cells (DH5α). The initial selection of the 
transformed colonies was throughout ampicillin resistance conferred by the vectors. 
To determine the ampicillin resistance clones had the target gene of interest in the 
correct orientation, restriction digestion with specific enzymes or PCR amplification 
using primers from the insert and from the vector was performed (Table 11). The 
complete sequence of the coding regions was carried out with specific universal 
(Table 12) or internal primers (Table 13) by Source BioScience and the results were 
compiled using BioEdit Software. 
Table 11.  
Molecular methods used to determine the orientation of the insert in the recombinant 
constructs. 
 
Vector Insert        Method for determining the orientation  
  Restriction Digestion PCR 
pAcYM1 EHDV-1 S2 EcoRV PH (F) + EHDV-1 S2 (R) 
EHDV-1 S5 XmaI + XhoI - 
EHDV-1 S7 - PH (F) + EHDV-1 S7 (R) 
EHDV-2 S2 HindIII - 
EHDV-2 S5 - PH (F) + EHDV-2 S5 (R) 
EHDV-7 S2 - PH (F) + EHDV-7 S2 (R) 
pRN296 EHDV-1 S5 - PH (F) + EHDV-1 S5 (R) 
EHDV-2 S5 - PH (F) + EHDV-2 S5 (R) 
EHDV-7 S5 - PH (F) + EHDV-7 S5 (R) 
ng of vector X size of insert (Kb) 
           size of vector (Kb) 
molar ratio of  X 
insert 
vector = ng of insert 
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pRN260 EHDV-1 S7 NruI PH (F) + EHDV-1 S7 (R) 
pRN306 EHDV-1 S3 - EHDV-1 S3 (F) and (R) 
PH (F): polyhedrin forward primer  
(R): Reverse primer 
 
Table 12.  
 
Universal primers for sequencing. 
 
Oligonucleotide name Sequence 5'-3' 
M13 (F) GTTTTCCCAGTGACGAC 
M13 (R) CAGGAAACAGCTATGAC 
Polyhedrin PH (F)  ACCATCTCGCAAATAAATAAG 
Polyhedrin  PH (R)  ACAACAATTGTCTGTAAATC 
C9 5' P-GACCTCTGAGGATTCTAAAC/iSp9/TCCAGTTTAG 
AATCC-OH3' 
FLAC2 5' P-GAGTTAATTAAGCGGCCGCAGTTTAGAATCCTC 
AGAGGTC 3' 
 
 
Table 13.  
EHDV-1, EHDV-2 and EHDV-7 internal primers used for sequencing. 
Oligonucleotide 
name 
Sequence 5'-3' Position 
(nucleotide) 
 
 
 
EHDV-1 S2 
CTACATCCGCGGATAGCGGA 400-420 
GGATGAGAGATCAGAATGT 821-840 
GGTGAGAGAAGATTATTT 1242-1260 
GGGACAAAAAAACCGCAGA 1661-1680 
GAAATCAACTACGGAGGA 2152-2170 
CAAATGGTAGAATTATACTAT 2569-2590 
EHDV1 S3 GAGGCATGGAAATAGCGGA 471-490 
GCGACGTGCTTACCGACA 890-908 
TGAAAACAGGGAGCCAGCG 1381-1400 
CCGCTAATCGAGTCGGTCTAT 1799-1820 
GCAAGATTGCAGGCAAATAT 2255-2275 
EHDV-1 S5 CATGATAAAATTTGACCCAA 400-420 
CCACAGACACTTGTGCAAAT 890-910 
GTATTTGGGAAAATGATGAAT 1308-1329 
EHDV-1 S7 CTACATCAATCGTATCCTCGA 465-486 
CAATGTTTACTCATATAAGA 820-840 
EHDV-2 S1 
 
 
CTATTAAGGTTTGGGCAGCAT 447-468 
ATGTGGGGAGTAGGCGCA 821-839 
CGCGCAAGTCTCAGAAGGAA 1228-1248 
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CGTCACCGGAGTACAAGAAAT 1659-1680 
GAGTATTACCAGTCTCAACT 2055-2075 
GATAATATCATCTGAGCGA 2494-2513 
GTTTCTTCTCGAAGATGGCAC 2961-2982 
CGTGATGCGTGGCTTCATAA 2409-3429 
EHDV-2 S2 CAGAGTCGAATTACATAGGGT 542-563 
GCGAAATATAGAATGGGA 1156-1174 
GTGGCTTCTTCCTCTACCGA 1734-1764 
GCGAGGAGGAGATCCGAGTGAT 2150-2172 
CTACAAAAGGTATAATTGCGGT 2681-2703 
EHDV-2 S3 GCCTTTATCTTGCATAACAT 434-454 
GATAATGAATATAGCGACGT 877-897 
CAGTATGATTGTAACGTAT 1307-1326 
CTTTTTCGATGCCAGACGAT 1632-1652 
GATGCTGACTGATCAGGTGTA 2101-2122 
GATTACCAGACAAATGAGA 2411-2430 
EHDV-2 S4 GACATTGAATGATGCGAAT 421-440 
TCTACATCAGGTTTGTTCTC 890-910 
TACCTTACGAATAGGTGC 1238-1256 
CGTATGGGCTTAGACGTCT 1643-1662 
EHDV-2 S5 GATTTAGATGATGTGTAT 402-420 
GTGATCCTACGGACACCA 879-897 
GTATGTATTTTACGAAGATTT 1232-1253 
EHDV-2 S6 CTATTTGGGAGAGACTTA 390-408 
GAGGGCGGATATAAGTTGAA 783-803 
CTACATTGCGTGGCGTCACA 1167-1187 
EHDV-2 S7 GACCGACAACCATTTGGTTA 380-400 
CAGGCACAAATTTTCAATGT 806-820 
EHDV-2 S8 GAGTTACCCGGGGTCCAGAGAT 445-467 
EHDV-2 S9 GTACGGAGTGAGTATTCCTGT 460-481 
EHDV-2 S10 CATAATACAACAACGGAGGCGA 452-474 
EHDV-7 S2 TGATTTCAAGGGAGAGCAG 338-407 
ATTCGGATAAAATCATAACG 882-902 
AGACACGATATATAAGTG 1312-1330 
TCAAGAAAGAGAATGAAATG 1716-1736 
GCGAGGAGGACATACGCAT 2151-2170 
AAACGAAAAGAAATAATTG 2564-2583 
EHDV-7 S5 ATGATTAAATATGACCCAAC 400-420 
TATGTGACTCAGCTGTTTG 802-821 
TACAACAGGAATGGAAGC 1242-1260 
 
2.1.4. Preparation of chemically competent E.coli cells  
Preparation method of the DH5α strain of E.coli used for transformation of the DNA 
constructs, was based on the modified Inoue protocol (Inoue et al., 1990, Sambrook 
and Russell, 2001). In brief, 5 µl of the bacterial stock stored at -80°C was inoculated 
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in 5 ml LB broth (Sigma-Aldrich, UK) and incubated at 37°C with vigorous shaking at 
200-250 rounds per minutes (rpm) overnight. The resulting culture was used for 
further inoculation of 200 ml LB medium which was incubated at 37°C with shaking 
at 200-250 rpm until the optical density (OD600) of 0.4 was reached. The cell culture 
was then incubated on ice for 10 min, transferred into pre-chilled 50 ml conical 
centrifuge tubes (Fisher Scientific) and centrifuged at 2,000 g for 10 min at 4°C 
(Beckman JA-10 rotor). The pellet formed after centrifugation was gently 
resuspended in 60 ml of ice-cold transformation buffer (55 mM MnCl2.4H2O; 15 mM 
CaCl2.2H2O; 250 mM KCl; 10 mM PIPES, pH 6.7) and centrifuged using the same 
condition described previously. The supernatant was discarded and the pellet was 
carefully resuspended in 20 ml of ice-cold transformation buffer. Subsequently, the 
bacterial suspension was mixed gently in the presence of 1.5 ml dimethyl sulfoxide 
(DMSO) (Sigma-Aldrich Ltd, UK), incubated on ice for 10 min, aliquoted in 100 µl 
and stored at - 80°C for further use. 
2.1.5. Transformation of competent E.coli cells  
An aliquot (100 µl) of DH5α competent cells was incubated on ice until complete 
thawing, and used for transformation of the DNA plasmid or the ligation mixture. 
After DNA was added and 30 min of incubation on ice, the competent cells were heat 
shocked at 42°C for 42 seconds (sec) and incubated again on ice for further 5 min. 
the LB medium (300 µl) was added to the cells which were then incubated at 37°C 
for 30 min in a shaking incubator. Following incubation, 100 µl of the bacterial culture 
was spread on LB agar plates supplemented with 100 µg/ml of ampicillin (Sigma-
Aldrich Ltd, UK) and incubated at 37°C overnight.  
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2.1.6. Electrocompetent E.coli cells 
 
For the construction of multiple gene expression recombinant baculoviruses (Noad et 
al., 2009), a Bacmid E3K2 modified from bMON14272 (Luckow et al., 1993) 
maintained in the E.coli strain EL350 (Lee et al., 2001) was prepared and purified as 
mentioned in DNA Bacmid and plasmid preparation (see section 2.1.2). The 
electrocompetent bacterial cells were prepared and stored at - 80°C using standard 
methods (Sambrook and Russell, 2001). In brief, a single bacterial colony was 
inoculated in 3 ml LB broth supplemented with 50 µg/ml kanamycin and 15 µg/ml 
chloramphenicol and incubated at 32°C overnight. An aliquot (100 µl) of the 
overnight culture was further inoculated in 10 ml LB containing the same antibiotics 
as above and incubated at 32°C until the OD600 of 0.4. To induce the expression of 
Cre recombinase genes, the culture was incubated at 42°C for 1 h. Subsequently, 
the bacterial culture was incubated on ice for 10 min followed by centrifugation at 
1.800 g for 10 min at 4°C (Beckman JA-10 rotor). The supernatant was discarded 
and the pellet resuspended carefully in 10 ml pre-chilled autoclaved distilled water, 
incubated on ice for further 10 min, centrifuged as above and resuspended again 
with the same volume of distilled water in the presence of 10% DMSO. Finally, the 
electrocompetent cells were centrifuged and the pellet resuspended with 1 ml chilled 
distilled water in 10% DMSO and divided into 200 µl aliquots in micro tube which 
were stored at - 80°C for further use.  
2.1.7. Lambda red recombination and Cre recombination in E.coli 
For lambda red recombination, 50 ng of the amplified PCR product (Table 10) 
containing specific EHDV gene was transformed into 100 µl of EL350 cells by 
electroporation at 2500 V in a microelectroporation chamber. Immediately, 900 µl LB 
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broth was added and the cells were recovered by incubation at 32°C for 2 h before 
plating on LB-agar (LBA) plates supplemented with 50 µg/ml kanamycin, 15 µg/ml 
chloramphenicol, 15 µg/ml Zeocin, 40 µg/ml Xgal and 0.2 mM IPTG. Plates were 
incubated overnight at 32°C and blue colonies were isolated and screened for the 
presence of the targeted genes.  
In order to flip out the selectable marker (Fig. 12), the expression of Cre 
recombinase was induced by culturing the positive recombinant Bacmid clones 
(ZeoR and LacZα positive) at 32°C in LB supplemented with 0.1% arabinose for 2 h. 
EL350 bacterial cells were then plated and cultured in the presence of kanamycin 
(50 µg/ml), chloramphenicol (15 µg/ml), Xgal (40 µg/ml) and IPTG (0.2 mM). To 
confirm the loss of the zeocin resistance gene, white colonies were re-streaked onto 
the same selection plates with/without zeocin. The generated colonies were then 
used for further cloning.    
2.1.8. Insect cell culture 
Standard protocols for working with insect cell cultures and baculovirus amplification 
were followed according to the methods and recommendations described by King 
and Possee (Possee et al., 1999). Two strains of insect cell lines derived from the 
fall army worm Spodoptera frugiperda (Sf21 and Sf9), were used for the expression 
of foreign genes by infection with the recombinant AcMNPV. Sf21 cells derived from 
ovarian tissue were used for the generation of recombinant baculoviruses and for 
virus titration. As Sf9 cells grow faster at higher cell densities than Sf21 cells, Sf9 
cells were used for the expression of recombinant proteins.  
Sf21 cells were grown at 28°C in suspension in round-bottom flasks on a magnetic 
stirrer at 100 rpm in TC-100 medium (Lonza Ltd, UK) supplemented with 10% Feotal 
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calf serum (FCS) (Sigam-Aldrich Ltd, UK)  and 1X antibiotic/antimycotic (100U 
penicillin, 100 µg/ml streptomycin and 250 µg/ml amphotericin B, AA) (Sigma-Aldrich 
Ltd, UK). Sf9 cells were grown at 28°C in conical flasks in Insect-XPRESS medium 
(Lonza Ltd, UK) in the presence of 100U/ml (AA). Both cells were maintained at cell 
densities between 0.5 x106 and 2 x 106 cells/ml and their viability was monitored by 
staining of 100 µl of cell culture with trypan blue (1:1) (Sigma-Aldrich Ltd, UK). 
2.1.9. Generation of single and multiple recombinant proteins in AcMNPV 
To generate the recombinant baculoviruses expressing single (Table 14) and multi-
protein complexes (Table 15), Sf21 cells were seeded at a density of 1.0 x 106 to 1.5 
x 106 per well in 6 well plates and incubated for 20 min at room temperature to allow 
the cells to settle down. For cotransfection, 2.0 µg of the Bacmid1629 DNA was 
incubated with 500 ng of the purified recombinant plasmids, 10 µl Insect GeneJuice 
transfection reagent (Novagen) and 100 µl TC-100 medium. The transfection mixture 
was incubated at room temperature for 20 min. Sf21 cells were washed twice with 
TC-100 medium and 1.0 ml of it was added to the cells. After incubation, the reaction 
mixture was added drop-wise to the cells and incubated at 28°C for 5 h. TC-100 
supplemented with 10% FCS (1 ml) was added to the cotransfected cells which were 
further incubated at 28°C for 4 days. The supernatant containing the recombinant 
baculovirus progeny was harvested and stored at 4°C for further use. As a control of 
the recombination efficiency, Sf21 cells were cotransfected with Bacmid1629 and the 
pRN43-GFP vector which drives the expression of green fluorescent protein (GFP) 
under the control of polyh promoter. The expression of GFP protein which was 
synthesised by the recombinant baculovirus, was examined daily and confirmed by 
visualisation under the light and ultraviolet (UV) microscopy (Fig. 18).  
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Table 14.  
Individual expression of the recombinants proteins for EHDV serotypes.  
Baculovirus DNA Recombinant vector 
 
 
 
Bacmid1629-Bsu36I 
pAcYM1-EHDV1.VP2 
pAcYM1-EHDV1.VP5 
pAcYM1-EHDV1.VP7 
pAcYM1-EHDV1.VP3 
pAcYM1-EHDV2.VP2 
pAcYM1-EHDV2.VP5 
pAcYM1-EHDV7.VP2 
pRN43-GFP 
 
Table 15.  
Baculovirus multiple genes expression of the recombinant proteins of EHDV serotypes. 
Baculovirus DNA Recombinant vector 
Bacmid1629:EHDV1.VP7.VP3 pAcYM1-AlwNI 
Bacmid1629:EHDV1.VP7.VP3.VP5 pAcYM1-AlwNI 
Bacmid1629:EHDV1.VP7.VP3.VP5 pAcYM1-EHDV1.VP2- AlwNI 
Bacmid1629:EHDV2.VP5 pAcYM1-EHDV2.VP2- AlwNI 
 
2.1.10. Isolation and propagation of recombinant baculoviruses  
For the isolation of individual recombinant clones from the recovered viruses after 
cotransfection, plaque assays were performed in Sf21 insect cells. Briefly, Sf21 
insect cells were seeded in 6 well plates at a density of 1 x 106 cells per well. Each 
virus sample was serially diluted (10-1 to 10-6) in serum-free medium and 200 µl of 
each dilution was added directly onto the cells. To allow virus absorption to the cells, 
plates were incubated at room temperature on an orbital shaker for 1 h. The 
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inoculums were removed after incubation and 2 ml of 1.5% (w/v) molten low melting 
point agarose (Sigma-Aldrich Ltd, UK) in TC-100 media supplemented with 5% FCS 
were added to each well. The TC-100 supplemented with 10% FCS was added on 
the top of agarose after incubation for 10 min at room temperature to allow the 
agarose to set. Plates were further incubated at 28˚C for 4-5 days. Consequently, 
the medium was removed and the cells were stained with 2 ml of filtered 1:20 dilution 
of neutral red (Sigma-Aldrich Ltd, UK) in 1X phosphate-buffered saline (PBS). 
Staining was performed at 28˚C for 5 h or overnight for better visualisation of the 
plaques. Individual and well separated plaques were isolated using sterile glass 
Pasteur pipettes, transferred into 300 µl of TC-100 medium containing 2% FCS and 
stored at 4˚C. To amplify a single plaque, three rounds of amplifications were carried 
out in 6 well plates by infecting Sf21 at a density of 1 x 106 per well and incubated at 
28˚C until the cytopathic effect (CPE) was observed in the cells, which occurred 42-
72 hours post infection (hpi). The supernatant was harvested by centrifugation of the 
cell culture at 9000 g for 5 min and stored at 4˚C while the pellet was washed once 
with 1X PBS and used to analyse the expression of recombinant proteins. Once the 
expression was correctly determined, a virus stock was prepared by infecting Sf9 
cells at a low MOI (0.01-0.1) plaque forming unit per cell [pfu/cell]) and stored at 
28˚C until 100% CPE was detected. The recombinant baculoviruses in the culture 
medium were harvested by centrifugation at 9000 g for 10 min and stored in media 
with 2% FCS at 4˚C. High titre of working virus stocks were generated by inoculating 
1 ml of the previously harvested virus into 100 ml of Insect-XPRESS media 
containing Sf9 cells at a concentration of 1 x 106 cells/ml which was incubated at 
28˚C until 100% CPE. The harvested baculoviruses were then stored at 4˚C for 
subsequent experiments.  
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2.1.11. Confirmation of the expression of recombinant proteins  
2.1.11.1. SDS-PAGE  
A standard SDS-PAGE procedure was performed to detect the expression of 
proteins that derived either from transfection or infection of insect cells or 
mammalian cells (Laemmli, 1970). To verify the expression of the proteins using 
baculovirus stocks, suspensions of Sf9 cells at density of 1.2 x 106 cells/ml were 
infected at MOI of 3 to 5 and incubated for 48-60 h at 28˚C. Infection conditions 
including incubation time and MOI were optimised for each recombinant protein. 
Cells infected with recombinant baculoviruses were harvested by centrifugation at 
1500 g for 15 min at 4˚C and washed twice with 1X PBS to remove the residual FCS 
that might affect the visualization of the proteins, and centrifuged at 10.000 g for 3 
min. Samples were resuspended in a sufficient amount of 1X protein loading buffer 
(40% glycerol; 4% SDS; 0.02% bromophenol blue; 50 mM Tris-HCl, pH 6.8; 10% β-
mercaptoethanol), and incubated at 100°C in a heat block for 5 min. The heated 
protein samples were then loaded on a discontinuous 10% polyacrylamide 
separating gel (1.5 M Tris-HCl, pH 8.8; 0.1% (w/v) SDS; 1% (v/v) TEMED; 10% (w/v) 
APS) and 5% (w/v) polyacrylamide stacking gel (13 mM Tris-HCl, pH 6.8; 0.1% (w/v) 
SDS; 1% (w/v) TEMED; 10% (w/v) APS). The running buffer was made up of (200 
mM glycine; 25 mM Tris-HCl, pH 8.8; 0.1% (w/v) SDS). All gels were 
electrophoresed at 50 mA per gel at a 180 V limit and protein samples were stained 
with coomassie brilliant-blue (40% methanol; 10% glacial acetic acid; 0.2% (w/v) 
coomassie brilliant blue) for 45 min followed by incubation in a destaining buffer 
(40% (v/v) methanol; 10% (v/v) acetic acid). The time of destaining was depended 
on the visualisation of the separated protein bands. Thereafter, SDS-PAGE gels 
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were dried between two sheets of cellophane at 40°C using the GelAir dryer (Bio-
Rad Laboratories Ltd, UK). 
2.1.11.2. Western blotting  
For protein detection and antibody specificity tests, proteins were analysed by SDS-
PAGE and transferred to Filters Immobilon-P transfer membranes (Fisher Scientific 
Ltd, UK). Briefly, after SDS-PAGE, the gels were incubated for 5 min in western 
blotting buffer (12 mM Tris base; 96 mM glycine, pH 8.3; 20% methanol). 
Membranes were incubated in 100% (v/v) methanol for 1 min followed by incubation 
in western blotting buffer for 3 min. Whatman filter papers (8 sheets of 3 MM paper) 
were also soaked in western blot buffer for 5 min. A transfer sandwich was 
assembled as follows (from the anode electrode plate to the cathode electrode 
plate): 4 filter papers, transfer membrane, SDS-PAGE gel and 4 filter papers. The 
transfer of proteins to the membranes were performed for 2 h at a constant current of 
1.2-2.5 mA/cm2 using a semi-dry transfer blotting according to the manufacturer’s 
procedure. As transference was completed, membranes were blocked in blocking 
buffer (10% dry skimmed milk powder; 1% Tween-20 in 1X PBS) for 1 h at room 
temperature then probed for 2 h in the presence of EHDV polyclonal as primary 
antibodies diluted in the same blocking buffer (Table 16). To remove the unbound 
antibody, the membrane was washed three times with blocking buffer followed by 
further incubation of the membrane for 1 h with the appropriate alkaline 
phosphatase-conjugated anti-species IgG (Sigma-Aldrich Ltd, UK) (Table 17). 
Membranes then were washed three times with the washing buffer (0.5% Tween-20 
in 1X PBS) to remove the unbound secondary antibody. The development of the 
colour was carried out by incubating the membrane blot in 10 ml of alkaline 
phosphatase buffer (100 mM Tris; 100 mM NaCl; 5 mM MgCl2) using 5-Bromo-4-
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chloro-3-indolylphosphate/Nitro blue tetrazolium (BCIP/NBT) substrate system 
(Sigma Aldrich Ltd, UK).  
Table 16.  
Primary antibodies used in western blotting.  
Protein/epitope 
 
Source Supplier Dilution 
EHDV-1 VLPs 
(VP2, VP5, VP7, VP3) 
 
Rabbits ThermoFisher Scientific, Pierce 
antibodies 
1:10.000 
EHDV-1 CLPs 
(VP7, VP3) 
 
Rabbits ThermoFisher Scientific, Pierce 
antibodies 
1:10.000 
EHDV-1 VP2 Guinea pigs ThermoFisher Scientific, Pierce 
antibodies 
1:5.000 
EHDV-12 VP2 Guinea pigs ThermoFisher Scientific, Pierce 
antibodies 
1:5.000 
 
Table 17.  
Secondary antibodies used in western blotting. 
Primary detected Source Supplier Dilution  
Anti-rabbit IgG (whole molecule)- Alkaline 
Phosphatase  
Goat Sigma-Aldrich Ltd, UK 1.10.000 
Anti-guinea pig IgG (whole molecule)- 
Alkaline Phosphatase 
Goat Sigma-Aldrich Ltd, UK 1.5.000 
 
2.1.12. Purification of the recombinants expressing EHDV-1 CLPs  
 
The EHDV-1 CLPs were purified from Sf9 cells infected with a single recombinant 
baculovirus Bacmid1629:EHDV1.VP7.VP3 expressing both the inner core proteins 
EHDV-1 VP7 and VP3. Briefly, 100 ml of Sf9 cells were cultivated in Insect-XPRESS 
media in a conical flask at 28°C to a density of 1 X 106 cells/ml and infected at MOI 
of 5. After incubation at 28°C for 72 h, the infected cells were harvested by 
centrifugation at 5000 g for 5 min at 4°C. The pellet was washed twice with cold PBS 
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and cell pellet was lysed in 1 ml ice-cold lysis buffer (150 mM NaCl; 50 mM Tris-HCl, 
pH 8.0; 0.5% NP-40; 1 mM EDTA; 0.75% (w/v) deoxycholate) for 1 x 107 of the cells. 
For complete lysis, the lysis mixture was incubated on ice for 10 min and 
homogenised with a glass Dounce homogeniser (10 strokes). Supernatants were 
collected by centrifugation at 4000 g for 10 min at 4°C, kept in ice and then loaded 
on top of pre-formed 25% (w/v) and 50% (w/v) discontinuous sucrose gradient in 
SW40 ultracentrifuge tubes. These gradients were formed with 2 ml 50% (w/v) and 4 
ml 25% (w/v) in sucrose in 150 mM NaCl; 50 mM Tris-HCl, pH 8.0; 0.5% NP-40; 1 
mM EDTA. Samples were centrifuged at 40.000 g for 90 min at 10°C in SW40 rotor 
(Beckman). At the end of the spin, two bands were visualised at both the 0-25% and 
25-50% sucrose interfaces. Protein content in each fraction was analysed by 10% 
SDS-PAGE.  
The sample collected from 25-50% sucrose interface which contained the CLPs 
proteins, was concentrated by further ultracentrifugation. In brief, the sample was 
diluted in 20 mM Tris-HCl, pH 8.0 and centrifuged at 45,000 g for 40 min at 10°C in 
TLS-55 rotor (Beckman). After centrifugation, the pellet was resuspended in 100 µl of 
20 mM Tris-HCl, pH 8.0 and kept at 4°C overnight. To verify the presence and purity 
of EHDV-1 CLPs proteins VP7 and VP3, 5 µl of the concentrated sample was 
analysed on 10% SDS-PAGE. The concentration of the CLPs proteins were 
determined by Bradford reagent (Sigma-Aldrich Ltd, UK) for further work.  
2.1.13. Purification of EHDV-1 VLPs and heterologous VLPs of EHDV-2  
For purification of EHDV-1 VLPs consisting of VP2, VP5, VP7 and VP3 and 
heterologous VLPs made up of the inner core protein of EHDV-1 CLPs (VP7 and 
VP3) and the outer capsid proteins of EHDV-2 (VP2 and VP5), 4 X 175cm2 flasks 
with Sf9 cells grown as monolayer cultures were infected with the appropriate 
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recombinant baculoviruses at a MOI of 5 pfu/cell. The cells were harvested by 
centrifugation at 5000 g at 4°C after 72 h of infection when the CPE was 100%. The 
cell were lysed in a total of 25 ml of chilled 2X lysis buffer (200 mM Tris-HCl, pH 8.8; 
100 mM NaCl; 20 mM EDTA; 0.2% NP-40) and incubated on ice for 10 min. After 
gentle homogenisation with a glass Douncer (10 times), cell lysates were centrifuged 
at 4000 g for 5 min at 4°C. The supernatants were collected and pellets were 
resuspended in 25 ml of 1X lysis buffer and the same steps were repeated. After 
centrifugation, the supernatants collected from the two lysis steps were pooled and 
loaded onto 4 ml 40% (w/v) and 3.5 ml 75% (w/v) sucrose discontinuous gradients in 
50 mM NaCl; 100 mM Tris-HCl, pH 8.8; 1 mM EDTA, pH 8.0; 0.02% NLS. Samples 
were centrifuged at 28,000 g at 16°C for 2 h. Each interface and pellet were carefully 
collected. A sample of each fraction was run on 10% SDS-PAGE to detect the 
presence of the four proteins VP2, VP5, VP7 and VP3. For further purification, the 
interfaces were diluted slowly 1 in 5 in 100 mM Tris-HCl, pH 8.8; 50 mM NaCl; 1 mM 
EDTA, pH 8.0; 0.02% NLS and loaded onto 3 ml 40% per 2 ml 70% (w/v) sucrose 
cushions prepared as before, then centrifuged at 28,000 g for 2 h at 16°C.  VLPs 
proteins were detected by 10% SDS-PAGE and coomassie brilliant blue staining. 
The samples were kept at 4°C for further work.   
2.1.14. Antibodies production 
 
To determine the total concentration of the EHDV-1 CLPs and VLPs proteins after 
purification, Bradford reagent (Sigma-Aldrich Ltd, UK) was used. A standard curve 
within the linear range was generated using a range of concentrations (1 to 5 µg/µl) 
of bovine serum albumin (BSA) protein. The protein concentration of the CLPs and 
VLPs samples was determined by comparison to that of a series of the BSA 
standard protein which was measured by NanoDrop®ND-1000 Spectophotometer 
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(NanoDrop Techlonogies, Inc, USA). For antibody production, 2.5 mg/ml of the 
EHDV-1 CLP proteins resuspended in 10 mM Tris-HCl, pH8.0 and 2.0 mg/ml of 
EHDV-1 VLPs were used to inoculate Rabbits by a commercial company 
(ThermoFisher Scientific, Pierce antibodies).  
Additionally, polyclonal antibodies against VP2 protein of EHDV-1 and EHDV-2 were 
raised in Guinea pigs by ThermoFisher Scientific. In brief, after separating the above 
proteins by electrophoresis on 10% SDS-PAGE, the gels were washed twice with 
autoclaved pre-chilled 1X PBS and then soaked with the pre-cold 250 mM KCl and 
incubated at 4°C until white bands of the specific protein were visualised. A total of 1 
mg of the detected proteins (based on BSA concentration) were excised from gel 
and incubated in 10 mM Tris-HCl, pH 8.0 supplemented with protease inhibitors and 
kept at - 20°C. The specificity of each antibody was analysed by western blotting. 
2.1.15. Electron Microscopy 
Aliquots (2 µl) of purified CLPs and VLPs were adsorbed onto copper 400-mesh 
Formvar carbon-coated grids (TAAB Laboratories Equipment Ltd, UK) for 2 min. 
After washing twice with 10 mM Tris-HCl, pH 8.0 (for CLPs) and 10 mM Tris-HCl pH 
8.8 (for VLPs) 30 seconds apart, the particles were stained with filtered 2% (w/v) 
phosphotungstic acid (PTA), pH 6.8. After blotting the stain, the grids were air-dried 
for 25 min and examined under JEOL 1200 EX transmission microscope. 
2.1.16. Neutralisation assay 
 
The antibodies raised against purified EHDV-1 VLPs were assayed for their 
neutralising activity against EHDV-1 virus. In addition, cross neutralising reactivities 
were tested against EHDV-2 and EHDV-6. In brief, 96 well plates were seeded with 
5 x 103 BSR cells/well and incubated overnight at 37°C with 5% CO2. The serum was 
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heat inactivated at 42°C for 20 min prior to use and two-fold serial dilution in 
Dulbecco Modified Essential Medium (DMEM) (Sigma-Aldrich Ltd, UK), was 
prepared in a total volume of 100 µl in triplicate. The amount of EHDV-1 virus was 
calculated as being equivalent to the tissue culture infectious dose 50 (TCID50) in 
100 µl per well. At the containment lab, the virus and the serum were added to the 
cells and incubated at 35°C in 5% CO2 for 3-4 days. For fixing, 50 µl of 10% (w/v) 
formaldehyde in PBS were added to each well and incubated for at least 3 h at room 
temperature. For visualisation, 200 µl of crystal violet staining were used, incubated 
for 5 min and washed with water. After drying, plates were observed for signs of 
neutralisation. The neutralisation activity was calculated as the higher dilution of sera 
that was able to inhibit virus replication. All dilutions were performed in triplicate and 
the assay was repeated at least three times.  
2.2. Reverse Genetics (RG) system 
2.2.1. Mammalian cell line 
BSR cells, a clone derived from the Baby Hamster Kidney cells (BHK) (Sato et al., 
1977) were used for virus propagation, titration and transfection with single-stranded 
(ssRNA) derived from cores or T7 clones. BSR cells were grown in DMEM 
supplemented with 5% FCS in the presence of 50U/ml antibiotic/antimycotic and L-
glutamine (Sigma-Aldrich Ltd, UK). The cells were grown as monolayers in vented 
tissue culture flasks at 37°C in the presence of 5% CO2. The sub-culturing of BSR 
cells was carried out by disrupting the monolayer by trypsinisation using trypsin-
EDTA solution diluted in PBS (Sigma-Aldrich Ltd, UK). 
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2.2.2. EHDV purification, propagation and titration  
The EHDV isolates used in all experiments were from cell culture adapted strains 
belonging to serotype 1 (New Jersey), serotype -2 (Alberta, CANADA), serotype 6 
(The Reunion Island, France) and serotype 7 (strain CSIRO 775). Virus purification, 
titration and recovery were performed in a P3 level containment laboratory using the 
safety procedures of Category III level (CATIII-DEFRA). For the isolation of individual 
virus plaques and titration, plaque assay was performed. In brief, 6 well plates were 
seeded with BSR cells to 80-90% confluency in DMEM supplemented with 5% FCS. 
EHDV stocks were ten-fold serially diluted in serum-free DMEM and 200 µl of each 
dilution was added to the cells after washing them twice with FCS-free DMEM 
medium and incubated at 35°C for 1 h. Following incubation, the inoculum was 
removed and 2 ml of 1.5% (w/v) molten low melting point agarose diluted in 1X 
DMEM supplemented with 2% FCS was added to the cells. The overlay was allowed 
to set for 5-10 min at room temperature and plates were incubated at 35°C for 2-3 
days until plaques were visible.  
To isolate individual virus clones, cells were stained with a solution of 2% (v/v) 
neutral red diluted in PBS incubated at 35°C for 4-5 h. Subsequently, single plaques 
were picked and amplified in BSR monolayers for the generation of virus stocks. For 
virus titration, plaque assays were fixed with 10% (w/v) formaldehyde in PBS for at 
least 4 h at room temperature. The agarose overlay was removed carefully and the 
monolayer cells were stained with 400 µl of 0.2% (w/v) crystal violet in 20% (v/v) 
ethanol for 3 min. The excess stain was washed away with ultra-pure deionised 
water and the plates were allowed to dry. The titre of EHDV virus was calculated as 
pfu/ml after counting the formed plaques.  
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2.2.3. Purification of dsRNAs from EHDV-2 infected BSR cells  
BSR cells were grown to 80% confluency in a 175 cm2 flask. Prior to infection, cells 
were washed twice with FCS-free DMEM medium and EHDV-2 at an MOI of 1.0 was 
added to the monolayer. The virus was allowed to absorb for 1 h at 35°C and 13 ml 
DMEM supplemented with 2% FCS were added. The infected BSR cells were 
incubated at 35°C until complete CPE was detected. Consequently, the infected 
culture and cells were harvested and transferred to a 15 ml sterile centrifuge tube. 
To clarify the sample, the culture was centrifugated at 2,500 g for 5 min at 4°C. The 
pellet was lysed in 10 ml Tri reagent (Sigma-Aldrich Ltd, UK) and incubated at room 
temperature for 30 min to 1 h. After incubation, the sample was safely removed from 
the containment lab and proteins were removed by the addition of 1 ml chloroform 
(Sigma-Aldrich Ltd, UK) mixed by vortex and centrifugated. The upper phase was 
collected and the RNA were precipitated by the addition of an equal amount of 
isopropanol followed by centrifugation at 6,000 g for 15 min at 4°C. The supernatant 
was discarded and the pellet was washed twice with 70% ethanol, air dried and 
resuspended in 400 µl of Diethylpyrocarbonate (DEPC) treated water. To specifically 
precipitate ssRNAs, 135 µl of 8 M LiCl (Sigma-Aldrich Ltd, UK) was added, mixed by 
inversion and incubated at 4°C overnight. The dsRNA was separated from ssRNA by 
centrifugation at 9,000 g for 20 min at 4°C. The supernatant was carefully collected, 
as it had the dsRNA, and was further precipitated by isopropanol as described. After 
centrifugation, the pellet was resuspended in 30 µl DEPC-treated water and the 
pattern of the segmented dsRNA as well as its concentration was determined by 
electrophoresis on 8% non-denaturing polyacrylamide gel.   
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2.2.4. Reverse transcription-PCR (RT-PCR) 
 
 
The cDNA copies of the 10 genome segments of EHDV-2 were amplified from 
dsRNA extracted and purified from infected BSR cells using the method of full-length 
amplification of cDNA (FLAC) in a sequence independent manner. A modified 35-
mer oligonucleotide ‘anchor primer’ (Maan et al., 2007) has a modification consisting 
in a C9 (phosphoramidite) spacer between a self-annealing sequence and 
phosphorylated 5' (Table 12) (Eurogenetic). The C9 primer was ligated into the 
unfractionated viral dsRNA in a total volume of 20 µl as follows: dsRNA (5 µg); C9 
primer (10 µg/µl); 10X T4 RNA Ligase Buffer (2 µl) (Fermantas); 10X BSA (2 µl); 10 
mM ATP (2 µl) and T4 RNA ligase enzyme (0.5 µl) (New England Bio Labs) and 
incubated at 4°C overnight.  
After ligation, the dsRNAs were separated on 1% agarose gel electrophoresis to 
excise the 10 segments of dsRNA genome. This step was performed to remove the 
excess C9 primer prior to DNA synthesis in order to prevent any mispriming by the 
free primer molecule. The ligated dsRNA was purified using Invitrogen PureLinkTM 
HiPure DNA Purification Kit (InvitrogenTM, UK) and precipitated in 0.3 M NaOAc and 
50% Isopropanol. After centrifugation, the RNA pellet was air dried and resuspended 
in 10 µl nfH2O.  
The synthesis cDNA from gel-purified genome segments was performed using 10U 
of RevertAid Premium Reverse transcriptase enzyme (Thermo Scientific) at 55°C for 
1.5 h in the presence of 1X RT buffer (Thermo Scientific), RNase inhibitors (RNasin 
Plus) (0.5U/µl) and 10 mM dNTPs. The cDNA was then used directly for PCR 
amplification using 10 µM of 5' phosphorylated FLAC2 primer (Table 12); 10 mM 
dNTPs; 1X Kapa buffer and Kapa DNA polymerase (1U/µl) (KAPA Biosystems). The 
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PCR amplification was detected on 0.8% agarose gel electrophoresis and the 
product was purified for further experiments.  
2.2.5. Construction of cDNA T7 plasmid clones 
Initially, to construct cDNA T7 plasmid clones for the 10 segments of EHDV-2 
genome to use as templates for ssRNAs generation, sequence analysis of each 
segment was carried out by Source BioScience, UK. Briefly, amplification products of 
the full length segments were ligated into a SmaI linearised and dephosphorylated 
pUC19 vector.  The ligation reactions were transformed into DH5α competent cells 
and colony PCR with FLAC2 primer was performed to detect the presence of each 
segment in the ampicillin resistant clones. The complete sequence of the 10 
segments was obtained using M13 (Table 12) and internal primers specific to each 
one (Table 13) and the results were compared with the exact gene sequence 
(GenBank accession numbers Table 8). Base on the data obtained from sequencing, 
primers with T7 promoter and specific restriction enzyme site were designed to 
amplify the full length of EHDV-2 10 segments (Table 18). After ligation, the 
presence of the inserts in the constructs was analysed by PCR using specific 
primers and by digestion with the exact enzyme inserted downstream each segment 
(Table 18). The results were visualised on 1% agarose gel electrophoresis.  
Table 18.  
EHDV-2 T7 primers used for cloning the 10 genome segments into pUC19. 
EHDV-2 T7 primers 
T7-S1 (F)a TAATACGACTCACTATAGTTAAAATGCAATGGTCGCAATTA 
T7 polymerase 
Conserved 
region 
BsmBI-S1 (R)b CGTCTCTGTAAGTATAATGCGGGT 
BsmBI  
Extra nucleotide 
T7-S2 (F)a TAATACGACTCACTATAGTTAAATTGTCCCCAGAATGGAGGA 
T7 polymerase 
Conserved 
region 
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BsaI-S2 (R)b  GGTCTCTGTAAGTTTGTTGTTCCCAGTA 
BsaI 
Extra nucleotide 
T7-S3 (F)a TAATACGACTCACTATAGTTAAATTTCCGGAGCGATGGCA 
T7 polymerase 
Conserved 
region 
BsaI-S3 (R)b GGTCTCTGTAAGTGTATTCCCGGT 
BsaI 
Extra nucleotide 
T7-S4 (F)a TAATACGACTCACTATAGTTAAAACATGCCGGAGCCACAT 
T7 polymerase 
Conserved 
region 
BsaAI-S4 (R)b TACGTAGTAAGTGTAACACGCA 
BsaAI  
Extra nucleotide 
T7-S5 (F)a TAATACGACTCACTATAGTTAAAAAGTTCTTCGTCGAC 
T7 polymerase 
Conserved 
region 
BsaI-S5 (R)b GGTCTCTGTAAGTGTAAAGTTCGAA 
BsaI 
Extra nucleotide 
T7-S6 (F)a 
TAATACGACTCACTATAGTTAAAAAGGAGGCACGTTCTTGCAT
C 
T7 polymerase 
Conserved 
region 
BbsI-S6 (R)b GAAGACTTGTAAGTGTAAGGAGTT 
BbsI 
Extra nucleotide 
T7-S7 (F)a TAATACGACTCACTATAGTTAAAATTTGGTGAAGATTGA 
T7 polymerase 
Conserved 
region 
BsaI-S7 (R)b GGTCTCTGTAAGTTGAATTTGGGAAGA 
BsaI 
Extra nucleotide 
T7-S8 (F)a TAATACGACTCACTATAGTTAAAAATTCCTTGTGCAAT 
T7 polymerase 
Conserved 
region 
BsmBI-S7 (R)b CGTCTCTGTAAGTGTAAATCCCTT 
BsmBI  
Extra nucleotide 
T7-S9 (F)a TAATACGACTCACTATAGTTAAAAATTGCGCATGTCAGCT 
T7 polymerase 
Conserved 
region 
BbsI-S9 (R)b GAAGACTTGTTAAATTAAATTGCGCGCGT 
BbsI 
Extra nucleotide 
T7-S10 (F)a TAATACGACTCACTATAGTTAAAAAGAGGTTGGCATCATGCT 
T7 polymerase 
Conserved 
region 
BbsI-S10 (R)b GAAGACTTGTAAGTGTGTCGAGGAT 
BbsI 
Extra nucleotide 
(F)a: Forward 
(R)b: Reverse 
 
 
 
 
2.2.6. Synthesis of EHDV-2 transcripts from cDNA plasmid clones 
The T7 plasmid templates for in vitro transcription were generated for the 10 
segments of EHDV-2 genome (as mentioned in the construction of cDNA plasmid 
clones) by digestion with a specific enzyme (Table 18). The complete linearisation of 
each recombinant plasmid was confirmed by 1% agarose gel electrophoresis 
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followed by precipitation with isopropanol in the presence of 0.15 M NaOAc. DNA 
pellets were washed twice with 70% (v/v) ethanol and dissolved in 10 mM Tris-HCl, 
pH 8.0. In order to produce capped ssRNA T7 transcripts, mMESSAGE mMACHINE 
T7 Ultra Kit (Ambion) was used. In brief, the transcription reactions were assembled 
at room temperature in the following order: T7 2X NTP/ARCA (5 µl); 10X T7 reaction 
buffer (1 µl); T7 linear DNA template (1 µg); T7 enzyme mix (1 µl) and RNasin Plus 
(0.25 µl). The reactions were mixed thoroughly, incubated at 37°C for 2 h followed by 
the addition of 1 µl of TURBO DNase to remove the DNA template and further 
incubated at 37°C for 15 min. The complete set of T7 EHDV-2 10 transcripts were 
extracted once with phenol-chloroform, followed by one extraction with chloroform. 
Microspin G-25 columns (GE Healthcare) were used to remove unincorporated 
ribonucleoside triphosphate by size fractionation according to the manufacturer’s 
instructions. The T7 transcripts were precipitated by adding equal volume of 
isopropanol, 0.5 µl glycogen and 0.3 M NaOAc and incubated at 4°C overnight. The 
ssRNA pellets were washed twice with 70% (v/v) ethanol and dissolved in 10 µl 
sterile DEPC treated water and stored at -80°C to be used in further experiments.  
2.2.7. Denaturing agarose gel electrophoresis 
 
The purified EHDV-2 ssRNAs were analysed by electrophoresis on 1% denaturing 
agarose in morpholinepropanesulfonic acid (MOPS) buffer in the presence of 6.3% 
formaldehyde according to the standard methods (Sambrook and Russell, 2001). 
Briefly, 5 µl of the 2X RNA loading buffer (Thermo Scientific) was mixed with 0.5 µl 
aliquots of ssRNAs and heated at 72°C for 2 min. The ssRNA samples were 
immediately loaded on agarose gel and run for 30 min at 100 V. As ladder, 1 µg of 
the RNA marker (Thermo Scientific) was included.  
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2.2.8. Purification of EHDV-2 virus cores 
In order to purify EHDV-2 cores, 6 x 175 cm2 flasks were seeded with BSR cells in 
25 ml DMEM supplemented with 5% FCS and incubated at 37°C, 5% CO2 until 75% 
confluency. The cells were infected with EHDV-2 at an MOI of 1.0 in a total volume 
of 5 ml serum-free media and incubated at room temperature for 1 h. After 
incubation, 20 ml of DMEM with 5% FCS were added and cells incubated at 35°C, 
5% CO2 until 100% CPE was observed. The transcriptionally active cores of EHDV-
2 were purified according to the modified methods of Mertens et al (Mertens et al., 
1987) and Van Dijk and Huismans (Van Dijk and Huismans, 1980). Briefly, the 
medium culture and infected cells were harvested and centrifuged at 2,500 g for 10 
min. The pelleted cells were lysed in a 30 ml pre-chilled lysis buffer (100 mM Tris-
HCl, pH 8.8; 50 mM NaCl; 10 mM EDTA; 0.1% NP-40) at 4°C for 10 min followed by 
centrifugation at 2,500 g for 5 min at 4°C to pellet the nuclei and intact cells. The 
supernatant was kept and the pellet was lysed as above using 25 ml of the lysis 
buffer. To remove the outer capsid proteins VP2 and VP5, the supernatants were 
pooled and α-Chymotrypsin was added to 60 µg/ml, and the samples were incubated 
at 35°C for 1 h. The sample was then made 0.2% (w/v) for N-lauroyl sarcosine 
(sodium sault, NLS) and incubated at room temperature for 1 h. Samples were 
loaded onto a sucrose cushion consisting of 40% (w/v) sucrose; 0.6 M MgCl2; 20 mM 
Tris-HCl, pH 8.0 and ultracentrifugation was carried out in SW28 rotor (BeckMan), at 
28,000 g at 20°C for 2 h. Subsequently, the pellet was gently resuspended in 200 µl 
20 mM Tris-HCl, pH 8.0; 0.5% NP-40 and incubated at 4°C overnight. A second 
ultracentrifugation spin was performed through a sucrose cushion consisting of 40% 
(w/v) sucrose; 20 mM Tris-HCl, pH 8.0 at 28,000 g and 20°C for 2 h. After spinning, 
the pellet was resuspended with 200 µl 20 mM Tris-HCl, pH 8.0 and stored at 4°C. 
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An aliquot of 10 µl of the purified cores were inactivated with 1X protein loading 
buffer and load on 10% SDS-PAGE.  
2.2.9. In vitro synthesis and purification of core derived EHDV-2 mRNA  
In order to establish the infectivity of core transcripts and with the final goal of 
developing a reverse genetics system for EHDV, full length authentic mRNAs 
derived from purified core were prepared. In brief, purified core particles were mixed 
at 40 µg/ml in transcription mix containing 100 mM Tris-HCl, pH 8.0; 4 mM ATP; 2 
mM GTP; 2 mM CTP; 2 mM UTP; 0.5 mM S-adenosylmethionine (SAM); 6 mM 
dithiothreitol (DTT); 9 mM MgCl2; 0.5U/µl RNAsin Plus (Promega) and 0.6 mM 
MnCl2. The transcription mixture was then incubated at 30°C for 5 h. For the 
purification of EHDV-2 core-derived mRNAs, a standard method described by Boyce 
and Roy was performed (Boyce and Roy, 2007). Briefly, cores were removed by 
performing ultracentrifugation in TLS-55 rotor at 45,000 g for 25 min at 4°C twice. 
The supernatant was collected carefully to avoid contamination with the pelleted 
cores. The supernatant from the second ultracentrifugation was made 2 M LiCl, 
using 8 M LiCl stock (Sigma), and incubated overnight at 4°C to precipitate the 
ssRNA. Subsequently, the samples were centrifuged at 15,000 g at 4°C for 20 min. 
The pellet was then resuspended in 200 µl Proteinase K (10 µg/ml in OptiMEM I 
[Invitrogen]) and incubated at 35°C for 30 min. After incubation, the samples were 
deproteinised by extraction with phenol-chloroform twice, treated with 0.1% SDS 
(w/v) and re-extracted with chloroform twice. The upper phase was collected and 
analysed by denaturing agarose gel electrophoresis as described in denaturing 
agarose gel electrophoresis.  
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2.2.10. Recovery of infectious EHDV-2 by transfection of BSR cells with the     
  core-derived or the complete set of synthetic T7 transcripts 
 
For the recovery of the infectious virus EHDV-2 from the ssRNAs, derived either 
from transcribing cores or from the T7 transcripts of the 10 segments, cell cultures 
were transfected as per protocol described by Boyce et al (Boyce and Roy, 2007). A 
total of 1.0-1.5 µg of the transcripts were mixed in Opti-MEM® I media in the 
presence of 0.1U/µl RNasin® Plus (Promega). The RNA mixture was incubated at 
room temperature for 30 min followed by incubation at 4°C for 10 min. The 
transfection reagent Lipofectamine 2000 (Invitrogen) was prepared according to the 
manufacturer’s instructions (2.5 µl Lipofectamine 2000/1 µg ssRNA) in Opti-MEM® I 
supplemented with 0.1U/µl RNasin® Plus, and incubated at room temperature for 10 
min. After incubation, the appropriate amount of transfection reagent was added to 
the ssRNAs mixture and the reactions were incubated at room temperature for 20 
min.  
Confluent BSR monolayers in 6- or 12- well plates were washed once with serum-
free DMEM and the transfection mixture was added directly on the top of the cells. 
Plates were incubated at 35°C for 5 h and 1.5 ml DMEM supplemented with 5% FCS 
was added and incubated overnight at 35°C. As it has been shown that a second 
transfection increases the yield of virus recovery (Matsuo and Roy, 2009), 18 h post 
first transfection, a second transfection was performed using the same conditions 
mentioned above. At 5 hours post transfection (hpt), the culture medium was 
replaced with a 1 or 2 ml overlay consisting of DMEM, 2% FCS and 1.5% (w/v) 4% 
agarose low melting point (Sigma-Aldrich Ltd, UK). Recovery experiments were 
incubated at 35°C in 5% CO2 for 72 h to allow plaques to appear. Subsequently, 
individual plaques were isolated, amplified and dsRNAs were extracted and purified 
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to detect the pattern of the segmented genome from the recovered infectious virus in 
comparison to that of those obtained from infected BSR cells. The results were 
visualised by electrophoresis on 1% agarose gel.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
90 
 
Chapter 3 
Expression of the outer capsid proteins of 
EHDV serotypes 
 
3.1.  INTRODUCTION ………………………………………………………….. 91 
3.2.  RESULTS ………………………………………………………………….. 92 
3.2.1.  Cloning and expression of EHDV-1 structural proteins …………... 92 
3.2.1.1.  Cloning of EHDV-1 S2 into pAcYM1 …………………………………..... 92 
3.2.1.2.  Expression of EHDV-1 VP2 recombinant protein in baculovirus 
expression system ……………………………………………………….... 
 
94 
3.2.1.3.  Cloning of EHDV-1 S5 into pAcYM1 …………………………………..... 97 
3.2.1.4.  Expression of EHDV-1 VP5 recombinant protein in baculovirus 
expression system ……………………………………………………….... 
 
99 
3.2.1.5.  Cloning of EHDV-1 S7 into pAcYM1 …………………………………..... 100 
3.2.1.6.  Expression of EHDV-1 VP7 recombinant protein in baculovirus 
expression system ……………………………………………………….... 
 
102 
3.2.1.7.  Expression of EHDV-1 VP3 recombinant protein in baculovirus 
expression system ……………………………………………………….... 
 
103 
3.2.2.  Cloning and expression of EHDV-2 outer capsid proteins ……..... 104 
3.2.2.1.  Cloning of EHDV-2 S2 and EHDV-2 S5 into pAcYM1 ……………….... 104 
3.2.2.2.  Single expression of EHDV-2 VP2 and EHDV-2 VP5 recombinant 
proteins in baculovirus expression system ……………………………... 
 
107 
3.2.3.  Antibodies development for EHDV-1 VP2 and EHDV-2 VP2 
recombinant proteins ………………………………………………….... 
 
109 
3.2.4.  Isolation of EHDV-7 outer capsid proteins ………………………….. 109 
3.2.4.1.  Cloning of EHDV-7 S2 into pAcYM1 …………………………………..... 111 
3.2.4.2.  Expression of EHDV-7 VP2 recombinant protein in baculovirus 
expression system ……………………………………………………….... 
 
112 
3.3.  DISCUSSION …………………………………………………………….... 114 
 
 
 
91 
 
3.1. INTRODUCTION 
In recent years, a dramatic increase in EHDV associated morbidity and mortality in 
animal farms, particularly in cattle, was recognised. The geographical distribution of 
these outbreaks was also increasing due to the emergent of more virulent serotypes 
to domestic ruminants (Yadin et al., 2008, Temizel et al., 2009, Breard et al., 2004, 
Anthony et al., 2009). Several studies have shown that among the most effective 
strategies to overcome the viral infection and prevention of spreading, vaccines have 
been shown to be the optimal solution.  
To date, no vaccine against EHDV is commercially available, apart from the live 
attenuated vaccine for EHDV-2 (IBAV) (Omori et al., 1969). Therefore, developing 
EHDV-1 VLPs, and heterologous VLPs of EHDV-2 and EHDV-7 using EHDV-1 CLP 
proteins as background, were the main aims of this study. This was based on the 
use of baculovirus expression system that offers advantage of expression of several 
large proteins simultaneously, by a single recombinant virus.  
In this study, prior to utilising the advanced baculovirus multiple genes expression 
system, individual expression of the outer and inner capsid proteins of EHDV-1 VP2, 
VP3, VP5 and VP7, EHDV-2 VP2 and VP5 and EHDV-7 VP2 were assessed. The 
transfer replicon, pAcYM1, which has the polyh promoter of AcMNPV, was used for 
this purpose. This was based on previous reports that demonstrated high expression 
level of the targeted genes from recombinant baculoviruses using pAcYM1 
(Matsuura et al., 1987, Romanowski et al., 1985, Emery and Bishop, 1987, Urakawa 
and Roy, 1988). For the individual expression of EHDV-1, -2 and 7 recombinant 
structural proteins, insect cells derived from Sf21 and Sf9 were used.  
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3.2. RESULTS  
3.2.1. Cloning and expression of EHDV-1 structural proteins 
3.2.1.1. Cloning of  EHDV-1 S2 into pAcYM1 
The EHDV-1 S2 gene that encodes the outer capsid protein VP2 of EHDV-1 (New 
Jersey strain) was previously cloned into pUC4K vector. However, to subclone the 
S2 coding region, specific primers with BglII restriction sites (Table 7) were designed 
and utilised to amplify the open reading frame (ORF) of EHDV-1 S2 gene. To identify 
the efficiency of amplification, the PCR product was examined by 1% agarose gel 
electrophoresis (Fig. 13) showing an exact band of the correct size of EHDV-1 S2 
segment (2968 bps) (Fig. 13, lane 3). Moreover, no bands were detected in the 
negative control without DNA template (Fig. 13, lane 2).  
 
Fig. 13. PCR amplification of the coding region of EHDV-1 S2 segment. The PCR was 
visualised by gel electrophoresis on 1% agarose gel, stained with ethidium bromide. Lane 1: DNA 
ladder, lane 2: negative control and lane 3: EHDV-1 S2. 
 
The amplified ORF of EHDV-1 S2 gene was then ligated into a BamHI site of the 
linearised and dephosphorylated pAcYM1vector (Fig. 14B, lane 2). To produce the 
recombinant plasmid pAcYM1-EHDV1.S2 (Fig. 14A), the ligation reaction was 
transformed into the E.coli DH5α competent cells and plated onto LBA plates. 
Bacterial colonies were grown in LB media supplemented with ampicillin and the 
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plasmid DNA was extracted. The purified recombinant plasmid was digested with the 
endonuclease enzyme BglII (Fig. 14B, lanes 3-7), and positive clones would release 
a fragment of size ~ 2700 bps. This was visualised in clone #1 (Fig. 14B, lane 3) 
after electrophoresis on a 1% agarose gel as two DNA bands; one to the predicted 
size of the vector pAcYM1 (~9171 bps) and another with the same length of EHDV-1 
S2 (~2968 bps) gene, while other 4 colonies were negative (Fig. 14, lanes 4-7).   
 
Fig. 14. Molecular analysis of the presence of EHDV-1 S2 in the recombinant pAcYM1-
EHDV1.S2. (A) Restriction map of pAcYM1-EHDV1.S2 showing BglII sites. (B) BglII digestion of the 
recombinant pAcYM1-EHDV1.S2. Lane 1: DNA ladder, lane 2: pAcYM1-BamHI and lanes (3-7) 
pAcYM1-EHDV1.S2 clones digested with BglII # 1-5. Colony # 1 was positive (lane 3).  
 
For the synthesis of EHDV-1 VP2 structural protein, the encoding region should be 
integrated in a correct orientation to the polyh promoter in the recombinant pAcYM1-
EHDV1.S2. Thus, depending on the restriction map of pAcYM1-EHDV1.S2, EcoRV 
endonuclease enzyme was chosen as it had two restriction sites in the recombinant; 
one in pAcYM1 and another in EHDV-1 S2 (Fig. 15A). Consequently, a correct 
position of EHDV-1 S2 in the recombinant was visualised on an agarose gel as 
shown in Figure 15B (Fig. 15B, lane 2). Further confirmation was carried out by PCR 
amplification as an alternative molecular method using PH (F) primer from pAcYM1 
and the specific (R) primer for EHDV-1 S2. Post electrophoresis of the PCR product, 
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a single band to the size of EHDV-1 S2 gene was observed (Fig. 15C, lane 3). An 
amplification reaction was undertaken without DNA template as a negative control 
revealing no fragments on the 1% agarose gel as shown in Figure 12C (Fig. 15C, 
lane 2).  
 
Fig. 15. Determining the orientation of EHDV-1 S2 in the recombinant pAcYM1-EHDV1.S2. (A) 
Restriction map with EcoRV sites. (B) EcoRV digestion of pAcYM1-EHDV1.S2. Lane 1: DNA ladder 
and lane 2: pAcYM1-EHDV1.S2 (clone # 1). (C)  PCR with PH (F) and EHDV-1 S2 (R) primers. Lane 
1: DNA ladder, lane 2: negative control and lane 3: correct orientation of EHDV-1 S2 # 1 in the 
recombinant.  
 
3.2.1.2. Expression of EHDV-1 VP2 recombinant protein in baculovirus 
expression system  
 
Baculovirus BAC10:KO1629 was utilised for the synthesis of the outer capsid protein 
EHDV-1 VP2. Therefore, the parental viral DNA was digested with the endonuclease 
enzyme Bsu36I, then mixed with the recombinant plasmid pAcYM1-EHDV1.S2 in the 
presence of transfection reagent cellfectin® II. However, the digestion of 
Bac10:KO1629 resulted linear baculovirus DNA incapable of replication in insect cells. 
Accordingly, cotransfection of Sf21 insect monolayers with the linearised 
Bac10:KO1629 and the recombinant plasmid pAcYM1-EHDV1.S2 restored orf1629 
and recircularised the virus DNA by allelic replacement. After cotransfection, two 
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rounds of baculoviral amplification were undertaken; followed by plaque assay for 
the isolation of the recombinant clonal population. Plaques were visualised by 
staining Sf21 cells with 10% neutral red and three independent plaques were picked 
and amplified three times in Sf9 insect monolayers to increase the titre of the 
recombinant baculovirus expressing EHDV-1 VP2 protein (Fig. 16). 
 
Fig. 16. Plaque assay of the recombinant baculovirus expressing EHDV-1 VP2 in Sf21 insect 
cells stained with 10% neutral red.  
 
The synthesis of the recombinant protein EHDV-1 VP2 was analysed by 10% SDS-
PAGE followed by coomassie blue staining, which showed high level of expression 
(Fig. 17A, lane 4). To analyse the antigenic properties of EHDV-1 VP2, the proteins 
were separated by 10% SDS-PAGE, transferred onto a nitrocellulose membrane and 
incubated with EHDV-1 polyclonal primary antibody raised in Rabbits, followed by 
the specific secondary antibody. Protein band was visualised after colour 
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development displaying a specific band with the correct size of EHDV-1 VP2 (112 
kDa) as shown in figure 17B, lane 4 (Fig. 17B, lane 4). 
 
 
Fig. 17. Analysis of the recombinant EHDV-1 VP2 protein expression from clonal populations. 
(A) 10% SDS-PAGE analysis. Lane 1: protein ladder, lane 2: Sf9 insect cells, lane 3: Sf9 insect cells 
infected with the recombinant AcMNPV pRN43-GFP and lane 4: lysate from cells infected with 
recombinant baculovirus expressing EHDV-1 VP2 (black arrow). (B) Western blotting using EHDV-1 
polyclonal antibody. Lane 1: protein ladder, lane 2: Sf9 insect cells, lane 3: Sf9 insect cells infected 
with the recombinant AcMNPV pRN43-GFP and lane 4: lysate from cells infected with recombinant 
baculovirus expressing EHDV-1 VP2 (black arrow). 
 
 
As a positive control of the recombination efficiency, Sf21 insect cells were 
cotransfected with the linearised Bac10:KO1629 and the plasmid construct pRN43-
GFP. The expression of the recombination GFP protein was confirmed by 
visualisation under the light (Fig. 18A) and fluorescence (Fig. 18B) microscopy at 24, 
48 and 72 hpt. 
97 
 
 
Fig. 18. GFP produced from insect cells transfected with recombinant AcMNPV pRN43-GFP. 
(A) GFP of transfected cells under a light microscopy at 24, 48 and 72 hpi. (B) The transfection of 
pRN43-GFP recombination under fluorescence microscopy at 24, 48 and 72 hpi, (100X amplification).   
 
3.2.1.3. Cloning of EHDV-1 S5 into pAcYM1 
To clone EHDV-1 S5 into pAcYM1, the coding sequences of S5 gene was amplified 
from pUC19-EHDV1.S5 (available in the lab) using specific sense and antisense  
primers for EHDV-1 S5 (Table 7). The PCR amplicon of the EHDV-1 S5 was 
identified after gel electrophoresis displaying an exact band of the expected size of 
EHDV-1 S5 (1640 bps) (Fig. 19, lane 3), whilst a negative control in lane 2 yielded 
no band (Fig. 19, lane 2). 
 
Fig. 19. PCR amplification of the coding region of EHDV-1 S5. The PCR product was visualised 
by gel electrophoresis on a 1% agarose gel, stained with ethidium bromide. Lane 1: DNA ladder, lane 
2: negative control and lane 3: EHDV-1 S5. 
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The PCR amplicon of EHDV-1 S5 was excised from agarose gel and cloned into 
BamHI site of the linearised and dephosphorylated pAcYM1 vector. E.coli DH5α 
competent cells were transformed with the ligation reaction mixture. A total of 4 
ampicillin resistance colonies were screened by digestion with BamHI to detect the 
presence of EHDV-1 S5 in the pAcYM1-EHDV1.S5 construct (Fig. 20B). The 
restriction digestion products were observed by agarose gel electrophoresis. Each of 
the four selected colonies had the insert of size corresponding to EHDV-1 S5 (1640 
bps) (Fig. 20B, lanes 2-5).  
To determine the orientation of EHDV-1 S5 in the recombinant pAcYM1-EHDV1.S5, 
the plasmid DNAs were extracted and purified from positive clones, followed by 
double restriction digestion with XmaI and XhoI (Fig. 20C). Based on the restriction 
analysis of the recombinant pAcYM1-EHDV1.S5 sequence, XhoI site was presented 
in pAcYM1 at 1900 bps and XmaI at 295 bps within the EHDV-1 S5 insert. The 
correct position of the targeted gene in pAcYM1-EHDV1.S5 was identified by gel 
electrophoresis for clone # 5 (Fig. 20D, lane 5) that produced the two predicted 
bands of 8354 bps and 2474 bps sizes. Whereas, the integration of the insert in the 
other three clones was in the wrong orientation, as seen in lanes 2, 3 and 4 of figure 
21D (Fig. 20D, lanes 2-4).  
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Fig. 20. Molecular analysis to detect the presence and the orientation of EHDV-1 S5 in the 
recombinant pAcYM1-EHDV1.S5. (A) Restriction map of pAcYM1-EHDV1.S5 showing BamHI sites. 
(B)  BamHI digestion of the construct pAcYM1-EHDV1.S5. Lane 1: DNA ladder, lanes 2-5: pAcYM1-
EHDV1.S5 and lane 6: pAcYM1 (BamHI). Colonies # 2, 3, 4 and 5 are positive. (C) Restriction map of 
pAcYM1-EHDV1.S5 with XmaI and XhoI sites. (D) Digestion of pAcYM1-EHDV1.S5 with XmaI and 
XhoI. Lane 1: DNA ladder, lanes 2-5: pAcYM1-EHDV1.S5. Clone # 5 is in correct orientation.  
 
 
 
3.2.1.4. Expression of EHDV-1 VP5 recombinant protein in baculovirus 
expression system  
 
A recombinant baculovirus was generated by the cotransfection of Sf21 insect cells 
with the circular recombinant pAcYM1-EHDV1.S5 and the Bsu36I linearised 
BAC10:KO1629. After the amplification of specific clones, the synthesis of 
recombinant EHDV-1 VP5 protein was analysed by 10% SDS-PAGE, stained with 
coomassie blue (Fig. 21A, lane 4) and also detected by immunoblotting. A band 
similar to the correct size of EHDV-1 VP5 protein was detected on a nitrocellulose 
membrane utilizing EHDV-1 polyclonal antibody (Fig. 21B, lane 4). 
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Fig. 21. Analysis of expression of recombinant EHDV-1 VP5 protein from clonal populations. 
(A) 10% SDS-PAGE analysis. Lane 1: protein ladder, lane 2: Sf9 insect cells, lane 3: Sf9 insect cells 
infected with recombinant AcMNPV pRN43-GFP and lane 4: lysate from cells infected with 
recombinant baculovirus expressing EHDV-1 VP5 (Black arrow). (B) Western blotting using EHDV-1 
polyclonal antibody. Lane 1: protein ladder, lane 2: Sf9 insect cells, lane 3: Sf9 insect cells infected 
with recombinant AcMNPV pRN43-GFP and lane 4: lysate from cells infected with recombinant 
baculovirus expressing EHDV-1 VP5 (~59 kDa) (Black arrow). 
 
 
3.2.1.5. Cloning of EHDV-1 S7 into pAcYM1 
To clone EHDV-1 S7 into pAcYM1 transfer vector, the available plasmid construct 
pUC19-EHDV1.S7 containing the complete sequence of EHDV-1 S7 gene was used 
as a template. To amplify S7, the gene coding region was amplified by PCR using 
EHDV-1 S7 specific (F and R) primers (Table 7). The results of PCR amplification 
were examined by gel electrophoresis displaying a single band with the anticipated 
size of EHDV-1 S7 (1162 bps) (Fig. 22, lane 3). Similarly, an amplification reaction 
was performed with no template and run on 1% agarose gel electrophoresis as a 
negative control (Fig. 22, lane 2).  
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Fig. 22. PCR amplification of the coding region of EHDV-1 S7. The PCR product was visualised 
by gel electrophoresis on a 1% agarose gel, stained with ethidium bromide. Lane 1: DNA ladder, lane 
2: negative control and lane 3: EHDV-1 S7. 
 
The excised EHDV-1 S7 amplicon was ligated into pAcYM1 vector previously 
digested with BamHI enzyme and dephosphorylated. After the transformation of the 
ligation mixture into bacterial competent cells, clones with the positive integration of 
the insert were examined by BamHI restriction digestion (Fig. 23A). Positive plasmid 
containing the recombinant pAcYM1-EHDV1.S7 was visualised on agarose gel as 
two DNA fragments of the same size of pAcYM1 vector and EHDV-1 S7 gene (Fig. 
23B, lane 3). The orientation of the integrated gene in the recombinant plasmid was 
determined by PCR using PH (F) and EHDV-1 S7 (R) primers. The results were 
visualised by agarose gel electrophoresis and a single specific fragment up to the 
exact size of EHDV-1 S7 (1162 bps) was shown as in Figure 24, lane 2 (Fig. 24, lane 
2).  
102 
 
 
Fig. 23. Molecular analysis of the presence of EHDV-1 S7 in the construct pAcYM1-EHDV1.S7. 
(A)  Restriction map of pAcYM1-EHDV1.S7. (B) BamHI digestion of the recombinant pAcYM1- 
EHDV1.S7. Lane 1: DNA ladder, lane 2: pAcYM1-BamHI and lane 3: the recombinant pAcYM1-
EHDV1.S7.  
 
                                                               
Fig. 24. Molecular analysis to determine the orientation of EHDV-1 S7 in the recombinant 
pAcYM1-EHDV1.S7 by PCR with PH (F) and EHDV-1 S7 (R) primers. Lane 1: DNA ladder, lane 2: 
negative control and lane 3: EHDV-1 S7 in the construct pAcYM1-EHDV1.S7.  
 
 
 
3.2.1.6. Expression of EHDV-1 VP7 recombinant protein in baculovirus 
expression system  
 
For individual synthesis of the outer layer core protein EHDV-1 VP7 from baculoviral 
clone, Sf21 insect cells were cotransfected with pAcYM1-EHDV1.S7 and the linear 
BAC10:KO1629. After 3-4 days of incubation at 27°C, recombinant baculovirus 
BAC10:KO1629:EHDV1.VP7 was generated and three plaques were isolated and 
amplified. To examine the expression of EHDV-1 VP7 recombinant protein, the total 
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cell extract was analysed on a 10% SDS-PAGE, wherein high level of the 
recombinant protein synthesis was observed in lane 3 (Fig. 25A, lane 3). As a 
negative control, uninfected Sf9 insect cell lysates were used (Fig. 25A, lane 2) 
which showed no specific band corresponding to the size of EHDV-1 VP7. The 
AcMNPV pRN43-GFP recombinant was used as a positive control showing a protein 
band corresponding to the size of baculovirus envelope gp64 protein (Fig. 25A, lane 
4). Further confirmation was carried out by western blot using polyclonal antibody for 
EHDV-1. The results were visualised on a nitrocellulose membrane as a single band 
of size of 39 kDa correlating to the molecular weight of EHDV-1 VP7 (Fig. 25B, lane 
3). 
 
 
Fig. 25. Analysis of expression of recombinant EHDV-1 VP7 protein from clonal populations. 
(A) 10% SDS-PAGE analysis. Lane 1: protein ladder, lane 2: Sf9 insect cells, lane 3: lysate from cells 
infected with recombinant baculovirus expressing EHDV-1 VP7 (Black arrow) and lane 4: Sf9 cells 
insect infected with recombinant AcMNPV pRN43-GFP (B) Western blotting using EHDV-1 polyclonal 
antibody. Lane 1: protein ladder, lane 2: Sf9 insect cells, lane 3: lysate from cells infected with 
recombinant baculovirus expressing EHDV-1 VP7 (39 kDa) (Black arrow) and lane 4: Sf9 insect cells 
infected with recombinant AcMNPV pRN43-GFP.  
 
 
3.2.1.7. Expression of EHDV-1 VP3 recombinant protein in baculovirus 
expression system 
 
The recombinant pAcYM1-EHDV1.S3 plasmid was already available in the lab, thus 
the expression of the inner core protein VP3 was accomplished by cotransfection of 
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Sf21 insect cells with the linearised Bac10:KO1629 and the circular pAcYM1-
EHDV1.S3. After 3 rounds of amplification of the individual clonal population, EHDV-
1 VP3 expression was detected by both 10% SDS-PAGE gel, (Fig. 26A, lane 4) and 
western blot using polyclonal antibodies against EHDV-1 (Fig. 26B, lane 4). In both 
methods, two relatively close protein bands to the size of EHDV-1 VP3 recombinant 
were visualised. Additionally, no non-specific bands were detected in the negative 
and positive controls, corresponding to the size of EHDV-1 VP3 protein (Fig. 26A, 
lanes 2 and 3) (Fig. 26B, lanes 2 and 3).  
 
Fig. 26. Expression of recombinant EHDV-1 VP3 protein from clonal populations. (A) 10% 
SDS-PAGE analysis. Lane 1: protein ladder, lane 2: Sf9 insect cells, lane 3: Sf9 insect cells infected 
with recombinant AcMNPV pRN43-GFP and lane 4: lysate from cells infected with recombinant 
baculovirus expressing EHDV-1 VP3 (B) Western blotting using EHDV-1 polyclonal antibody. Lane 1: 
protein ladder, lane 2: Sf9 insect cells, lane 3: Sf9 insect cells infected with recombinant AcMNPV 
pRN43-GFP and lane 4: lysate from cells infected with recombinant baculovirus expressing EHDV-1 
VP3 (103 kDa) (Black arrows). 
 
3.2.2. Cloning and Expression of EHDV-2 outer capsid proteins 
3.2.2.1. Cloning of EHDV-2 S2 and S5 into pAcYM1 
 
The cDNAs of EHDV-2 S2 (3002 bps) and EHDV-2 S5 (1641 bps) provided from our 
collaborator’s, Dr. Richt, Kansas State University (KSU), were cloned into the pGEM-
T vector. Prior to subcloning the two genes into pAcYM1 transfer vector, both of S2 
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and S5 were sequenced to determine the absence of any unwarranted stop codons, 
insertions or deletions in the coding regions in comparison to the published 
sequence. Subsequently, to amplify the coding regions of EHDV-2 S2 and S5, the (F 
and R) primers were designed with SmaI and BamHI restriction sites, respectively 
(Table 7). To improve the efficiency of ligation, particularly for EHDV-2 S2, primers 
were phosphorylated by adding a phosphate group to the 5' end using T4 PNK 
enzyme. After amplification, the PCR product containing the coding regions of 
EHDV-2 S2 and S5 were visualised on 1% agarose gel electrophoresis as single 
specific bands of sizes of EHDV-2 S2 (Fig. 27A, lane 3) and EHDV-2 S5 (Fig 27B, 
lane 3). No amplification was observed with negative controls (Fig. 27A, lane 2) and 
(Fig. 27B, lane 2).  
 
Fig. 27. PCR amplification of the coding region of EHDV-2 S2 and S5. The PCR product was 
visualised on a 1% agarose gel electrophoresis, stained with ethidium bromide. (A) Lane 1: 
DNA ladder, lane 2: negative control and lane 3: EHDV-2 S2. (B) Lane 1: DNA ladder, lane 2: 
negative control and lane 3: EHDV-2 S5. 
 
 
  
The amplified genes were excised, purified from gel and ligated into pAcYM1 
transfer vector. The ligation reactions were then transformed into the competent cells 
DH5α and plated onto ampicillin plates. To detect the presence of the inserts EHDV-
2 S2 and S5 in the recombinants pAcYM1-EHDV2.S2 and pAcYM1-EHDV2.S5 
plasmids, colony PCR using specific primers for each gene was performed. In total, 
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four ampicillin resistance colonies of pAcYM1-EHDV2.S2 and three of pAcYM1-
EHDV2.S5 were picked and screened (Fig. 28, A and B). Accordingly, each of the 
selected colonies had the targeted genes EHDV-2 (S2 and S5) in the recombinants 
pAcYM1-EHDV2.S2 (Fig. 28A, lanes 4-7) and pAcYM1-EHDV2.S5 (Fig. 28B, lanes 
2-4), respectively.  
To detect the direction of EHDV-2 S2 in pAcYM1-EHDV2.S2, the recombinant 
plasmids were extracted, purified and digested with HindIII endonuclease enzyme. 
The HindIII enzyme has two restriction sites in the vector pAcYM1 at (5498 and 
4457) bps and one in the insert EHDV-2 S2 at 2935 bps (Fig. 29A). For correct 
orientation, three fragments of sizes 10,600 bps, 1041 bps and 471 bps were 
expected. This was the case for pAcYM1-EHDV2.S2 clone # 4 (Fig. 29B, lane 7).  
With respect to EHDV-2 S5, the orientation in the recombinant plasmid pAcYM1-
EHDV1.S5 was determined by PCR using PH (F) primer from pAcYM1 and EHDV-2 
S5 (R) primer (Fig. 30A). Defined DNA bands corresponding to the size of EHDV-1 
S5 in the positive control pGEM-T-EHDV2.S5 (Fig. 30B, lane 3) were visualised in 
the three recombinant clones (Fig. 30B, lanes 4-6), while no fragment was observed 
in the negative control (Fig. 30B, lane 2).  
 
 
Fig. 28. Analysis of the presence of EHDV-2 S2 and S5 in the recombinants pAcYM1-
EHDV2.S2 and pAcYM1-EHDV2.S5. (A) Colony PCR with EHDV-2 S2 (F&R) primers. Lane 1: DNA 
ladder, lane 2: negative control, lane 3: positive control (pGEMT-EHDV2.S2) and lanes (4-7) 
pAcYM1-EHDV2.S2 clones (All are positive). (B) Colony PCR with EHDV-2 S5 (F&R) primers. Lane 
1: DNA ladder, lanes (2-4) pAcYM1-EHDV2.S5 clones (All are positive), lane 5: negative control and 
lane 6: positive control (pGEMT-EHDV2.S5).  
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Fig. 29. Molecular analysis of the orientation of EHDV-2 S2 in the construct pAcYM1-
EHDV2.S2. (A) Restriction map of the construct pAcYM1-EHDV2.S2 with HindIII site. (B) HindIII 
digestion of the recombinant pAcYM1-EHDV2.S2. Lane 1: DNA ladder, lane 2: EHDV-2 S2, lane 3: 
pAcYM1 and lanes (4-6) negative orientation of EHDV-2 S2 in the recombinant and lane 7: correct 
orientation of EHDV-2 S2 in pAcYM1-EHDV2.S2. 
 
 
 
 
Fig. 30. Molecular analysis of the orientation of EHDV-2 S5 in the construct pAcYM1-
EHDV2.S5. (A) Analysis map of the construct pAcYM1-EHDV2.S2 showing PH (F) and EHDV-2 S5 
(R) primers. (B) Colony PCR of the recombinant pAcYM1-EHDV2.S5 with EHDV-2 S5 (R) and PH (F) 
primers. Lane 1: DNA ladder, lane 2: negative control, lane 3: pGEM-T-EHDV2.S5 positive control 
and lanes (3-6) pAcYM1-EHDV2.S5 recombinants (All are in correct orientation).  
 
 
3.2.2.2. Single expression of the EHDV-2 VP2 and VP5 recombinant proteins 
in baculovirus expression system 
 
 
To synthesise EHDV-2 VP2 and VP5 recombinant proteins, monolayers of Sf21 
insect cells were cotransfected with the circular recombinants pAcYM1-EHDV2.S2 or 
pAcYM1-EHDV1.S5 and the Bsu36I linearised BAC10:KO1629.  After the second 
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round of amplification, plaque assays were performed, stained with 10% neutral red 
and individual clones were isolated and amplified.  
The successful expression of both EHDV-2 VP2 and VP5 recombinants were 
analysed on 10% SDS-PAGE followed by coomassie blue staining. Protein bands 
with expected sizes of EHDV-2 VP2 (~ 114 kDa) (Fig. 31A, lane 4) and EHDV-2 VP5 
(~ 59 kDa) (Fig. 31B, lane 5) were observed equivalent to that of the positive controls 
EHDV-1 VP2 (Fig. 31A, lane 5) EHDV-1 VP5 (Fig. 31B, lane 4). The uninfected Sf9 
insect cells were used as a negative control (Fig. 31A and B, lane 2), and the 
recombinant baculovirus AcMNPV pRN43-GFP was used as a positive control of the 
cotransfection efficiency (Fig. 31A and B, lane 3).  
 
 
 
Fig. 31. 10% SDS-PAGE analysis of recombinant EHDV-2 VP2 and VP5 proteins from clonal 
populations. (A) Lane 1: protein ladder, lane 2: Sf9 insect cells, lane 3: Sf9 insect cells infected with 
recombinant AcMNPV pRN43-GFP, lane 4: lysate from cells infected with recombinant baculovirus 
expressing EHDV-2 VP2 (black arrow) and lane 5: lysate from cells infected with recombinant 
baculovirus expressing EHDV-1 VP2 (Positive control). (B) Lane 1: protein ladder, lane 2: Sf9 insect 
cells, lane 3: Sf9 insect cells infected with recombinant AcMNPV pRN43-GFP, lane 4: lysate from 
cells infected with recombinant baculovirus expressing EHDV-1 VP5 (Positive control) and lane 5: 
lysate from cells infected with recombinant baculovirus expressing EHDV-2 VP5 (black arrow).  
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3.2.3. Antibodies development against the recombinant protein VP2 of EHDV-1 
and EHDV-2  
 
 
Specific polyclonal antisera were commercially produced in Guinea Pigs for each of 
the recombinant proteins; EHDV-1 VP2 and EHDV-2 VP2. The specificity of each 
antibody was tested by blotting on a nitrocellulose membrane using the suitable 
secondary antibodies. Post colour development, a defined protein band 
corresponding to the size of EHDV-1 VP2 (~ 112 kDa) (Fig. 32A, lane 4) and EHDV-
2 VP2 (~ 114 kDa) (Fig. 32B, lane 4) were detected. Negative (Sf9 insect cells) and 
positive (AcMNPV pRN43-GFP) controls gave no bands with the antisera resulting in 
non-specific reactivities, as shown in (Fig. 32A, lanes 2 and 3) and (Fig. 32B, lanes 2 
and 3).  
 
Fig. 32. Immunoblotting analysis of specificity of the polyclonal antibodies for the 
recombinant VP2 of EHDV-1 and EHDV-2. (A) Lane 1: protein ladder, lane 2: Sf9 insect cells, lane 
3: Sf9 insect cells infected with recombinant AcMNPV pRN43-GFP and lane 4: lysate from cells 
infected with recombinant baculovirus expressing EHDV-1 VP2 (112 kDa) (Black arrow) (B) Lane 1: 
protein ladder, lane 2: Sf9 insect cells, lane 3: Sf9 insect cells infected with recombinant AcMNPV 
pRN43-GFP and lane 4: lysate from cells infected with recombinant baculovirus expressing EHDV-2 
VP2 (114 kDa) (Black arrow). 
 
 
3.2.4. Isolation of EHDV-7 outer capsid proteins  
Prior to isolate viral genomic RNAs for cloning purpose, EHDV-7 virus was cloned to 
ensure the purity of the virus that was obtained from a laboratory of a collaborator. 
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Therefore, in order to isolate individual clones of EHDV-7 (strain CSIRO 775), plaque 
assay was performed in confluent BSR monolayers.  After staining with 10% neutral 
red, five plaques were selected and the clonal populations were amplified. The virus 
cultures harvested from the infection with plaques # 1 and 2, were used to extract 
dsRNA. Following extraction, the dsRNA were purified as described in Materials and 
Methods, and analysed on 0.8% agarose gel electrophoresis in order to visualise the 
profile of the ten segments (Fig. 33, lanes 3 and 4). As a positive control, dsRNA of 
EHDV-2 previously purified were used. As in Figure 33, lane 2, different mobilities 
were seen for S2, S5, S6 and S10 (Fig. 33, lane 2).  
 
 
Fig. 33. Agarose gel electrophoresis analysis of the segmented EHDV-7 dsRNA genome on 
0.8% agarose gel electrophoresis. Lane 1: DNA ladder, lane 2: EHDV-2 dsRNA (control positive) 
and lanes 3 and 4: EHDV-7 dsRNA isolated from individual plaque (Lane 3: plaque # 1 and Lane 4: 
plaque # 2).  
 
 
To ligate EHDV-7 S2 (3002 bps) (Fig. 33, lane 4) (upper black arrow) into pAcYM1 
transfer vector, the dsRNA band was excised from gel and purified as described in 
Materials and Methods. For subsequent amplification of the coding region of S2 
gene, specific (F and R) primers with NruI endonuclease enzyme were designed 
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(Table 7). The EHDV-7 S2 amplification was detected by electrophoresis on 1% 
agarose gel; a single band of size of EHDV-7 S2 (3002 bps) was detected (Fig. 34A, 
lanes 3 and 4). The PCR reaction with no DNA template was used as negative 
control and gave no amplification (Fig. 34A, lane 2).  
To generate a baculovirus multiple gene expression vector containing EHDV-7 
genes, EHDV-7 S5 (1769 bps) (Fig. 33, lane 4) (lower black arrow) was purified from 
gel and the (F and R) primers were designed with BamHI restriction sites. The PCR 
product of EHDV-7 S5 was observed by electrophoresis on agarose gel (Fig. 34B, 
lanes 3 and 4) displaying DNA fragment with the estimated length (1769 bps) of 
EHDV-7 S5. No amplification was identified from the negative control as shown in 
lane 2 (Fig. 34B, lane 2).  
 
 
Fig. 34. PCR amplification of the coding region of EHDV-7 S2 and S5. (A) The PCR product was 
visualised by gel electrophoresis on a 1% agarose gel, stained with ethidium bromide. Lane 1: DNA 
ladder, lane 2: negative control and lanes 3 and 4: EHDV-7 S2. (B) The PCR product was visualised 
by gel electrophoresis on a 1% agarose gel, stained with ethidium bromide. Lane 1: DNA ladder, lane 
2: negative control and lanes 3 and 4: EHDV-7 S5. 
 
3.2.4.1. Cloning of EHDV-7 S2 into pAcYM1 
The amplified coding regions of EHDV-7 S2 was ethanol precipitated followed by 
ligating into the SmaI site of the linearised and dephosphorylated pAcYM1 (Fig. 35, 
lane 3). After transformation into DH5α competent cells, the integration and 
orientation of EHDV-7 S2 in the recombinant pAcYM1-EHDV7.S2 plasmid were 
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analysed simultaneously. This was performed by colony PCR on seven ampicillin 
resistance colonies using PH (F) primer and EHDV-7 S2 (R) primer. The amplified 
products were detected by electrophoresis on 1% agarose gel, demonstrating a 
positive integration and accurate direction of EHDV-7 S2 in the recombinant 
pAcYM1-EHDV7.S2 in clone # 3 (Fig. 36, lane 4), whereas other 6 colonies were 
found to be negative (Fig. 36, lanes 2, 3, 5, 6, 7 and 8).  
 
Fig. 35. Molecular analysis of the transfer vector pAcYM1. Lane 1: DNA ladder, lane 2: pAcYM1 
(circular) and lane 3: SmaI linearised pAcYM1.  
 
 
Fig. 36. Colony PCR with PH (F) and EHDV-7 S2 (R) primers to check the presence and the 
orientation of EHDV-7 S2 in the recombinant pAcYM1-EHDV7.S2. Lane 1: DNA ladder and lanes 
(2-8) pAcYM1-EHDV2.S2 recombinants (lane 4: is positive).  
 
3.2.4.2. Expression of EHDV-7 VP2 recombinant protein in baculovirus 
expression system 
 
The recombinant EHDV-7 VP2 protein expressed well in Sf21 insect cells post 
cotransfection with the linearised BAC10:KO1629 and the circular recombinant 
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pAcYM1-EHDV7.S2. To analyse the synthesis of EHDV-7 VP2 protein, cell lysate of 
Sf9 infected cells with the recombinant baculovirus expressing the above protein was 
visualized on 10% SDS-PAGE gel stained with coomassie blue. Intense protein 
bands were observed corresponding to the estimated sizes of EHDV-7 VP2 (~ 114 
kDa) (Fig. 37, lanes 4 and 5), and to that of the positive controls EHDV-1 VP2 (112 
kDa) (Fig. 37, lane 7) and EHDV-2 VP2 (~ 114 kDa) (Fig. 37, lane 6).  
 
Fig. 37. 10% SDS-PAGE Analysis of the recombinant EHDV-7 VP2 protein from clonal 
populations. Lane 1: protein ladder, lane 2: Sf9 insect cells, lane 3: Sf9 insect cells infected with 
recombinant AcMNPV pRN43-GFP, lanes 4 and 5: lysate from cells infected with recombinant 
baculovirus expressing EHDV-7 VP2, lane 6: lysate from cells infected with recombinant baculovirus 
expressing EHDV-2 VP2 (control positive) and lane 7: lysate from cells infected with recombinant 
baculovirus expressing EHDV-1 VP2 (control positive). All recombinant proteins are indicatied in black 
arrows.  
 
 
In conclusion, in this chapter it was possible to achieve all the clones of EHDV-1 (S2, 
S5 and S7), EHDV-2 (S2 and S5) and EHDV-7 (S2 and S5), that are necessary for 
the formation of VLPs. All clones were also shown to be able to express in 
baculovirus expression system. Moreover, antisera against the most variable protein 
VP2 of EHDV-1 and EHDV-2 were commercially raised in Guinea Pigs and 
confirmed to be specific by western blotting. 
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3.3. DISCUSSION  
Currently, the only vaccine available to control EHD caused by EHDV is a live-
attenuated vaccine (Aradaib et al., 2009). This vaccine was developed and used in 
Japan against EHDV-2 (IBAV) following outbreaks that occurred in 1980, during 
which it was demonstrated to be effective and safe, at least until 1997, due to the 
emergence of more virulent serotypes (Ohashi et al., 1999). Thus, to combat EHD, 
the development of a safer and more effective vaccine for EHDV serotypes is 
economically important, particularly, following the outbreaks in cattle in different 
countries bordering to Europe. However, generating such universal vaccine is 
hampered by the divergent and immunologically distinct seven serotypes for EHDV.   
As a safe type of subunit vaccine, the aim of this study was to develop VLPs of 
EHDV. The choice of VLP as a viable vaccine was based on several studies showing 
a complete protective neutralising antibody response in vaccinated animals with BTV 
VLPs (Roy, 1995a), that proved to be closely related to EHDV both  genetically and 
structurally (French et al., 1990, Ritter and Roy, 1988). However, the production of 
VLPs containing multiple interacting capsid proteins is more challenging in 
comparison to those that are formed by one ‘papillomavirus’ or two ‘influenza virus’ 
major capsid proteins, as more qualifications are needed. 
As a preliminary step for the production of EHDV VLPs and heterologous VLPs, it 
was essential to determine the possibility of an individual expression of each 
structural protein VP2, VP5, VP7 and VP3 of EHDV serotypes 1, 2 and 7 using 
baculovirus vector BAC10:KO1629. The plasmid replicon, pAcYM1, containing 
AcMNPV polyh promoter, was utilized to generate recombinant viruses that express 
high level products of the targeted genes. This was based on previous studies of 
many genes, for which high expression was obtained with a recombinant baculovirus 
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using the pAcYM1 transfer vector (Matsuura et al., 1987, Romanowski et al., 1985, 
Emery and Bishop, 1987, Urakawa and Roy, 1988).  
No published studies are available showing the cloning of the three EHDV structural 
genes in to pAcYM1 apart from EHDV-1 S3 (2768 bps) (Le Blois et al., 1991). 
However, other work demonstrated the cloning of EHDV-1 S7 gene into pUC 
plasmids (pUC8 or pUC19) (Iwata et al., 1992), and EHDV-2 S5 into pGEM-T Easy 
(3015 bps) transfer vector (Ohashi et al., 2002). Cloning the targeted genes into pUC 
or pGEM-T Easy vectors is not as difficult as to that of pAcYM1 due to their small 
sizes. In this work, after several attempts, a successful subcloning of the full-length 
ORF of EHDV-1 S5 (1803 bps), EHDV-1 S7 (1162 bps) and EHDV-2 S5 (1803 bps) 
were achieved into pAcYM1 vector.  
Cloning S2 coding region of EHDV-1 and EHDV-2 serotypes into pAcYM1 was not 
so straightforward technique. S2 has large molecular weight, making it more difficult 
to manage and harder to clone. Moreover, the ligation of S2 ORF of the three EHDV 
serotypes into pAcYM1 was not previously described for this vector, although there 
was report of cloning the coding region of Ibaraki (EHDV-2) S2 into pGEM-T Easy 
vector (Ohashi et al., 2002). Additionally, cloning of EHDV-7 S2 into pAcYM1 and 
EHDV-7 S5 into pRN296 vector was very difficult as the FLAC method was not 
suitable to amplify cDNAs from dsRNAs of both genes.  
To overcome these challenges, several molecular techniques were performed. The 5’ 
and 3’ termini of the amplified S2 PCR product was phosphorylated using T4 DNA 
polynucleotide or digested with specific endonuclease enzymes presented in the 
designed primers, however both were inefficient. Thus, alternative method was used 
to prepare the insert for ligation. The (F and R) primers of S2 of EHDV-1, EHDV-2 
and EHDV-7 were phosphorylated prior to the PCR reaction which proved to be 
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successful for ligation. Furthermore, chemically competent E.coli cells suitable for 
high efficiency transformation were prepared and used following the protocol by Tang 
et al (Tang et al., 1994).  
Due to the nature of sticky ends of the PCR product, it could be inserted into a 
plasmid in either of two orientations. Thus, determining the orientation of the targeted 
gene in the recombinant was rather essential, as the wrong direction would lead to a 
non-functional protein. This issue was overcome by applying a number of molecular 
methods. Firstly, single restriction endonuclease digestion was performed for EHDV-
1 S2 in pAcYM1-EHDV1.S2 with EcoRV, while HindIII used for EHDV-2 S2 pAcYM1-
EHDV1.S2. Double restriction digestion with XmaI and Xhol was carried out for 
EHDV-1 S5 in pAcYM1-EHDV1.S5. Secondly, PCR as an alternative strategy was 
undertaken using PH (F) primer from the vector pAcYM1 and specific (R) primer 
from the insert. Thirdly, colony PCR as a rapid and convenient high-throughput 
method was applied for analysing the presence or absence of the DNA insert in the 
recombinants and determining its orientation.  
Post transformation of the recombinant plasmid pAcYM1-EHDV1.S2, pAcYM1-
EHDV-2.S2 into DH5α competent cells, small and large colonies were developed on 
ampicillin plates; however, only small colonies proved to be potentially correct. Due 
to the slow growth rate, small colonies developed after 2 days, which also allowed 
satellite colonies to develop. The DNA yield was extremely low from a correct colony 
when was scaled up for maxi-preparation. Based on these observations, it was likely 
that the insert S2 was toxic to the bacterial cells resulting in the instability of the 
vector. In addition, the ligation of S2 ORF of the three EHDV serotypes into pAcYM1 
was not previously described for this vector, although there was report of cloning the 
coding region of Ibaraki (EHDV-2) S2 into pGEM-T Easy vector (Ohashi et al., 2002). 
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Prior to protein expression, examining the full-length sequence of each insert was 
necessary for the production of VLPs and heterologous VLPs. The results were 
verified by BlastN and shown to be corresponding to the published sequence of 
EHDV structural coding regions. After alignment with PubMed published data, no 
deletions, insertions or frame shifts were revealed.  
The individual expression of the recombinant proteins of EHDV-1 VP2, VP3, VP5 
and VP7, EHDV-2 VP2 and VP5 and EHDV-7 VP2 were successfully achieved in 
Sf21 insect cells using baculovirus expression system. None of the expressed 
proteins was previously reported either in baculovirus or in yeast or E.coli except for 
EHDV-1 VP3, for the formation of heterologous CLPs which made up of EHDV-1 
VP3 and BTV-10 VP7 (Le Blois et al., 1991). The expression of VP2 protein of EHDV 
serotypes was quite difficult not just due to its large size (over 112 kDa) but also 
maybe due to the sequences of the genes. For instance, VP3 also has large size 
(103 kDa), but was shown to be amenable to expression by baculovirus both for 
EHDV and BTV (Le Blois et al., 1991, French and Roy, 1990). Therefore, in this 
work, the expression of VP2 of EHDV serotypes was not only possible by 
baculovirus expression system, but also proved to be highly efficient.  
In this project, the modified DNA baculovirus BAC10:KO1629 was used for 
recombination due to variant distinct factors. Basically, BAC10:KO1629 has an 
insertion in the orf1629, which is essential for its replication. Such knockout in the 
viral genome prevents completion of baculovirus replication unless complemented by 
recombination from a transfer vector. Other studies showed that applying this 
modification, the recombination protocols were shortened and made all recovered 
viruses as recombinants and thus allowing high throughput protein expression 
strategies (Zhao et al., 2003, Kitts and Possee, 1993). Moreover, work by Kitts and 
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Possee introduced a Bsu36I restriction enzyme in the wild type (Hawtin et al., 1997) 
Baculovirus DNA generating a unique site for linearisation. This point mutation 
reduced the background of the WT baculovirus in comparison to the recombinant 
ones (Kitts and Possee, 1993). However in this case it does not matter about 
background virus as the Bacmid has a knockout in orf1629, linearization in our 
protocol is performed as it has been shown to improve recombination efficiency 
between Bacmid and transfer vector (Zhao et al 2003).  
To examine the successful recombination and the level of recombinant protein 
produced, the construct pRN43GFP was used as a positive control. The GFP protein 
has been reported to be successfully expressed in different host organisms and cells 
such as Sf21 and Sf9 cells (Reilander et al., 1996). Furthermore, unlike other 
reporter tags such as luciferase, β-galactosidase, or fluorescent-tagged antibodies, 
GFP does not require fixation techniques that are toxic to the cells under 
investigation (Chalfie et al., 1994). The expression of GFP was monitored 48 and 72 
hpt which was correlated with the expression of the very late genes of baculovirus 
coding for products including polyhedrin protein.  
For single gene expression, the recombinant baculoviruses; 
BAC10:KO1629:EHDV1.(S1, S5, S7), BAC10:KO1629:EHDV2.(S2, S5) and 
BAC10:KO1629:EHDV7.S2 were successfully generated in Sf21 insect cells. Plaque 
assays were performed from the first or second rounds of amplification to purify 
clonal population of the generated recombinant baculoviruses, which correlated with 
the expressed recombinant proteins. For instance, no plaques were visualised after 
the first amplification, particularly for VP2 of EHDV-1, -2 and 7 and VP5 of EHDV-1 
and 2. Therefore, the need for higher number of amplifications were required. Such 
an outcome might not be solely due to the size of these proteins, but may also be 
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due to the sequence and the function of the proteins. For example, VP5 (~ 59 kDa) 
size is less than half of VP2 (~ 112 kDa). However, it has an essential function that 
allows the protein to cause permeabilisation in host cell membrane (Forzan et al., 
2004). Such function tends to slow cell growth rate, reduce cell density, and kill the 
host cells in some cases. In contrast, clear plaques post neutral red staining were 
observed using baculovirus collected from the second transfection of Sf21 insect 
cells with, EHDV-1 (VP7 and VP3) which were more stable and easier to be  
expressed.  
The positive control GFP was also detected for protein expression as an indication to 
the changes of the viral titre. Generally, more GFP was recognised at 48 hpi 
indicating that the time required to increase the expression of the protein might be 
decreased with each round of amplification. This was consistent with Pennock GD 
findings as remarkable high levels of the foreign gene (β-galactosidase) were 
achieved at 48 hpi (Pennock et al., 1984). 
Successful expression of the outer and inner capsid proteins of EHDV three 
serotypes was achieved. Generally, no significant variations of the expressed 
proteins were found between the three serotypes, though VP2 expression was more 
difficult compared to the other structural proteins (VP3, VP5 and VP7). The high 
specificity of antisera raised against VP2 of EHDV-1 and EHDV-2 was confirmed to 
be high by western blotting.  
Singly EHDV structural protein expression is well tolerated in the system chosen and 
indicates that multigene expression may well be successful, allowing this study to be 
taken further.  
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4.1. INTRODUCTION 
In North America, EHDV-1 (New Jersey strain) was found to be the causative agent 
of a highly fatal disease in wild deer, which known to be endemic (Shope et al., 
1960).  The significant morbidity and mortality, particularly, in white tailed deer, was 
of concern of wildlife managers because of clinical disease in populations. 
Additionally, the pathological signs and clinical lesions produced by EHDV, are 
indistinguishable from that formed by BTV, making these viral diseases of interest to 
veterinary pathologists (Wilson, 1994). Therefore, in this study, the main aim was to 
develop EHDV-1 VLPs, which would be used as a candidate vaccine against the 
virulent virus.  
Several VLPs for orbiviruses, BTV in particular, have been generated successfully by 
baculovirus expression system (French et al., 1990). The VLPs for BTV-10 were 
shown to elicit strong neutralising antibodies in guinea pigs (French et al., 1990). 
Following this success, VLPs were developed for a number of BTV serotypes; -1, -2, 
-13 and 17 and heterologous VLPs of BTV-4, -11 and 16 (Stewart el al., 2010, 
Stewart et al., 2012). Further, high level of protection was demonstrated in VLP-
vaccinated animals against virulent virus challenges (Roy et al., 1994).  
Baculovirus multiple gene expression system, with some further improvement, was 
mainly used for the generation of EHDV-1 VLPs. In previous reports, the 
simultaneous expression of multiple gene products has enabled efficient production 
of protein complexes including VLPs (Roy and Noad, 2009). To date, several 
drawbacks have affected the expression of multiple large proteins (>100 kDa), such 
as the need to produce large recombinant plasmids, repeat use of promoters and 
homologous sequences. These issues were addressed by the production of 
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baculovirus multiple gene expression system, which allowed the integration of up to 
8 genes at different loci into baculovirus genome (Noad et al., 2009). 
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4.2. RESULTS  
 
4.2.1. The use of baculovirus multiple genes expression system to develop 
EHDV-1 CLPs 
 
4.2.1.1. Generation of the recombinant Bacmid1629:EHDV1.S7  
The recombinant plasmid pRN260-EHDV1.S7 was constructed by cloning the ORF 
of EHDV-1 S7 (1162 bps) into pRN260 vector under polyh promoter control. The 
linearisation of pRN260 plasmid was confirmed by electrophoresis on 1% agarose 
gel (Fig. 38, lane 3).  As shown in Figure 39, lanes 4 and 6, positive insertion was 
detected in two ampicillin resistance colonies ; two bands of estimated sizes of 
EHDV-1 S7 (1162 bps) and the vector pRN260 (5500 bps) were obtained upon 
BamHI digestion of the corresponding plasmid DNA (Fig. 39B, lanes 4 and 6).  
The orientation of EHDV-1 S7 in recombinant pRN260-EHDV1.S7 plasmid (Fig. 
40A), was determined by restriction digestion with NarI endonuclease enzyme. A 
correct orientation was identified in one of the recombinant clones as evident from 
the presence of two DNA fragments corresponding to the sizes of 5593 bps and 
1990 bps on agarose gel (Fig. 40B, lane 3). Further confirmation of EHDV-1 S7 
direction in the recombinant plasmid was carried out by PCR using PH (F) and 
EHDV-1 S7 (R) primers. The PCR product was visualised by gel electrophoresis as 
a single amplified fragment corresponding to the size of EHDV-1 S7 (Fig. 40C, lane 
3). 
 
Fig. 38. BamHI digestion of pRN260 transfer vector. Lane 1: DNA ladder, lane 2: pRN260 
(circular) and lane 3: pRN260 (linear).  
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Fig. 39. Molecular analysis to detect the presence of EHDV-1 S7 in the recombinant pRN260-
EHDV1.S7. (A) Restriction map of pRN260-EHDV1.S7 showing BamHI sites (B)  BamHI digestion of 
the construct pRN260-EHDV1.S7. Lane 1: DNA ladder, lane 2: pRN260 and lanes 3-6: pRN260-
EHDV1.S7. Colonies # 4 and 6 are positives. 
 
 
Fig. 40. Molecular analysis to detect the orientation of EHDV-1 S7 in the recombinant 
pRN260-EHDV1.S7. (A) Restriction map of pRN260-EHDV1.S7 with NruI (B) NruI digestion of 
pRN260-EHDV1.S7. Lane 1: DNA ladder, lane 2 and 3: pRN260-EHDV1.S7. Clone # 3 is in correct 
orientation (C) PCR with PH (F) and EHDV-1 S7 (R) primers. Lane 1: DNA ladder, lane 2: negative 
control and lane 3: EHDV-1 S7 in the construct pRN260-EHDV1.S7.  
 
For lambda red recombination of the cloning cassette in the recombinant plasmid 
pRN260-EHDV1.S7, each of the selectable and expression markers were amplified 
using specific primers pRN260-Exact (F and R) (Table 10) (Fig. 41A). The amplified 
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PCR product was observed after electrophoresis on 1% agarose gel, showing one 
band corresponding to the size of 3472 bps (Fig. 41B, lane 2). 
 
Fig. 41. Amplification of the selectable and expression cassettes flanked by AcMNPV 
sequences. (A) pRN260-EHDV1.S7 map showing pRN260-Exact (F and R) primers. (B) PCR 
amplification with pRN260-Exact (F and R) primers. Lane 1: DNA ladder and lane 2: PCR product.    
 
After excising and purifying the PCR fragment from agarose gel, it was 
electroporated into the E3K2 bacterial competent cells, to be integrated into the 
baculovirus genome at egt locus. To detect the construction of the recombinant 
Bacmid1629:EHDV1.S7, several blue colonies were screened with EHDV-1 S7 
specific primers (Fig. 42A). Subsequently, the positive insertion was observed by 1 
% agarose gel as one band corresponding to the size of EHDV-1 S7 (Fig. 42B, lane 
4). No amplification was obtained from Bacmid1629 (WT), which was used as a 
negative control (Fig 42, lane 2). The recombinant plasmid pRN260-EHDV1.S7 was 
used as a positive control as shown in lane 3 (Fig. 42B, lane 3).  
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Fig. 42. Molecular analysis to detect the presence of EHDV-1 S7 in the Bacmid1629:EHDV1.S7. 
(A) Analysis map of the Bcamid1629:EHDV1.S7 in E3K2 cells showing the presence of the expression, 
selectable cassettes and specific AcMNPV sequence for homologous recombination. (B) PCR 
amplification of EHDV-1 S7 using specific (F and R) primers. Lane 1: DNA ladder, lane 2: Bacmid1629 
(WT), lane 3: EHDV-1 S7 in the recombinant pRN260-EHDV1.S7 (positive control) and lane 4: EHDV-
1 S7 in the recombinant Bacmid1629: EHDV1.S7.  
 
 
For the incorporation of the next gene encoding for the second inner core protein 
EHDV-1 VP3 into the recombinant Bacmid1629:EHDV1.S7, the selectable marker 
needed to be flipped out (Fig. 43A). In order to confirm the presence of the EHDV-1 
S7 gene in the recombinant Bacmid1629:EHDV1.S7 after flipping out the selectable 
marker, several white colonies were screened. The results in Figure 43, lanes 4-6 
(Fig. 43, lanes 4-6) show a single DNA fragment similar to the size of the positive 
control EHDV-1 S7 in the recombinant plasmid pRN260:EHDV1.S7 (Fig. 43, lane 3). 
No signs of amplification similar to that of EHDV-1 S7 were detected in lane 2 in 
which Bacmid1629 was used as negative control (Fig. 43B, lane 2).  
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Fig. 43. Molecular analysis to determine the presence of EHDV-1 S7 after flipping out the 
selectable marker. (A) Analysis map showing the recombinant Bacmid1629:EHDV1.S7 at egt locus 
after flipping out the selectable cassette. (B) PCR amplification of EHDV-1 S7 using specific (F and R) 
primers. Lane 1: DNA ladder, lane 2: Bacmid1629 (WT), lane 3: EHDV-1 S7 (positive control) and lanes 
4-6: EHDV-1 S7 in the recombinant Bacmid1629: EHDV1.S7.  
 
 
4.2.1.2. Generation of the recombinant Bacmid1629:EHDV1.S7.S3  
To integrate EHDV-1 S3 (2768 bps) gene into the recombinant 
Bacmid1629:EHDV1.S7 at 39k locus, EHDV-1 S3 ORF was successfully subcloned 
into the pRN306 transfer vector. For fast and directional ligation, primers were 
designed with specific 15 bps sequences overlapping with the vector at its ends 
(Table 7).  The positive ligation was examined by colony PCR of several colonies 
using EHDV-1 S3 primers. In total, three recombinant plasmids had the insert in 
correct direction to the polyh (Fig. 44, lanes 3-5), and one colony was shown to be 
negative (Fig. 44. lane 2).   
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Fig. 44. Molecular analysis to detect the presence of EHDV-1 S3 in the recombinant pRN306-
EHDV1.S3. (A) Restriction map of pRN306-EHDV1.S3 (B) Colony PCR using EHDV-1 S3 (F and R) 
specific primers. Lane 1: DNA ladder, lane 2-5: pRN306-EHDV1.S3. Colony # 2 is negative. Colonies 
# 3, 4 and 5 are positives.  
 
 
For the generation of the recombinant plasmid pRN306-EHDV1.S3, pRN306-ec (F 
and R) primers (Table 10), were used to amplify both the selectable and expression 
cassettes (Fig. 45A). Amplification results were visualised by agarose gel 
electrophoresis as specific band of the size of ~4000 bps (Fig. 45B, lanes 3 and 4). 
Following excision and purification of the PCR product, the amplified fragment was 
electroporated into E3K2 electrocompetent cells containing the recombinant 
Bacmid1629:EHDV1.S7. (Fig. 46A). The presence of targeted gene EHDV-1 S3 in the 
recombinant Bacmid1629:EHDV1.S7.S3 was identified by screening 11 blue colonies. 
Gel electrophoresis displayed a total of 5 positive colonies (Fig. 46B, lanes 3, 4, 6, 7 
and 8), and the others were negative (Fig. 46B, lanes 5, 9-13).  
The resistant marker was flipped out effectively and PCR reaction was performed to 
test the existence of EHDV-1 S3 in the baculovirus recombinant at the 39k site (Fig. 
47A). The results were visualised by 1 % agarose gel electrophoresis as DNA bands 
(Fig. 47, lanes 4 and 5) corresponding to the size of the positive control EHDV-1 S3 
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in the recombinant plasmid pRN306-EHDV1.S3 (Fig. 47, lane 3). The Bacmid1629 
was used as a negative control, and showed no amplification (Fig. 47, lane 2). 
 
Fig. 45. Amplification of the selectable and expression cassettes flanked by AcMNPV 
sequences. (A) pRN306-EHDV1.S3 map showing pRN306-ec (F and R) primers. (B) PCR 
amplification with pRN306-ec (F and R) primers. Lane 1: DNA ladder, lane 2: negative control and 
lanes 3 and 4: amplification of the cassettes.    
 
 
 
Fig. 46. Molecular analysis to detect the presence of EHDV-1 S3 in the recombinant 
Bacmid1629:EHDV1.S7.S3. (A) Analysis map of the Bcamid1629:EHDV1.S7.S3 in E3K2 cells showing 
the presence of the expression, selectable cassettes and specific AcMNPV sequence for homologous 
recombination. (B) PCR amplification of EHDV-1 S3 using specific (F and R) primers. Lane 1: DNA 
ladder, lane 2: Bacmid1629 (WT), lane 3: pRN306-EHDV1.S3, lanes 3-13: EHDV-1 S3 in the 
recombinant Bacmid1629:EHDV1.S7.S3 (Lanes 3, 4, 6, 7 and 8 are positives) and lane 14: DNA 
ladder.  
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Fig. 47. Molecular analysis to determine the presence of EHDV-1 S3 after flipping out the 
selectable marker. (A) Analysis map of the recombinant Bacmid1629:EHDV1.S7.S3 after flipping out 
the selectable cassette. (B) PCR amplification of EHDV-1 S3 using specific (F and R) primers. Lane 1: 
DNA ladder, lane 2: Bacmid1629 (WT), lane 3: EHDV-1 S3 (positive control) and lanes 4-5: EHDV-1 S3 
in the recombinant Bacmid1629:EHDV1.S7.S3.  
 
 
4.2.1.3. Expression, purification and assembly of EHDV-1 CLP Particles in 
AcMNPV  
 
The expression of the inner capsid proteins EHDV-1 (VP7 and VP3) was tested in 
Sf21 insect cells by cotransfecting them with the circular recombinant 
Bacmid1629:EHDV1.S7.S3 and the empty AlwNI transfer vector pAcYM1 (Fig. 48). 
The linearised pAcYM1 vector was used to recover the viral genome by homologous 
recombination enabling the replication in Sf21 insect cells.  
                                                    
Fig. 48. Restriction map of the vector pAcYM1 with AlwNI site. 
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Following cotransfection, plaque assay was performed and several individual 
plaques were isolated. The clonal populations of the recombinant baculovirus were 
amplified three times in Sf9 insect cells to increase the titre of the virus and protein 
production. To analyse the assembly of VP3 and VP7 of EHDV-1 into CLPs, 25-50% 
sucrose discontinuous gradient centrifugation was performed. Two protein bands 
were observed at both 0-25% and 25-50% sucrose interface corresponding to the 
correct sizes of EHDV-1 (VP3 and VP7) (Fig. 49A). Fractions of the sucrose gradient 
were collected from 0-25%, 25%, 25-50%, as well as from the pellet. The expression 
of the recombinant proteins of EHDV-1 [VP3 (103 kDa), VP7 (39 kDa)] were 
detected by 10% SDS-PAGE gel, particularly, in the 25-50% sucrose fraction (Fig. 
49B, lane 4). Additionally, aggregation of the cellular proteins was visualised in the 
samples obtained from the fraction 25-50% sucrose (Fig. 49, lane 4) and from the 
pellet (Fig. 49, lane 5). Additionally, non-specific protein bands were also found in all 
fractions (Fig. 49, lanes 2-5).   
          
Fig. 49. 10% SDS-PAGE analysis of EHDV-1 CLPs. (A) Sucrose gradient centrifugation of EHDV-
1 CLPs. Two bands were visible at both the 0-25% and 25-50% sucrose interface (B) 10% SDS-
PAGE analysis of EHDV-1 CLPs. Lane 1: protein ladder, lane 2: sample collected from 0-25% 
sucrose interface, lane 3: sample collected from 25% sucrose interface, lane 4: sample collected from 
25-50% sucrose interface showing EHDV-1 [VP3 (103 kDa) and VP7 (39 kDa)] (black arrows) and 
lane 5: sample collected from the pellet.  
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To remove the non-specific bands and to concentrate EHDV-1 CLPs, a second 
gradient was carried out to purify the sample collected from 25-50% sucrose fraction. 
The analysis of the purified CLPs proteins by 10% SDS-PAGE demonstrated the 
presence of the inner layer recombinant proteins VP7 and VP3 of EHDV-1 at correct 
molecular ratios (Fig. 50, lane 2). 
To identify whether the bands composing of VP7 and VP3 was assembled into CLP 
particles, EM analysis was performed. The EM micrographs of the negatively stained 
samples showed a spiky morphology (Fig. 51A) similar in size and appearance to the 
authentic EHDV purified cores (Fig. 51B)  
 
Fig. 50. 10% SDS-PAGE analysis of the purified and concentrated sample of EHDV-1 CLPs 
from 20-25% sucrose fraction. Lane 1: protein ladder and lane 2: purified EHDV-1 CLPs.  
 
Fig. 51. Electron micrographs of EHDV-2 cores (A) and EHDV-1 CLPs (B). The bars indicate 
100 nm.  
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In total, 2 ml (2.5 mg/ml) of the purified and concentrated EHDV-1 CLP samples 
were sent to Sigma-Aldrich to raise polyclonal antibody in Rabbits, and sera were 
collected post inoculation at different days (0, 35 and 56 + 58). The specificity of the 
developed antisera was tested by western immunoblotting, in which two specific 
protein bands were visualised with equal sizes of EHDV-1 VP3 (103 kDa) and 
EHDV-1 VP7 (39 kDa) (Fig. 52, lane 3). The AcMNPV pRN43-GFP recombinant 
protein was used as a negative control, and EHDV-2 core particles as positive 
control. Two protein bands were observed in lane 4 from EHDV-2 cores (Fig. 52, 
lane 4), similar to the size of EHDV-1 CLP recombinant proteins VP7 and VP3. To 
detect whether there was interaction between BTV-10 CLP proteins and the 
produced antisera against EHDV-1, western blotting was performed. As shown in 
Figure 52, lane 5, protein bands corresponding to the estimated sizes of BTV-10 
VP3 (~ 103 kDa) and BTV-10 VP7 (~ 38 kDa) were detected (Fig. 52, lane 5). No 
non-specific protein bands were found in the negative control in lane 2 
corresponding to the sizes of either VP3 or VP7 (Fig. 52, lane 2).   
 
Fig. 52. Immunoblotting analysis of EHDV-1 CLPs proteins VP3 and VP7. Lane1: protein 
ladder, lane 2: Sf9 insect cells infected with recombinant AcMNPV pRN43-GFP, lane 3: lysate from 
cells infected with recombinant Bacmid1629:EHDV1.VP3.VP7 expressing EHDV-1 VP3 and VP7 
proteins, lane 4: EHDV-2 cores showing EHDV-2 VP3 and VP7 proteins and lane 5: BTV-10 CLPs 
VP3 and VP7 proteins. All recombinant proteins are indicated in black arrows. AcMNPV gp64 protein 
is indicated in head arrow.    
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4.2.2. The use of baculovirus multiple genes expression system to develop 
EHDV-1 VLPs 
 
4.2.2.1. Generation of the recombinant Bacmid1629:EHDV1.S5.S7.S3  
Next step towards the production of EHDV-1 VLPs by baculovirus multiple synthesis 
method was the integration of the coding sequences of the outer capsid protein of 
EHDV-1 VP5 into the recombinant Bacmid1629:EHDV1.S7.S3. Therefore, EHDV-1 S5 
ORF was subcloned into the BamHI linearised and dephosphorylated pRN296 
transfer vector (Fig. 53, lane 3). The correct cloning was determined by restriction 
digestion with BamHI enzyme (Fig. 54A), and observed by agarose gel as two bands 
of sizes of pRN296 (5930 bps) and EHDV-1 S5 (1640 bps) (Fig. 54B, lane 3). The 
PCR amplification using PH (F) and S5 (R) primers was performed to determine the 
correct orientation of the insert in the recombinant plasmid pRN296-EHDV1.S5. A 
single band corresponding to the estimated size of EHDV-1 S5 was visualised in 
Figure 55, lane 3 post 1% gel electrophoresis (Fig. 55, lane 3).   
 
Fig. 53. BamHI digestion of pRN296 transfer vector. Lane 1: DNA ladder, lane 2: pRN296 
(circular) and lane 3: pRN296 (linear).  
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Fig. 54. Molecular analysis to detect the presence of EHDV-1 S5 in the recombinant pRN296-
EHDV1.S5. (A) Restriction map of pRN296-EHDV1.S5 showing BamHI sites. (B)  BamHI digestion of 
the construct pRN296-EHDV1.S5. Lane 1: DNA ladder, lane 2: pRN296 (Linear) and lane 3: pRN296-
EHDV1.S5.  
                                        
Fig. 55. Molecular analysis to detect the orientation of EHDV-1 S5 in the recombinant 
pRN296-EHDV1.S5 using PH (F) and EHDV-1 S5 (R) primers. Lane 1: DNA ladder, lane 2: negative 
control and lane 3: EHDV-1 S5 in the construct pRN296-EHDV1.S5.  
 
Prior to the insertion of EHDV-1 S5 into the recombinant Bacmid1629:EHDV1.S7.S3, 
PCR amplification of the selectable and synthesis markers was carried out using 
pRN296-ec primers (Table 10). The amplified product was identified on agarose gel 
as a DNA band similar to the size of 4770 bps (Fig. 56, lane 3). No DNA fragments 
were detected in the negative control without template in Lane 2 (Fig. 56, lane 2).   
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After electroporation, the PCR fragment containing EHDV-1 S5 failed to be 
integrated into the recombinant Bacmid1629:EHDV1.S7.S3 at odv-e56 locus. 
Therefore, EHDV-1 S5 gene was inserted into an empty Bacmid1629 genome at odv-
e56 locus (Fig. 57A). The initial selection of the positive recombinant was based on 
blue-white screening followed by PCR amplification. Amplified DNA fragment was 
shown in Figure 57B, lane 9 (Fig. 57B, lane 9), corresponding to the size of the 
positive control EHDV-1 S5 in the recombinant plasmid pRN296-EHDV1.S5 (Fig. 
57B, lane 10). Thereafter, each of EHDV-1 (S3 and S7) genes were successfully 
incorporated in baculovirus genome at 39k and egt loci, respectively, generating 
Bacmid1629:EHDV1.S5.S7.S3 (Fig. 58).  
The PCR amplification was carried out to identify the presence of the all three genes 
coding for the capsid proteins; EHDV-1 (VP5, VP7 and VP3) in the recombinant 
Bacmid1629:EHDV1.S5.S7.S7. Gel electrophoresis in Figure 59A, Lane 4 (Fig. 59A, 
lane 4), showed amplification equivalent to the size of that seen from the positive 
control EHDV-1 S5 in the recombinant plasmid pRN296-EHDV1.S5. In parallel, 
according to the data observed in Figure 59B, lane 4 by gel electrophoresis, the 
presence of EHDV-1 S7 in the recombinant Bacmid1629:EHDV1.S5.S7.S3 was 
detected (Fig. 59B, lane 4). Moreover, a positive incorporation was found for EHDV-
1 S3 using specific primers (Fig. 59C, lane 4). No amplification similar to the 
estimated sizes of the three tested genes was observed in the negative control, 
Bacmid1629 (WT).  
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Fig. 56. Amplification of the selectable and expression cassettes flanked by AcMNPV 
sequences. (A) pRN296-EHDV1.S5 map showing pRN296-ec (F and R) primers. (B) PCR 
amplification with pRN296-ec (F and R) primers. Lane 1: DNA ladder, lane 2: negative control and 
lane 3: amplification of the cassettes.    
 
 
 
 
Fig. 57. Molecular analysis to detect the presence of EHDV-1 S5 in the recombinant 
Bacmid1629:EHDV1.S5. (A) Analysis map of the Bacmid1629:EHDV1.S5 in E3K2 cells showing the 
presence of the expression, selectable cassettes and specific AcMNPV sequence for homologous 
recombination. (B) PCR amplification of EHDV-1 S5 using specific (F and R) primers. Lane 1: DNA 
ladder, lane 2: Bacmid1629 (WT), lanes 3-11: EHDV-1 S5 in the recombinant Bacmid1629:EHDV1.S5 
(Lane 9 is positive) and lane 12: pRN296-EHDV1.S5 (positive control).  
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Fig. 58. Molecular analysis map of the recombinant Bacmid1629:EHDV1.S5.S7.S3 showing the 
presence of EHDV-1 (S5 at odv-e56, S7 at egt and S3 at 39k) loci after flipping out the 
selectable markers.  
 
  
      
 
 
Fig. 59. Molecular analysis to detect the presence of EHDV-1 S5, S7 and S3 after flipping out 
the selectable marker. (A) PCR amplification of EHDV-1 S5 using specific (F and R) primers. Lane 
1: DNA ladder, lane 2: Bacmid1629 (WT), lane 3: EHDV-1 S5 (positive control) and lane 4: EHDV-1 S5 
in the recombinant Bacmid1629:EHDV1.S5.S7.S3. (B) PCR amplification of EHDV-1 S7 using specific 
(F and R) primers. Lane 1: DNA ladder, lane 2: Bacmid1629 (WT), lane 3: EHDV-1 S7 (positive control) 
and lane 4: EHDV-1 S7 in the recombinant Bacmid1629:EHDV1.S5.S7.S3. (C) PCR amplification of 
EHDV-1 S3 using specific (F and R) primers. Lane 1: DNA ladder, lane 2: Bacmid1629 (WT), lane 3: 
EHDV-1 S3 (positive control) and lane 4: EHDV-1 S3 in the recombinant 
Bacmid1629:EHDV1.S5.S7.S3.  
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4.2.2.2. Expression and purification of EHDV-1 triple proteins (VP5, VP7 and 
VP3) in AcMNPV  
 
To express the outer and inner capsid proteins from the recombinant 
Bacmid1629:EHDV1.S5.S7.S3, Sf21 insect monolayers were cotransfected with the 
circular Bacmid1629:EHDV1.S5.S7.S3 and the linearised empty pAcYM1 vector to 
recover baculovirus genome. The 25-50% sucrose discontinuous gradients 
purification was accomplished and three protein bands corresponding to the correct 
sizes of EHDV-1 [VP3 (103 kDa), VP5 (59 kDa) and VP7 (39 kDa)] were seen at 25-
50% fraction on a 10% SDS-PAGE (Fig. 60, lane 4). In addition, non-specific protein 
band similar in size to that found in the fraction collected from 0-25% sucrose were 
visualised (Fig. 60, lane 4, head arrow). In contrast, several cellular protein bands 
were detected in the samples collected from 0-25% sucrose fraction (Fig. 60, lane 2) 
and 25% sucrose fraction (Fig. 60, lane 3) and the pellet (Fig. 60, lane 5).  
         
Fig. 60. 10% SDS-PAGE analysis of EHDV-1 Triple recombinant proteins VP5, VP7 and VP3. 
Lane 1: protein ladder, lane 2: sample collected from 0-25% sucrose interface, lane 3: sample 
collected from 25% sucrose interface, lane 4: sample collected from 25-50% sucrose interface 
showing EHDV-1 [VP3 (103 kDa), VP5 (59 kDa) and VP7 (39 kDa)] and lane 5: sample collected from 
the pellet. All recombinant proteins are indicated with black arrows. Non-specific protein band is 
indicated in head arrow.  
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4.2.3. Generation, purification and assembly of EHDV-1 VLP particles in 
AcMNPV  
 
The EHDV-1 VLPs consisting of the four structural proteins VP2, VP3, VP5 and VP7 
was expressed in Sf21 insect cell monolayers as follows. The cells were 
cotransfected with the AIwnI linearised recombinant plasmid pAcYM1-EHDV1.S2 
and the circular recombinant Bacmid1629:EHDV1.S5.S7.S3. To demonstrate that all 
four proteins of EHDV-1 were correctly expressed, cell lysates infected with 8 clones 
of baculovirus were analysed by 10% SDS-PAGE. In Figure 61, lane 7, SDS-PAGE 
analysis shown four unique proteins bands and the sizes corresponded to the 
expected sizes of the structural proteins of EHDV-1 [VP2 (112 kDa), VP3 (103 kDa), 
VP5 (59 kDa) and VP7 (39 kDa)] (Fig. 61, lane 7), respectively. The expression of 
the complete set of the four recombinant proteins was not detected from other cell 
lysates of other 7 clones (Fig. 61, lanes 3-6, 8-10) 
             
Fig. 61. 10% SDS-PAGE analysis of the expression of EHDV-1 VLPs proteins from clonal 
populations. Lane 1: protein ladder, lane 2: Sf21 insect cells, lanes 3-10: lysate from cells infected 
with recombinant baculovirus expressing EHDV-1 (VP2, VP3, VP5 and VP7) proteins. Lane # 7 is 
correct (black arrows).   
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To examine whether the expressed recombinant proteins (Fig. 61, lane 7) could be 
assembled into EHDV-1 VLPs, Sf9 insect cell monolayers were infected with the 
recombinant baculovirus expressing the four structural proteins of EHDV-1. The 
infected cells were harvested at 64-72 hpi, and the EHDV-1 VLPs were purified 
using 40-75% sucrose discontinuous gradients. Purification protocol was optimised 
to maintain the integrity of the particles by using cell lysis buffer with pH and ionic 
strength similar to that used for the virion purification. The 10% SDS-PAGE analysis 
of the purified VLPs of EHDV-1 showed that all four capsid proteins EHDV-1 [VP2 
(112 kDa), VP5 (59 kDa), VP3 (103 kDa), and VP7 (39 kDa)] were present (Fig. 62, 
lane 3). As positive controls, lysates from cells expressing individual structural 
proteins of EHDV-1 were used (Fig. 62. VP2, lane 4; VP3, lane 5; VP5, lane 6 & 
VP7, lane 7).  
          
Fig. 62. 10% SDS-PAGE analysis of EHDV-1 VLPs proteins. Lane 1: protein ladder, lane 2: lysate 
from cells infected with recombinant pRN43-GFP, lane 3: purified EHDV-1 VLPs from 40-75% 
sucrose fraction (VP2, VP3, VP5 and VP7), lane 4: EHD-1 VP2 (positive control), lane 5: EHDV-1 
VP3 (positive control), lane 6: EHDV-1 VP5 (positive control) and lane 7: EHDV-1 VP7 (positive 
control). Each EHDV-1 proteins is indicted by black arrows.   
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Samples of the purified EHDV-1 VLPs were prepared and then sent to a commercial 
company to raise polyclonal antibodies in Rabbits. After 2 doses of inoculation, the 
specificity of the antisera raised commercially against EHDV-1 VLP proteins were 
tested by western blotting. Protein bands equivalent to the estimated sizes of the 
EHDV-1 (VP2, VP3, VP5 and VP7) recombinant proteins were observed on a 
nitrocellulose membrane (Fig. 63, lane 4). Two negative controls were used and no 
distinct protein band was detected corresponding to the size of any of the four 
structural capsid proteins in the uninfected Sf9 insect cells (Fig. 63, lane 2), or that 
infected with the recombinant AcMNPV pRN43-GFP (Fig. 63, lane 3). 
 
Fig. 63. Immunoblotting analysis of the synthesis of the EHDV-1 VLP proteins from clonal 
populations. Lane 1: protein ladder, lane 2: Sf9 insect cells, lane 3: Sf9 insect cells infected with 
recombinant AcMNPV pRN43-GFP and lane 3: lysate from cells infected with the recombinant 
Bacmid1629:EHDV1.VP2.VP5.VP3.VP7 expressing EHDV-1 [VP2 (112 kDa), VP3 (103 kDa), VP5 (59 
kDa) and VP7 (39 kDa)] (black arrows).   
 
EM analysis was carried out to examine whether the four expressed recombinant 
proteins from purified sample of infected Sf9 cells, were assembled into EHDV-1 
VLPs. The negatively stained sample in Figure 64 (Fig. 64) exhibiting similar in size 
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and morphology of EHDV-1 VLP particles to that reported for BTV-10 VLPs (Fig. 
4B), but lack the dsRNA viral genome.  
 
Fig. 64. Electron micrographs of EHDV-1 VLP particles. The bar indicates 100 nm.  
 
4.2.4. Analysis of the neutralising antibody response 
Since the VLPs were generated for vaccine purpose, it was necessary to test 
whether the polyclonal antisera raised against EHDV-1 VLPs would neutralise 
EHDV-1 in vitro in BSR cells. Serum neutralisation with TCID50 was performed as 
described in the Material and Methods, and neutralisation of EHDV-1 was detected 
at dilution of 1:64 (Table 19). As controls, FSC serum was added to the BSR 
monolayers infected with EHDV-1 showing 100% CPE, while uninfected cells were 
used as negative control. Additionally, cross neutralising activities were tested 
against EHDV-2 and EHDV-6 which detected at a low dilution of 1:8 for both 
serotypes (Table 19).   
Table 19: EHDV-1 VLPs antisera neutralization titre with TCID50 in BSR cells infected with 
EHDV-1, EHDV-2 and EHDV-6.  
 
EHDV serotype EHDV-1 VLPs Sera dilution 
EHDV-1 1:64 
EDHD-2 1:8 
EHDV-6 1:8 
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In summary, using baculovirus multiple gene expression system, the genes encoding 
for the four structural proteins of EHDV-1 (VP2, VP5, VP3 and VP7), were 
successfully subcloned into specific transfer vector and integrated into baculovirus 
genome at different loci. The assembly of the expressed proteins; EHDV-1 VP7 and 
VP3 into CLPs and VP2, VP5, VP7 and VP3 into VLP particles, respectively, were 
tested by EM analysis. Antisera further raised against EHDV-1 CLP and VLP 
proteins, demonstrated their specificity in western immunoanalysis. Furthermore, 
neutralisation activities against EHDV-1, -2 and 6 serotypes were tested using 
EHDV-1 VLPs antibodies, and neutralising data demonstrated that at high antibody 
titre, low cross neutralising activities were presented.  
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4.3. DISCUSSION  
 
Several reports of multigene expression by recombinant baculovirus have depended 
on the use of homologous recombination or locus specific transposition (Tn7 
transposition), to obtain the required recombinant baculoviruses (Berger et al., 2004, 
Latham and Galarza, 2001, Stewart et al., 2010). The major target of these studies 
was to develop a highly immunogenic and safe vaccine, like the new-generation 
HPV vaccines (Koutsky et al., 2002, Harper et al., 2004). The efficacy of a current 
baculovirus multiple loci cloning system has been demonstrated via the production of 
VLPs for influenza A and BTV-1 (Noad et al., 2009), for which VLPs immunogenicity 
has been shown to be efficient against both infectious viruses (Roy et al., 1994, 
Galarza et al., 2005).  
In expression studies, two specific loci; polh and/or p10 in the baculovirus genome 
were frequently used. For heterologous protein expression, v-cath was also reported 
in a few studies (Berger et al., 2004, Fitzgerald et al., 2006), but foreign gene 
expression from other loci remained mostly uncharacterised, until 2009. In 2009, 
seven genetic loci (i.e. egt, orf51, gp37, 39k, iap2, odv-e56 and ctx) were identified 
by Noad et al (Noad et al., 2009) in addition to polh and p10.  The expression level of 
foreign gene products from these new loci was similar to that obtained from the latter 
two loci. A recent study evaluated the utility of those loci for the expression of a large 
protein, VP2 of AHSV which is ~110 kDa in size, and the level of expression was 
determined by comparing with that of polh and p10 (Kanai et al., 2013). The 
synthesis of this recombinant protein was found to be high from odv-e56, egt, p10 
and 39k loci (Kanai et al., 2013). It is notable to mention that expression cassettes in 
each of the loci, have either polh or p10 promoters, the two known strong promoters.  
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In this study, a similar approach was undertaken to develop EHDV-1 VLPs by 
simultaneous expression of the outer and inner capsid proteins from a single 
recombinant baculovirus. To address this aim, successful subcloning of the gene 
encoding the three structural proteins of EHDV-1 (VP5, VP7 and VP3) was 
performed into transfer vectors, each targeting a specific genetic locus at baculovirus 
genome (Noad et al., 2009, Kanai et al., 2013). As subcloning of the large and the 
most variable gene S2, was difficult, the previously generated recombinant plasmid 
pAcYM1-EHDV1.S2 was used to recover the recombinant baculovirus. Although 
achievable, the overall progress was affected by several drawbacks which eventually 
were all solved. 
Prior to the development of EHDV-1 VLPs, EHDV-1 CLPs (VP7 and VP3) and 
EHDV-1 VLPs composed of the three structural proteins (VP5, VP7 and VP3) were 
generated. This was to detect the expression of each gene after its integration into 
the baculovirus genome in order to determine whether the correct stepwise 
assembly of VLPs could be achieved. High expression level of EHDV-1 CLP 
recombinant proteins was achieved from egt and 39k loci as shown by SDS-PAGE 
gel analysis. Purification of cores indicated that correct assembly was successful. A 
similar molar ratio of the protein components to that predicted from the core structure 
of BTV-10 was observed, this was similar to the pattern seen for BTV-10 CLPs and 
heterologous CLPs composed of BTV-10 (VP7) and EHDV-1 (VP3) (Le Blois et al., 
1991). In contrast to the extensive work performed to produce CLPs and/or VLPs for 
BTV, to date no published reports exist regarding the formation of EHDV CLPs or 
VLPs using individual or dual expression vectors.  
To further validate the purification data, the assembly of the recombinant proteins 
into EHDV-1 CLPs was analysed by EM of purified CLPs. The EM micrographs 
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confirmed to assembly of EHDV-1 CLPs of the same size, morphology and 
organisation of VP3 and VP7 as found in the authentic EHDV-2 cores.  Here, the 
available EHDV-2 cores were purified from EHDV-2/Alberta strain and used as 
positive control, in which a nuclear-protein centre surrounded by two distinct layers 
formed by VP3 and VP7 were identified by electron micrographs. These results were 
consistent with that shown by French and Roy (French and Roy, 1990) for BTV-10 
suggesting that the structure of EHDV cores, which is closely similar to BTV, is 
maintained by the inner capsid proteins. Moreover, in contrast to the core proteins, 
none of the minor proteins, non-structural proteins or dsRNAs are necessary, 
indicating that these viral components do not play any role in the assembly of VP7 
and VP3 proteins into CLPs in Sf9/Sf21 insect cells. This is not surprising due to its 
close phylogenetic relationship to BTV. 
No antiserum directed specifically against EHDV-1 CLPs proteins has previously 
been described. This issue was addressed in this work, by raising polyclonal 
antibodies against EHDV-1 CLPs commercially by subcutaneous inoculation of 
rabbits with the purified and concentrated samples. The specificity of the antibodies 
were tested by western immunoblotting in which two unique protein bands were 
observed at low dilution of 1:10,000, indicating high specific antibody titres were 
elicited in vivo and thus indicated the high immunogenic nature of the CLPs. Each 
identified protein size was similar with the estimated sizes of the inner core structural 
proteins EHDV-1 VP7 and VP3.   
Genetic analysis of S3 and S7 of EHDV serotypes both on the nucleotide levels and 
amino acid sequences exhibited high degree of similarity (Anthony et al., 2009). 
Such high conservation was also detected by similarity with BTV, particularly for VP3 
protein, as Le Blois et al (Le Blois et al., 1991) previously demonstrated that EHDV-1 
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VP3 protein could replace the corresponding BTV protein in a heterologous CLPs. 
These results suggest that between BTV and EHDV the structure of core particles 
and their protein constituents are highly conserved in molecular interactions and 
folding. Here, antisera developed for EHDV-1 CLPs had shown strong interactions 
with the VP3 and VP7 of EHDV-2 cores as well as with BTV-10 CLPs. On serological 
bases, these outcomes were consistent with the above reports demonstrating that 
the inner capsid proteins VP3 and VP7 are not only highly preserved within EHDV 
serotypes but also react well with those of BTV serotypes. Taken together, these 
results indicated successful expression, assembly and purification of EHDV CLPs 
was achieved using the multi-locus baculovirus expression platform.  
To validate the next step of assembly of EHDV-1 VLPs, the gene sequences coding 
for the second outer capsid protein EHDV-1 VP5 needed to be integrated first into 
the recombinant baculovirus Bacmid1629:EHDV1.S7.S3. However, after several 
attempts, it was still not possible to achieve. An attempt to integrate the ORF of S5 at 
odv-e56 locus into Bacmid1629:EHDV1.S7 or Bacmid1629:EHDV1.S3, were both 
unsuccessful. However, the successful insertion was accomplished at ovd-e56 locus 
into Bacmid1629, followed by the integration of S7 and S3 of EHDV-1 in a sequential 
manner. These data suggest that the gene encoding VP5 protein is probably less 
stable and harder to be integrated into baculovirus DNA in the presence of other 
genes.  
This research presented an appropriate order of cloning the structural genes 
essential for the formation of the orbiviruses VLPs. After excising the selectable 
marker and prior to the insertion of the next gene into baculovirus genome, detecting 
the presence of the previous integrated gene was crucial step for the completion of 
this work to ensure correct expression of the targeted VLPs. 
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The simultaneous expression of the 3 capsid proteins was analysed by SDS-PAGE 
gel, showing high expression level of EHDV-1 (VP5, VP7 and VP3). In order to 
generate EHDV-1 VLPs, the expression of all four major structural proteins was 
achieved by cotransfection Sf21 insect cells with the linear pAcYM1-EHDV1.S2 and 
the circular recombinant Bacmid1629:EHDV1.S5.S7.S3. Although, variability in the 
expression level of the gene products was shown between clones, utilising this 
method, a consistent yield of recombinant proteins could be achieved from each cell 
in the culture and in the same ratio (Bertolotti-Ciarlet et al., 2003). This was 
confirmed by SDS-PAGE gel showing that EHDV-1 (VP2, VP5, VP7 and VP3) 
recombinant proteins were expressed well in an optimal proportion from the purified 
Sf9 cell lysate. The successful assembly of the recombinant proteins into VLPs was 
morphologically examined by EM using BTV VLPs as positive control. The particles 
exhibited a thick outer shell, morphologically similar to that of double-capsid 
authentic particles (French et al., 1990). Such appearance permitted an easy 
differentiation between the particles of VLPs and that of CLPs.  
Commercially, antisera were raised against the purified EHDV-1 VLPs, and their 
specificity was analysed by western immunoblotting at a dilution of 1:5,000, in which 
the antibody titre in vivo was not as strong as that of EHDV-1 CLPs. Strong 
interactions were shown for both VP7 and VP5 proteins. Additionally, high reaction 
was also observed for VP2 but less for VP3 proteins. Hypothetically, such variable 
affinity to each protein might be associated with the number of molecules per 
particles that reported for BTV; 180 molecules of VP2, 360 molecules for VP5, 120 
molecules for VP3 and 780 molecules for VP7.  
The biological ability of the raised antisera to neutralise EHDV-1 was confirmed by 
neutralisation assay with reasonably high titre (1:64), which is higher than the typical 
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neutralisation level in natural convalescent sera (1:20) collected from deer infected 
with either EHDV-1 or  EHDV-2 (Dubay et al., 2004). This data indicates that EHDV-
1 VLPs will likely to afford complete protection against EHDV-1 infection in animals.  
Further, cross neutralising activities were also detected against the genetically 
related EHDV-2 and EHDV-6 serotypes at low dilution of 1:8 which is less than that 
of the respective serotype. These data were consistent with earlier studies for 
orbiviruses, BTV in particular, demonstrating that although VP2 is the most variable 
protein and is the serotype specific antigen (Huismans and Erasmus, 1981), certain 
domains of VP2 of different serotypes are conserved based on sequence analysis. 
Overall, new data were presented in this work regarding the development of EHDV-1 
CLPs and EHDV-1 VLPs, using baculovirus as multiple gene expression system. To 
date, no work has been published addressing the assembly of the recombinant 
structural proteins into CLPs and VLPs, which was successfully confirmed in this 
study by EM analysis. In addition, the raised antisera were confirmed to neutralise 
EHDV-1, and cross neutralising reactivities were shown against EHDV-2 and EHDV-
6 serotypes. These results validate the potential efficacy of the VLPs produced in 
this study as a neutralising vaccine and strongly suggest its use as vaccine 
candidate.   
 
 
 
 
 
 
151 
 
Chapter 5 
Generation of heterologous VLPs of EHDV 
serotypes 
 
5.1.  INTRODUCTION ……………………………………………………… 
 
152 
5.2.  RESULTS ……………………………………………………………… 
 
154 
5.2.1.  The use of the baculovirus multiple genes expression 
system for the synthesis of EHDV-2 outer capsid proteins …. 
 
 
154 
5.2.1.1.  Cloning of EHDV-2 S5 into pRN296 transfer vector ………………. 
 
154 
5.2.1.2.   Generation of the recombinant Bacmid1629:EHDV2.S5 …………… 
 
155 
5.2.1.3.   Dual expression of EHDV-2 VP2 and VP5 recombinant proteins 
in baculovirus expression system …………………………………… 
 
 
157 
5.2.2.  Generation of heterologous VLPs of EHDV-2 ………………….. 
 
159 
5.2.3.  The use of the baculovirus multiple genes expression 
system for the synthesis of EHDV-7 outer capsid proteins …. 
 
 
160 
5.2.3.1.  Cloning of EHDV-7 S5 into pRN296 transfer vector ………………. 
 
160 
5.2.3.2.  Generation of the recombinant Bacmid1629:EHDV7.S5 …………… 
 
161 
5.3.  DISCUSSION ………………………………………………………….. 
 
163 
 
 
 
 
 
 
152 
 
5.1. INTRODUCTION  
 
For a long time, EHDV-1 and 2 were thought to be the only two serotypes 
responsible for causing EHD disease particularly in white-tailed deer. In 2006, this 
assumption had changed when neutralisation assay and serotype-specific (RT-PCR) 
of isolates recovered from white-tailed deer belonged to neither EHDV-1 nor EHDV-2 
(Allison et al., 2010). Serological tests and genetic analysis showed the causative 
agent to be EHDV-6, which was identified in Australia and became pathogenic in 
cattle in Morocco, Algeria, Turkey and the USA (Temizel et al., 2009, Breard et al., 
2004).  
Genetic characteristics of the emerging serotypes EHDV-6 and EHDV-7 responsible 
for the recent outbreaks, revealed a reassortment between outer capsid proteins 
(VP2 and VP5) of EHDV-6 and EHDV-7 and core proteins (VP3 and VP7) of EHDV-
2 which supposed to be the parental serotype (Allison et al., 2010). Furthermore, the 
comparison analysis of the inner core proteins sequence of the EHDV seven 
serotypes indicated a high conservation among these proteins, with identity up to 
80% for VP7 and 90% for VP3. These data were consistent with that found in 
orbiviruses, especially for BTV and AHSV.  
To overcome the disease caused by the virulent strain, earlier studies reported the 
rapid generation of heterologous VLPs of BTV-2, -4 and 9, based on the used on the 
inner structural conserved proteins of specific serotype (Stewart et al., 2010). 
Therefore, in the present study, the high sequence identity between EHDV inner 
capsid proteins would be exploited to generate heterologous VLPs of EHDV-2 and 
EHDV-7 by exchanging the outer capsid proteins (VP2 and VP5) of the latter two 
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serotypes, and coating them onto EHDV-1 CLPs which would be used as a 
foundation.  
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5.2. RESULTS  
5.2.1. The use of baculovirus multiple gene expression system for the 
synthesis of EHDV-2 outer capsid proteins  
 
5.2.1.1. Cloning of EHDV-2 S5 into pRN296 transfer vector 
To generate the recombinant Bacmid1629:EHDV2.S5 expressing the second variable 
structural protein, VP5, the ORF of EHDV-2 S5 had to be subcloned into pRN296 
transfer vector. Therefore, S5 (1641 bps) was amplified by PCR using specific 
primers from the previously constructed recombinant pAcYM1-EHDV2.S5. The PCR 
product was visualised on agarose gel as a DNA fragment corresponding to the size 
of 1641 bps (Fig. 65, lane 2). The purified gene was then ligated into pRN296 under 
the control polyh promoter (Fig. 66A). The accurate construction of the recombinant 
plasmid pRN296-EHDV2.S5 was determined by PCR screening of several ampicillin 
resistance colonies, using EHDV-2 S5 primers (Table 7). Three colonies were shown 
to contain the targeted gene (Fig. 66B, lanes 3, 4 and 6), corresponding to the size 
of the positive control EHDV2.S5 in the recombinant plasmid pAcYM1-EHDV2.S5 
(Fig. 66B, lane 2). Another amplification was carried out to identify the orientation of 
EHDV-2 S5 using PH (F) and EHDV-2 S5 (R) primers. A correct orientation of S5 
gene was detected in two recombinants (Fig. 67, lanes 3 and 5) when visualised on 
1% agarose gel.  
 
Fig. 65. Molecular analysis of the PCR amplification of EHDV-2 S5 using EHDV-2 S5 (F and R) 
primers. Lane 1: DNA ladder and lane 2: EHDV-2 S5 (1641 bps).  
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Fig. 66. Molecular analysis to detect the presence of EHDV-2 S5 in the recombinant pRN296-
EHDV2.S5 using EHDV-2 S5 (F and R) primers. Lane 1: DNA ladder, lane 2: positive control 
(pAcYM1-EHDV2.S5) and lanes 3-6: EHDV-2 S5 in the construct pRN296-EHDV2.S5. Clones in 
lanes # 3, 4 and 6 are positives.   
 
 
Fig. 67. Molecular analysis to detect the orientation of EHDV-2 S5 in the recombinant 
pRN296-EHDV2.S5 using PH (F) and EHDV-2 S5 (R) primers. Lane 1: DNA ladder, lane 2: negative 
control and lanes 3-5: EHDV-2 S5 in the construct pRN296-EHDV2.S5. Colonies in lanes 3 and 5 are 
positives.  
 
5.2.1.2. Generation of the recombinant Bacmid1629:EHDV2.S5 
 
To integrate EHDV-2 S5 into the recombinant baculovirus, both expression and 
selectable markers were amplified using pRN296-ec (F and R) primers (Table 10) 
(Fig. 68A). Amplification products were identified by agarose gel as one band 
corresponding to the estimated size of 4800 bps (Fig. 68B, lane 2). The amplified 
DNA fragment was then integrated into Bacmid1629 genome at odv-e56 locus, and the 
correct integration was tested by PCR amplification using EHDV-2 S5 primers. Gel 
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electrophoresis in Figure 69, lane 4 displayed the DNA amplicon corresponding to 
the predicted size of EHDV-2 S5 from the positive control pRN296-EHDV2.S5 (Fig. 
69. lane 3). Negative control, the WT Bacmid1629, used, showed no amplification in 
Figure 69, lane 2 (Fig. 69, lane 2).  
 
 
Fig. 68. Amplification of the selectable and expression cassettes flanked by AcMNPV 
sequences. (A) pRN296-EHDV2.S5 map showing pRN296-ec (F and R) primers. (B) PCR 
amplification with pRN296-ec (F and R) primers. Lane 1: DNA ladder and lane 2: amplification of the 
cassettes.    
 
 
Fig. 69. Molecular analysis to detect the integration of EHDV-2 S5 in the recombinant 
Bacmid1629:EHDV2.S5 using specific EHDV-2 S5 (F and R) primers. Lane 1: DNA ladder, lane 2: 
Bacmid1629 wild type, lane 3: EHDV-2 S5 in the recombinant pRN296-EHDV2.S5 (positive control) and 
lane 4: Bacmid1629:EHDV2.S5.  
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For simultaneous synthesis of EHDV-2 VP2 and VP5 capsid proteins, the selectable 
cassette was flipped out by the addition of 0.1% arabinose to the bacterial culture 
(Fig. 70A). Following flipping the marker out, colony PCR was performed on two 
clones to determine whether the targeted gene was presented in the 
Bacmid1629:EHDV2.S5 recombinant. The resulted data were verified on agarose gel 
as one specific band of size of EHDV-2 S5 (Fig. 70B, lane 3), and no amplification 
corresponding to S5 was identified in another clone (Fig. 70B, lane 2).  
 
 
Fig. 70. Molecular analysis to determine the presence of EHDV-2 S5 after flipping out the 
selectable marker. (A) Analysis map of the recombinant Bacmid1629:EHDV2.S5 after flipping out the 
selectable cassette. (B) PCR amplification of EHDV-2 S5 using specific (F and R) primers. Lane 1: 
DNA ladder, lanes 2 and 3: Bacmid1629: EHDV2.S5. Clone in lane 3 is positive.   
 
5.2.1.3. Dual expression of EHDV-2 VP2 and VP5 recombinant proteins in 
baculovirus expression system  
 
 
To produce dual recombinant baculovirus expressing EHDV-2 outer layer proteins, 
Sf21 insect monolayers were cotransfected with Bsu36I linearised recombinant 
Bacmid1629:EHDV2.S5 and the recombinant plasmid pAcYM1-EHDV2.S2. The 
efficient expression of the recombinant proteins VP2 and VP5 were analysed by 10% 
SDS-PAGE. As seen in Figure 71, lane 4, two intense protein bands corresponding 
to the sizes of EHDV-2 VP2 (114 kDa) and EHDV-2 VP5 (59 kDa) (Fig. 71, lane 4), 
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from the infected lysate of Sf9 insect cells were identified. As positive controls, the 
individual synthesis of EHDV-2 VP2 (Fig. 71, lane 5), EHDV-1 VP2 (112 kDa) (Fig. 
71, lane 6), EHDV-2 VP5 (59 kDa) (Fig. 71, lane 7) and EHDV-1 VP5 (59 kDa) (Fig. 
71, lane 8), were used. Negative controls, uninfected Sf9 insect cells (Fig. 71, lane 2) 
and the recombinant AcMNPV pRN43-GFP (Fig. 71, lane 3), were utilised.  
 
Fig. 71. 10% SDS-PAGE analysis of the recombinants EHDV-2 VP2 and VP5 expression in 
Bacmid1629:EHDV2.VP2.VP5 from clonal populations. Lane 1: protein ladder, lane 2: Sf9 insect 
cells, lane 3: Sf9 insect cells infected with the recombinant AcMNPV pRN43-GFP, lane 4: lysate from 
cells infected with dual baculovirus expressing EHDV-2 VP2 and EHDV-2 VP5, lane 5: individual 
expression of EHDV-2 VP2 (positive control), lane 6: individual expression of EHDV-1 VP2 (positive 
control), lane 7: individual expression of EHDV-2 VP5 (positive control) and lane 8: individual 
expression of EHDV-1 VP5 (positive control). All recombinant proteins are indicated in black arrows.  
 
 
 
For further confirmation of the synthesis of the most variable protein EHDV-2 VP2, 
western blot with the raised antisera against this recombinant protein was performed. 
Post blotting, a defined band equivalent to the estimated size of EHDV-2 VP2 (114 
kDa) was visualised on a nitrocellulose membrane (Fig. 72, lane 3), similar to that 
detected from the individual expression of EHDV-2 VP2 protein (Fig. 72, lane 4). No 
precise protein band of the size of VP2 was found in Sf9 insect cell lysate infected 
with the recombinant AcMNPV pRN43-GFP (Fig. 72, lane 2).  
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Fig. 72. Immunoblotting analysis of the expression of EHDV-2 VP2 in the dual baculovirus 
Bacmid1629:EHDV2.VP2.VP5. Lane 1: protein ladder, lane 2: Sf9 insect cells infected with 
recombinant AcMNPV pRN43-GFP, lane 3: lysate from Sf9 insect cells infected with purified dual 
recombinant baculovirus expressing EHDV-2 VP2 (114 kDa) (black arrow) and lane 4: individual 
expression of EHDV-2 VP2 (114 kDa) (positive control). 
 
 
5.2.2. Generation of heterologous VLPs of EHDV-2  
To develop heterologous VLPs composing of EHDV-1 and EHDV-2, monolayers of 
Sf21 insect cells were coinfected with dual recombinant baculoviruses each 
synthesising two proteins; EHDV-1 VP3 and VP7 and EHDV-2 VP2 and VP5. 
Several rounds of amplifications were performed in Sf9 insect cells from clonal 
populations to increase the titre of baculovirus. To detect whether the four structural 
proteins were expressed in correct ratios, 10% SDS-PAGE analysis was undertaken. 
The detection of each of the recombinant proteins of VP2 (114 kDa) and VP5 (59 
kDa) of EHDV-2, VP3 (103 kDa) and VP7 (39 kDa) of EHDV-1 was shown in Figure 
73, lane 3 (Fig. 73, lane 4), similar to the sizes of EHDV-1 protein components that 
were used as positive control (Fig. 73, lane 3).   
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Fig. 73. 10% SDS-PAGE analysis of EHDV-2 heterologous VLPs. Lane 1: protein ladder, lane 2: 
Sf9 insect cells infected with the recombinant AcMNPV pRN43-GFP, lane 3: EHDV-1 VLPs and lane 
4: Heterologous VLPs of EHDV-2 (red arrows).  
 
5.2.3. The use of baculovirus multiple genes expression system for the 
synthesis of EHDV-7 outer capsid proteins 
 
5.2.3.1. Cloning of EHDV-7 S5 into pRN296 transfer vector 
 
 
The PCR amplification of EHDV-7 S5 coding region (1769 bps) generated in chapter 
3, was successfully cloned into pRN296 BamHI linearised and dephosphorylated 
vector. The cloned recombinant DNA was analysed by agarose gel electrophoresis 
which showed DNA fragment of the size of 1769 bps in lane 7 (Fig. 74, lane 7). 
Further PCR amplification was undertaken using PH (F) and EHDV-7 S5 (R) primers 
to identify the orientation of EHDV-7 S5 in the recombinant plasmid pRN296-
EHDV7.S5. Figure 75, lane 3 of agarose gel electrophoresis showed one band 
equivalent to the size of EHDV-7 S7 (Fig. 75. lane 3). PCR reaction without DNA 
template was performed as a negative control, showing no bands in lane 3, Figure 
75 (Fig. 75, lane 3).  
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Fig. 74. Molecular analysis to detect the presence of EHDV-7 S5 in the recombinant pRN296-
EHDV7.S5 using EHDV-7 S5 (F and R) primers. Lane 1: DNA ladder and lanes 2-8: pRN296-
EHDV7.S5. Clone in lane # 7 was positive.   
 
 
Fig. 75. Molecular analysis to detect the orientation of EHDV-7 S5 in the recombinant 
pRN296-EHDV7.S5 using PH (F) and EHDV-7 S5 (R) primers. Lane 1: DNA ladder, lane 2: negative 
control and lane 3: EHDV-7 S5 in the construct pRN296-EHDV7.S5.  
 
 
 
5.2.3.2. Generation of the recombinant Bacmid1629:EHDV7.S5 
 
To incorporate EHDV-7 S5 into Bacmid1629, the expression marker containing S5 
gene and polyh promoter, lacZα and ZeoR genes were amplified by pRN296-ec 
primers (Table 10). After electroporation of the PCR fragment into E3K2 
electrocompetent cells, the presence of the recombinant Bacmid1629:EHDV7.S5 was 
identified in a number of blue colonies. Using EHDV-7 S5 primers, three positive 
amplicons were visualised by agarose gel electrophoresis (Fig. 76, lane 4, 6 and 7), 
having DNA fragment similar to the size of EHDV-7 S5 in the positive control 
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pRN296-EHDV7.S5 (Fig. 76, lane 3). As a negative control, the WT Bacmid1629, was 
used showing no amplification (Fig. 76, lane 2).  
 
Fig. 76. Molecular analysis to detect the integration of EHDV-7 S5 in the recombinant 
Bacmid1629:EHDV7.S5 using specific EHDV-7 S5 (F and R) primers. Lane 1: DNA ladder, lane 2: 
Bacmid1629 wild type and lanes 3-7: EHDV-7 S5 in the recombinant pRN296-EHDV7.S5. Clones in 
lanes # 3, 4, 6 and 7 are positives.   
 
 
To conclude, the ORFs of EHDV-2 S2 and S5 encoding for the outer capsid proteins, 
essential in the formation of heterologous VLPs, were successfully inserted into 
baculovirus at polh and odv-e56 loci. High expression level of both recombinant 
proteins; VP2 and VP5 in the dual Bacmid1629:EHDV2.VP2.VP5, was efficiently 
achieved in Sf21 insect monolayers. The expression of EHDV-2 VP2 recombinant 
protein was further confirmed by western blotting using antisera raised against VP2. 
A successful formation of EHDV-2 heterologous VLPs were performed and further 
analysed by SDS-PAGE. An initial attempt to produce EHDV-7 heterologous VLPs 
using EHDV-1 CLPs as scaffold was undertaken.  
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5.3. DISCUSSION  
 
For the control of EHD, commercial vaccines are not widely available except the live 
attenuated vaccine, which was developed for IBAV/EHDV-2 infectious virus in Japan 
and proved to be safe until 1997 (Ohashi et al., 1999). Since 2006 several outbreaks 
of severe disease in cattle were documented in the USA and European boarding 
counties, via multiple strains of EHDV. Hence, the overlapping outbreaks of different 
EHDV serotypes, particularly EHDV-2 (Omori et al., 1969, Campbell and St George, 
1986), EHDV-6 and EHDV-7 (Yadin et al., 2008, Temizel et al., 2009), highlighted 
the necessity for rapid VLPs production against multiple serotypes.   
Developing VLPs for the seven immunogically distinct serotypes of EHDV is far more 
challenging for several reasons. Generating VLPs require the synthesis of four viral 
structural proteins (VP2, VP5, VP7 and VP3), two of the genes coding for VP2 and 
VP3 proteins are large in their sizes (~3 kb). Transfer vectors containing the four viral 
genes are more than 12 kb in length. More importantly, in practice, re-cloning S2 and 
S5 genes is not an easy approach due to their toxicity features to the host cell. Thus, 
the rational solution was the development of heterologous VLPs for EHDV 
serotypes. 
In this study, the aim was the use of baculovirus as a multiple gene expression 
system for simultaneous synthesis of heterologous VLPs for EHDV. As earlier shown 
in the previous chapter, to integrate the four structural genes into baculovirus 
genome at different loci, a specific order should be followed, in which S5 gene 
should be the first then S3 and S7. However, subcloning the latter gene into specific 
vectors and inserting them into baculovirus is difficult and time consuming. 
Therefore, heterologous VLPs were produced for EHDV-2 using EHDV-1 CLPs as a 
background. In a similar manner, an attempt was carried out to generate a 
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heterologous VLPs of EHDV-7. The choice of the three serotypes was based on their 
economic importance and genetic relationships at both the amino acid and 
nucleotide levels (Allison et al., 2010). 
Previous report demonstrated the assembly of heterologous VLPs of BTV-1, -2, -10, 
-11, -13 and -17 serotypes by coinfection of Sf21/9 insect cell lines with three 
recombinant baculoviruses (Loudon et al., 1991). Though achievable, the resultant 
recombinant proteins were not expressed in each infected cell in the same expected 
ratio (Bertolotti-Ciarlet et al., 2003). This was consistent with the results obtained in 
this work when coinfection with three viruses; EHDV-1 CLPs, EHDV-2 VP2 and VP5 
was performed in Sf9 insect cells. No expression was seen from EHDV-2 VP2 and 
only low expression of EHDV-2 VP5 was detected, although, both inner core proteins 
of EHDV-1 were highly expressed.  
 
Thus, to achieve this target, the previously synthesised single-shelled CLPs of 
EHDV-1 was subsequently used to prepare the modified VLPs. This was based on 
the fact that the inner core proteins are relatively well preserved among Orbivirus 
members in comparison to the outer capsid proteins. Moreover, Belyaev and Roy 
have shown that the outer capsid proteins from different BTV serotypes could be 
coated onto a heterologous inner core protein using baculovirus expression vectors 
(Belyaev and Roy, 1993). Following such findings, an improved strategy was 
recently developed for the generation of heterologous VLPs for BTV-2, -4 and 9 
serotypes (Stewart et al., 2010), in which BTV-10 core proteins (VP3 and VP7) were 
used for the generation of heterologous vaccines by replacing the most variable 
outer capsid proteins (VP2 and VP5) of BTV-2, -4 and -9 (Stewart et al., 2010). 
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For the formation of dual recombinant baculovirus, VP5 was inserted into the odv-
e56 locus as published literature reported that this site was proven to be suitable for 
high levels of expression (Noad et al., 2009, Kanai et al., 2013). In order to validate 
the stable expression of EHDV-2 outer capsid proteins (VP2 and VP5) in insect cells 
a dual expression virus was recovered and expression level detected on SDS-
PAGE, which demonstrated bands of the correct predicted sizes for EHDV-2 VP2 
and VP5 viral proteins. For further confirmation, EHDV-1 (VP2 and VP5) proteins 
that individually expressed using baculovirus were used. A slight difference in terms 
of size was detected by SDS-PAGE between VP2 of EHDV-1 and that of EHDV-2, 
but not for VP5 proteins, which is consistent with the molecular weight of these 
proteins; EHDV-1 VP2 (~ 112 kDa), EHDV-2 VP2 (~ 114 kDa) and ~ 59 kDa for 
EHDV-1 and EHDV-2 VP5. These results demonstrate the variability in the 
outermost VP2 proteins of EHDV presumably due to host selective pressure of the 
humoral immune response, consistent with variability reported in BTV serotypes. 
Despite the extensive protein expression work that has been undertaken in the 
baculovirus system for BTV (the closely similar virus to EHDV) (French et al., 1990, 
French and Roy, 1990), very little literature is available describing the expression of 
the recombinant proteins for EHDV serotypes. In this report, the antigenic properties 
of the most variable recombinant protein EHDV-2 VP2 in the purified dual 
baculovirus Bacmid1629:EHDV2.VP2.VP5 were examined by blotting with specific 
antibodies produced previously. Strong signals of the expressed EHDV-2 VP2 
protein were visualised exhibiting similar reactivity to that of VP2 from EHDV-2 
virions, indicating that the expressed recombinant VP2 protein in baculovirus system 
retained the nature of the epitope of the authentic virion.  
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The incorporation of outermost shell proteins of EHDV-2 (VP2 and VP5) into EHDV-
1 CLPs (VP7 and VP3) was analysed by coinfecting the Sf9 insect with the dual 
recombinant baculoviruses. Each of these recombinants expressed two of the capsid 
proteins: Bacmid1629:EHDV2.VP2.VP5 and Bacmid1629:EHDV1.VP7.VP3. The results 
obtained from purified Sf9 infected cell lysate, showed the presence of four protein 
bands equivalent to the size of EHDV-2 (VP2 and VP5), EHDV-1 (VP7 and VP3) in 
correct ratios when compared to EHDV-1 and EHDV-2 authentic virions. Such 
findings gave an opportunity for determining the conservative nature of the 
interacting sites of the structural outer capsid proteins between EHDV-1 and EHDV-2 
serotypes.  
A preliminary step was conducted in this project to study the possibility of developing 
heterologous VLPs composed of EHDV-1 CLPs (VP7 and VP3) and EHDV-7 outer 
capsid proteins (VP2 and VP5). Using baculovirus multiple loci expression system, 
the coding region of the EHDV-7 S5 was subcloned into transfer vector pRN296 and 
successfully inserted into baculovirus genome at odv-e56 locus, however due to time 
restrictions further study that needed to be performed to validate this heterologous 
VLP was not possible.  
Overall, new data were presented in this report showing a successful generation of 
the heterologous VLPs of EHDV serotypes. This was achieved by using EHDV-1 
CLPs, due to their conservative nature among orbiviruses, which coated by the outer 
capsid proteins of EHDV-2 (VP2 and VP5). High level synthesis of the recombinant 
proteins EHDV-2 (VP2 and VP5) was identified from a dual expression baculovirus 
coinfection. Post coinfection of Sf9 insect cells, the authenticity of the structural 
proteins forming heterologous VLPs EHDV-2 (VP2 and VP5), EHDV-1 (VP7 and 
VP3), was confirmed by SDS-PAGE in terms of sizes. Further confirmation of 
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antigenic reactions of the recombinant EHDV-2 VP2 protein in the dual 
Bacmid1629:EHDV2.VP2.VP5, were identified by immunoblotting. Moreover, an initial 
step to produce heterologous VLPs of EHDV-7 by exchanging the variable outer 
capsid proteins EHDV-7 (VP2 and VP5) on the conserved EHDV-1 CLPs was 
established.  
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6.1. INTRODUCTION 
EHDV is genetically closely related to BTV, which has been considered as a model 
for other members of Orbivirus genus. Since both EHDV and BTV have similar 
properties of viral structure and replication, the RG system for EHDV can also 
contribute to vaccine development, similar to BTV. Hence, using RG system, the aim 
of this study was to develop a rationally designed attenuated vaccine against EHDV-
2, the causative agent of several outbreaks in both cattle and deers (Omori et al., 
1969, Campbell and St George, 1986).   
The first indication that RG system could be possible for the members of Reoviridae 
family was reported by Roner and Joklik (Roner and Joklik, 2001). They reported the 
ability of recovering the infectious reovirus using core transcripts, synthesised in 
vitro, combining with a transcript of one of the virus genome segments (Roner and 
Joklik, 2001). Later, Boyce et al has shown that the recovery of BTV-1 virus entirely 
from ssRNA extracted from cores could be achieved without using helper vector 
(Boyce and Roy, 2006). In this study, aimed at generating a RG system for EHDV-2, 
the possibility of recovering the infectious EHDV-2 from core transcripts in vitro 
synthesised would be examined in BSR monolayers.  
Infectious BTV has been entirely produced from cDNA, by generating in vitro T7- 
transcripts for each of the 10 RNA segments, and by transfecting the permissive 
cells with the generated transcripts (Boyce et al., 2008). Such successful findings 
allowed the generation of specific mutations that could be exploited in the 
development of an attenuated vaccine. Therefore, to investigate whether EHDV-2 
could be recovered from the 10 synthetic T7 transcripts, exact copy of the 10 
segments needed to be cloned into pUC19 transfer vector, wherein the segments 
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are flanked by T7 promoter at the 5` end and a restriction enzyme site at the 3` end, 
respectively.  
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6.2. RESULTS  
6.2.1. Isolation of EHDV-2 virus 
 
To ensure the purify of a clonal population of EHDV-2, Alberta/Canada (CAN1962) 
strain provided from a collaborator’s laboratory, BSR monolayers were infected with 
EHDV-2 and individual plaques were isolated from varying dilutions of the viral 
stocks, and grown in BSR monolayer. To examine the migration pattern of the 
segmented genome, the dsRNAs were extracted and purified as discussed in the 
Materials and Methods. The profile and the purity of the genome segments were 
visualised on the nondenaturing 9% PAGE gel. Ethidium bromide staining showed 
10 segments of the dsRNAs S (1-10) from large to small RNA segment, in order of 
their migration. Each RNA segment size was correlated to the estimated sizes of S1 
(3942 bps), S2 (3002 bps), S3 (2768bps), S4 (1983 bps), S5 (1803 bps), S6 (1641 
bps), S7 (1162 bps), S8 (1186 bps), S9 (1143 bps) and S10 (810 bps) (Fig. 77, lane 
2). As a positive control, BTV-1 genomic RNAs were used (Fig. 77, lane 1).   
 
Fig. 77. 9% PAGE analysis of the 10 RNA segments of EHDV-2 showing the migration pattern 
of each segment. Lane 1: BTV-1 dsRNAs (positive control) and lane 2: EHDV-2 dsRNAs from plaque 
#1.  
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6.2.2. Purification of EHDV-2 cores and in vitro synthesis of EHDV-2 ssRNAs 
To analyse whether EHDV-2 cores were transcriptionally active, confluent BSR 
monolayers were infected with EHDV-2 and the virus titre was analysed by plaque 
assay (Fig. 78). For the preparation and purification of EHDV-2 cores, BSR cells 
were infected with the virus at a MOI of 1.0.  Following purification, 10% SDS-PAGE 
analysis of the purified cores was carried out showing the existence of all five 
proteins (VP1, VP3, VP4, VP6 and VP7) that forms the cores in the expected ratios 
with the absence of the outer capsid proteins, VP2 and VP5 (Fig. 79, lane 4). For the 
synthesis of EHDV-2 ssRNAs, core concentration was estimated using 0.2 µg/µl 
(Fig. 79, lane 2) and 0.5 µg/µl (Fig. 79, lane 3) of BSA protein. Using Bradford 
protein assay, the total concentration of the purified cores was estimated 
approximately equal to 0.3 µg/µl (Fig. 79, lane 4).  
 
 
Fig. 78. Quantification of EHDV-2 virus in BSR cells. BSR monolayer fixed with 10% 
formaldehyde and stained with crystal violet 3 days post infection.  
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Fig. 79. 10% SDS-PAGE analysis of the purified EHDV-2 cores. Lane 1: protein ladder, lane 2: 
0.2 µg/µl of BSA protein, lane 3: 0.5 µg/µl of BSA protein and lane 4: EHDV-2 core proteins.  
 
In vitro, EHDV-2 ssRNAs were synthesised using the in vitro transcription conditions 
for the cores which are discussed in the Materials and Methods. To remove the 
infectious cores from the newly synthesised RNA transcripts, at the end of 
transcription process, ultracentrifugation was performed twice followed by two 
rounds of phenol-chloroform extraction to deproteinize the sample. The total RNA 
containing both the ssRNA transcripts and dsRNA was isolated. The ssRNAs were 
selectively precipitated by 2 M LiCl treatment as discussed in the Materials and 
Methods, and examined on 1% denaturing agarose gel electrophoresis using 0.5 
µg/µl of the purified transcripts. Figure 80, lane 2 displays the 10 viral transcripts; no 
premature termination or degradations were observed (Fig. 80, lane 2).  
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Fig. 80. Denaturing 1% agarose gel electrophoresis of purified EHDV-2 ssRNAs. Lane 1: 
ssRNAs marker (1 µg) and lane 2: 1.5 µg EHDV-2 ssRNAs  
 
 
6.2.3. Recovery of the infectious EHDV-2 from BSR cells transfected with 
purified EHDV-2 ssRNAs 
 
To examine the probability of recovering the infectious virus EHDV-2 from ssRNA 
transcripts, BSR cells were transfected twice, 18 hours apart, with a total of 1.0 µg or 
1.5 µg of ssRNAs for each transfection as described for BTV (Matsuo and Roy, 
2009). After 48 hours of incubation, CPEs similar to that caused by EHDV-2 
infection, were detected in BSR cells transfected with 1.0 µg ssRNAs (Fig. 81B). A 
complete CPE was observed at 3 dpt, in the BSR monolayers transfected with 1.0 µg 
of EHDV-2 ssRNAs (Fig. 81D), while 100% CPE was detected in BSR cells 
transfected with 1.5 µg of ssRNAs just after 18 hours of the first transfection (Fig. 
81C). The untreated BSR cells were used as negative control (Fig. 81A).  
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Fig. 81. The recovery of EHDV-2 virus from ssRNA transcripts. (A) Untreated BSR cells (B) BSR 
cells transfected with 1.0 µg of EHDV-2 ssRNAs at 48 hpt (C) BSR cells transfected with 1.5 µg of 
EHDV-2 ssRNA at 18 hpt and (C) BSR cells transfected with 1.0 µg of EHDV-2 ssRNA at 72 hpt.  
 
To detect whether the viral ssRNAs were replicated to produce the genomic dsRNAs 
were extracted at 72 hpt and purified from BSR cells that had been transfected with 
1.0 µg of EHDV-2 ssRNAs. The dsRNA genome profile was analysed by 
electrophoresis on 1% agarose gel (Fig. 82). Gels show 10 discrete segments of 
dsRNA derived from transfection (Fig. 82, lane 3), indistinguishable from that 
obtained from EHDV-2 virus (Fig. 82, lane 2), confirming that the dsRNAs were 
efficiently synthesised in the BSR cells transfected with EHDV-2 core transcripts 
(Fig. 82, lane 3).  
Simultaneously, BSR cells were inoculated with 60 µl of 1 ml supernatant harvested 
from transfected cells, to determine the presence of the infectious virus. After 3 days 
of inoculation, a 100% CPE was detected through the entire culture confirming the 
presence of the infectious virus (Fig. 83B).   
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Fig. 82. 1% agarose gel electrophoresis of the synthesis of EHDV-2 dsRNAs from the 
recovered virus. Lane 1: DNA marker, lane 2: EHDV-2 dsRNAs extracted from BSR cells infected 
with EHDV-2 virus and lane 3: dsRNAs extracted from transfected BSR cells 72 hpi.  
 
 
 
Fig. 83. Infection of BSR cells with the culture harvested from cells transfected with 1.0 µg 
ssRNA. (A) Uninfected BSR cells (B) 2.5 X105 BSR cells infected with 60 µl of the culture harvested 
from cells transfected with 1.0 ssRNA. The images were captured 3 days post infection (dpi).  
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The recovered virus was quantified and the pattern of the plaques were determined 
in the infected BSR monolayers overlaid with low melting agarose gel. Plaques 
produced from the recovered virus (Fig. 84A) had the same morphology as that 
obtained by viral infection (Fig. 84B). Individual plaques were picked and amplified 
by infecting monolayers of 106 BSR cells, followed by extraction of dsRNAs from one 
plaque. The separated dsRNAs analysed by 0.8% agarose gel electrophoresis 
demonstrated 10 dsRNA segments (Fig. 85, lane 2) similar in terms of sizes and 
mobility to that obtained from infection (Fig 85, lane 1).  
 
 
Fig. 84. Plaques morphology in BSR cells infected with the recovered EHDV-2 virus (A) and 
the wild type EHDV-2 (B) fixed with 10% formaldehyde and stained with crystal violet 3 dpi.  
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Fig. 85. 0.8% agarose gel analysis of the segmented pattern of EHDV-2 dsRNAs. Lane 1: 
EHDV-2 dsRNAs extracted from BSR cells infected with EHDV-2 virus and lane 2: dsRNAs extracted 
from BSR cells infected with the recovered EHDV-2.  
 
6.2.4. The recovery of EHDV-2 from plasmid-derived T7 transcripts 
 
6.2.4.1. Amplification of the 10 RNA segments of EHDV-2  
 
Following the successful recovery of the infectious EHDV-2 from core transcripts, the 
recovery of the virus entirely from the 10 plasmid-derived T7 transcripts using RG 
system was examined. The cDNA copies of the 10 genomic segments of EHDV-2 
were amplified from viral dsRNA in a sequence-independent manner using the 
method of FLAC. After ligating the self-priming anchor-primer C9 (Table 12) at both 
sides of the 10 segments of viral dsRNA, the unlinked oligos were removed by 
electrophoresis of dsRNA on 0.8 % agarose gel. For the synthesis of first-strand 
cDNA, the 10 segments of dsRNA were excised, purified from gel and subjected to 
the RT-PCR step using Premium RevertAid RT enzyme. Subsequently, the full-
length cDNA copies of all 10 EHDV-2 genome segments were amplified using 
FLAC2 primer (Table 12). The PCR products were visualised on 1% agarose gel as 
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a single specific band corresponding respectively to the published sizes of EHDV-2 
S (1-10) (Table 8) (Fig. 86, A–H).  
 
Fig. 86. 1% agarose gel analysis of the full-length cDNA copies from the 10 segments of 
EHDV-2 generated by FLAC2 primer.  (A) EHDV-2 S1. Lane 1: DNA ladder and lane 2: EHDV-2 S1.  
(B) EHDV-2 S2. Lane 1: DNA ladder and lane 2: EHDV-2 S2. (C) EHDV-2 S3. Lane 1: DNA ladder 
and lane 2: EHDV-2 S3. (D) EHDV-2 S4. Lane 1: DNA ladder and lane 2: EHDV-2 S4. (E)  EHDV-2 
S5. Lane 1: DNA ladder and lane 2: EHDV-2 S5. (F) EHDV-2 S6. Lane 1: DNA ladder and lane 2: 
EHDV-2 S6. (G) EHDV-2 S (7+8+9). Lane 1: DNA ladder and lane 2: EHDV-2 S (7+8+9). (H) EHDV-2 
S10. Lane 1: DNA ladder and lane 2: EHDV-2 S10.  
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6.2.4.2. Cloning of the 10 cDNAs of EHDV-2 into pUC19 vector 
The amplified cDNA copies were purified from 1% agarose gel and cloned into a 
SmaI linearized pUC19 vector (Fig. 87A). Efficient linearisation of pUC19 was 
identified by gel electrophoresis (Fig. 87B, lane 3) in comparison to the circular 
vector (Fig. 87B, lane 2). To detect the generation of the 10 recombinants plasmids 
containing each of EHDV-2 segments, colony PCR was performed using FLAC2 
primer. The correct integration of each segment was visualized by 1% agarose gel 
electrophoresis as single specific band corresponding to the estimated size of each 
segment as shown in Figure 88 (Fig. 88, A-F) and Figure 89 (Fig. 89, A-D).  
The recombinant plasmids were extracted and sequenced using primers specific to 
the vector M13 (F and R) (Table 12) and the respective gene (Table 13). The results 
of the full sequences were confirmed by BlastN to be EHDV-2 S (1-10) (Table 8). 
 
 
 
Fig. 87. Molecular analysis of pUC19 vector. (A) Map of pUC19 transfer vector showing M13 (F 
and R) primers and SmaI endonuclease enzyme site. (B) SmaI restriction digestion of pUC19 vector 
visualized by1% agarose gel electrophoresis. Lane 1: DNA ladder, lane 2: pUC19 (circular) and lane 
3: pUC19 (linear).   
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Fig. 88. Colony PCR with FLAC2 primer visualised by 1% agarose gel electrophoresis to 
detect the correct cloning of EHDV-2 (S1-S6) in pUC19 vector. (A) pUC19-EHDV2.S1. Clone in 
lane 5 is positive. (B) pUC19-EHDV2.S2. Clone in lane 3 is positive. (C) pUC19-EHDV2.S3. Clones in 
lanes 3 and 4 are positives. (D) pUC19-EHDV2.S4. Clones in lanes 2 and 4 are positives. (E) pUC19-
EHDV2.S5. Clones in lanes 3, 4, 5, and 6 are positives and (F) pUC19-EHDV2.S6. All clones are 
positives. 
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Fig. 89. Colony PCR with FLAC2 primer visualised by 1% agarose gel electrophoresis to 
detect the correct cloning of EHDV-2 (S7-S10) in pUC19 vector. (A) pUC19-EHDV2.S7. Clones in 
lanes 2 and 4 are positives. (B) pUC19-EHDV2.S8. Clones in lanes 2, 4 and 5 are positives. (C) 
pUC19-EHDV2.S9. Clones in lanes 3 and 4 are positives. (D) pUC19-EHDV2.S10. Clone in lane 3 is 
positive. 
 
 
6.2.4.3. The construction of T7 clones of EHDV-2 10 segments  
Once a complete set of the 10 EHDV-2 clones was achieved, primers with T7 
promoter and reverse primer containing a specific endonuclease enzyme for each 
segment were designed (Table 18). To introduce the T7 promoter upstream of the 
genome segment and the restriction enzyme site downstream, each segment was 
amplified by PCR and the products were visualised by 1% agarose gel 
electrophoresis. Figure 90 shows 10 precise DNA fragments corresponding to the 
correct sizes of EHDV-2 genes (Fig. 90, lanes 2-11).   
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Fig. 90. Amplification of the functional cassettes containing T7 promoter, EHDV-2 segments 
and specific enzyme visualised by 1% agarose gel electrophoresis. Lane 1: DNA marker, lane 2: 
EHDV-2 S1, lane 3: EHDV-2 S2, lane 4: EHDV-2 S3, lane 5: EHDV-2 S4, lane 6: EHDV-2 S5, lane 7: 
EHDV-2 S6, lane 8: EHDV-2 S7, lane 9: EHDV-2 S8, lane 10: EHDV-2 S9 and lane 11: EHDV-2 S10.  
 
The amplified EHDV-2 segments were subcloned into SmaI linearised pUC19 vector. 
The introduction of each enzyme in a correct orientation was confirmed by restriction 
digestion with the enzyme sites had been incorporated into the primers. For 
instance, BsmbI digestion was performed to detect the integration of EHDV-2 S1 
gene into pUC19-EHDV2.S1. The results were visualised on agarose gel as two 
fragments, one corresponding to the size of EHDV-1 S1 (3942 bps) and another to 
the size of pUC19 (2500 bps) (Fig. 91, lane 3). In lane 5, Figure 91, two bands were 
shown equivalent to EHDV-2 S2 (3002 bps) and pUC19 post digestion with BsaI 
(Fig. 91, lane 5), while lane 4 revealing the circular recombinant pUC19-EHDV2.S2 
(Fig. 91, lane 4). Additionally, the construct pUC19-EHDV2.S3 (Fig. 92, lane 2) was 
linearised by BsaI enzyme and the data shown as one band in lane 3, Figure 92 (Fig. 
92, lane 3). The presence of the BsaAI enzyme site in the recombinant plasmid 
pUC19-EHDV2.S4 was shown in lane 5, Figure 92 (Fig. 92, lane 5). Recombinant 
plasmids; pUC19-EHDV2.S5 and pUC19-EHDV2.S6 were digested by BsaI and 
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BbsI, respectively. The efficient linearisaion was detected in lanes 7 and 9 post 
electrophoresis on a 1% agarose gel (Fig. 92, lanes 7 and 9).  
The four small segments S (7-10), were linearised with BsaI, BsmbI, BsbI and BsbI, 
respectively, and data displayed by gel electrophoresis (Fig. 93, lane 3), (Fig. 93, 
lane 5), (Fig. 94, lane 3) and (Fig. 94, lane 5), correspondingly. After the successful 
generation of the 10 T7 clones, the existence of T7 promoter was defined by 
sequencing using M13 F primer.  
 
Fig. 91. Molecular analysis to determine the presence of EHDV-2 S1 and S2 in the 
recombinant plasmids by 1% agarose gel electrophoresis. Lane 1: DNA marker, lane 2: pUC19-
EHDV2.S1 (circular), lane 3: BsmbI digestion of pUC19-EHDV2.S1, lane 4: pUC19-EHDV2.S2 
(circular) and lane 5: BsaI digestion of pUC19-EHDV2.S2.  
 
Fig. 92. Molecular analysis to determine the presence of EHDV-2 S3, S4, S5 and S6 in the 
recombinant plasmids by 1% agarose gel electrophoresis. Lane 1: DNA marker, lane 2: pUC19-
EHDV2.S3 (circular), lane 3: BsaI digestion of pUC19-EHDV2.S3, lane 4: pUC19-EHDV2.S4 
(circular), lane 5: BsaAI digestion of pUC19-EHDV2.S4, lane 6: pUC19-EHDV2.S5 (circular), lane 7: 
BsaI digestion of pUC19-EHDV2.S5, lane 8: pUC19-EHDV2.S6 (circular) and lane 9: BbsI digestion 
of pUC19-EHDV2.S6.  
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Fig. 93. Molecular analysis to determine the presence of EHDV-2 (S7 and S8) in the 
recombinant plasmids by 1% agarose gel electrophoresis. Lane 1: DNA marker, lane 2: pUC19-
EHDV2.S7 (circular), lane 3: BsaI digestion of pUC19-EHDV2.S7, lane 4: pUC19-EHDV2.S8 (circular) 
and lane 5: BsmbI digestion of pUC19-EHDV2.S8. 
 
 
Fig. 94. Molecular analysis to determine the presence of EHDV-2 (S9 and S10) in the 
recombinant plasmids by 1% agarose gel electrophoresis. Lane 1: DNA marker, lane 2: pUC19-
EHDV2.S9 (circular), lane 3: BbsI digestion of pUC19-EHDV2.S9, lane 4: pUC19-EHDV2.S10 
(circular) and lane 5: BbsI digestion of pUC19-EHDV2.S10. 
 
6.2.4.4. The synthesis of EHDV-2 transcripts from the 10 T7 plasmids clones 
 
To generate the 5` cap analogue of the 10 EHDV-2 T7 transcripts, 1µg of the 
restriction digested T7 plasmid clones of each segment was used. For efficient 
generation of the capped transcripts, mMESSAGE mMACHINE T7 Ultra Kit was 
used. The precipitated RNA of each individual transcript was predicted to have 
equivalent size to that of the messenger RNA (mRNA) strands corresponding to the 
EHDV-2 genome segments as visualised on 1% denaturing agarose gel (Fig. 95).  
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Post transcription, BSR monolayers were transfected with 150 to 250 ng of each 
EHDV-2 transcript. Transfection process was performed twice, 18 hours apart, as 
discussed in detail in Materials and Methods. After the second transfection, the 
transfected monolayers were overlaid with agarose and incubated at 35°C for 72 
hours. However, though a clear difference was observed between the transfected 
and non-transfected BSR cells morphology, no plaques were observed (Fig. 96, A 
and B), indicating no virus recovery.  
 
Fig. 95. Denaturing 1% agarose gel electrophoresis of EHDV-2 T7 transcripts generated from 
digested clones. Lane 1: ssRNA marker (1.0 µg), lane 2: EHDV-2 S1, lane 3: EHDV-2 S2, lane 4: 
EHDV-2 S3, lane 5: EHDV-2 S4, lane 6: EHDV-2 S5, lane 7: EHDV-2 S6, lane 8: EHDV-2 S7, lane 9: 
EHDV-2 S8, lane 10: EHDV-2 S9 and lane 11: EHDV-2 S10.  
 
 
Fig. 96. BSR cells transfection with the entire T7 transcripts of EHDV-2 showing a difference 
between the treated and untreated cells. (A) Untreated BSR cells. (B) BSR cells transfected with 
1.0 µg of EHDV-2 T7 transcripts 72 hpt. (C) BSR cells transfected with 1.5 µg of EHDV-2 T7 
transcripts 72 hpt. 
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In conclusion, EHDV-2 was successfully recovered from ssRNAs after the efficient in 
vitro synthesis of the ssRNA transcripts from purified EHDV-2 cores. The entire 10 
T7 transcripts of EHDV-2 were efficiently generated from the linearised T7 plasmid-
derived clones, which, in this study, were all cloned into pUC19 vector with the 
designed specific primers from a purified clonal population of EHDV-2. Due to the 
limited time for this study, it was not possible to investigate further the concentrations 
of T7 transcripts required for the recovery of infectious virus.   
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6.3. DISCUSSION  
 
The aim of this study was to establish of a plasmid-based RG system for EHDV 
entirely based on synthetic transcripts, in a manner similar to that of BTV and AHSV. 
Since EHDV is genetically closely related to BTV, a similar RG system for EHDV 
could be utilised for the development of a rationally designed attenuated vaccine. 
EHDV-2 was chosen in particular, since this serotype has been circulating in many 
countries in the past and more recently, caused outbreaks in both domestic and wild 
animals (Omori et al., 1969, Campbell and St George, 1986).  
The RG system set up for BTV (Boyce et al., 2008, Boyce and Roy, 2007) has been 
demonstrated to be a novel approach for the generation of a highly successful 
defective vaccine strain (Roy et al., 2009, Matsuo et al., 2011). The production of 
such defective virus strains was due to the understanding of BTV virus infection at 
molecular levels, which permitted to the generation of specific mutations in the 
enzymatic protein that is essential for the viral replication (Matsuo and Roy, 2009, 
Kaname et al., 2013).  
Applying the RG system, a rapid generation of attenuated vaccines against several 
emerging serotypes could be achieved. This was previously reported by using a 
consistent genetic background of the defined attenuated serotype (i.e. BTV-1), and 
replacing the antigenically genome segments encoding the variable outer capsid 
proteins VP2 and VP5 with the serotype of highly virulent strain (i.e. BTV-8) (Matsuo 
et al., 2011).  
These vaccines would be as safe as the live attenuated vaccines but retain the 
ability to produce viral proteins at the infection sites. Moreover, protective immune 
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responses could be elicited in vaccinated animals but lose the ability to revert to the 
virulent strain making them safer than the current live vaccines.  
Generally, in the members of Reoviridae family, the core particles have two 
functions; the synthesis of ssRNAs in the cytoplasm of infected cells which then act 
as mRNAs for viral protein formation, and also serve as templates for the production 
of the new dsRNA genome. Several published literatures confirmed that BTV (Boyce 
and Roy, 2007) and AHSV (Matsuo et al., 2010) core transcripts were infectious 
when BSR monolayers were transfected with them. This work investigated the 
possibility of recovering the infectious EHDV-2 from the transcripts synthesised in 
vitro from cores, without the use of helper virus (Roner and Joklik, 2001).  
Several attempts were carried out to increase the yield and purity of EHDV-2 cores. 
Eventually, following the optimised protocols described for BTV, the EHDV-2 cores 
were successfully prepared and purified from infected cells, and cores purity was 
shown to be high by 10% SDS-PAGE gel analysis. In consistent with BTV and AHSV 
findings (Boyce and Roy, 2007, Matsuo et al., 2010), all five core proteins (VP1, 
VP3, VP4, VP6 and VP7) were detected in the expected ratios. 
For in vitro synthesis of EHDV-2 ssRNAs, this study was based on the protocols 
described for BTV, due to the lack of published reports regarding EHDV. Similarly to 
Matsuo et al. (Matsuo et al., 2010), 60 µM MnCl2 was added to the transcription 
reaction mixture, which enhances the efficiency of in vitro transcription synthesis. A 
sufficient amount and high purity profile of the 10 transcripts synthesised in vitro as 
observed on denaturing agarose gel electrophoresis, with no indications of early 
termination or noticeable degradation.  
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The recovery of EHDV-2 infectious virus from ssRNA was successfully achieved in 
BSR cells transfected twice with the core transcripts. This was based on earlier study 
demonstrated that double-transfection is more effective in the recovery of AHSV 
serotype 4 than singly transfecting alone (Matsuo et al., 2010). Additionally, the 
study confirmed that virus recovery was not due to the quantity of ssRNAs, but due 
to the primary replication (Matsuo et al., 2010). Such findings prevented the need for 
high concentration of transcripts, such as that used for the recovering of BTV-1 from 
ssRNAs in double transfection (4-8 µg) (Boyce and Roy, 2007).  
Since, no previous reports were published addressing the recovery of EHDV from 
core transcripts, in this study, the sufficient amount of EHDV-2 ssRNAs needed to 
recover the infectious virus was determined by transfecting BSR monolayers twice, 
18 hours apart, with 1.0 µg or 1.5 µg. The 1.0 µg of ssRNAs were found to be the 
optimal quantity, as a 100% CPE was observed at 72 (hpt). In contrast, a complete 
CPE was shown in less than 24 h of the first transfection when 1.5 µg of ssRNAs 
were used, indicating that this amount of ssRNAs is too much and not suitable for 
the recovery of EHDV-2 virus. For further confirmation of the obtained data, the 
experiment was repeated twice followed by BSR cells infection with the supernatant 
harvested from that transfected with 1.0 µg and 1.5 µg of the ssRNAs. The presence 
of the infectious virus was detected in BSR cells infected with supernatant harvested 
from transfected cells with 1.0 µg, while no CPE was observed from that infected 
with the supernatant harvested from BSR cells transfected with 1.5 µg. Comparing 
the morphology of the plaques produced from BSR cells transfected with EHDV-2 
ssRNAs to that generated by EHDV-2 infection, no recognisable differences in terms 
of size and appearance were identified. These results confirmed that infectious 
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EHDV-2 was effectively produced in BSR cells transfected with purified ssRNAs and 
the utility of the RG system described for BTV to other closely related orbiviruses.  
Whilst recovery from core ssRNA transcripts demonstrates the utility of the RG 
system, in order to effectively design attenuated vaccine strains transcripts must be 
amenable to manipulation by molecular biology techniques. To such an end, the 
synthesis of in vitro RNA transcripts by T7 RNA polymerase of cDNA clones is 
required, as shown in earlier studies (Boyce et al., 2008). This RG system has been 
established using two different approaches; either by mixing the viral transcripts and 
T7 transcripts, or by utilising complete set of the in vitro synthesised T7 transcripts 
(Matsuo et al., 2010, Boyce et al., 2008). In this work, in order to investigate whether 
EHDV-2 could be recovered from transcription of cDNA clones of its ten segments, 
an attempt of recovery from 10 in vitro transcribed, T7 transcripts was carried out.  
To date, no published reports were found regarding the establishment of an EHDV-2 
RG system. Therefore, to design exact T7 primers containing gene specific 
sequence, the full-length sequences of the 10 segments were cloned and compared 
with published data. Applying a FLAC2 technique, RT-PCR amplification was 
undertaken using the purified EHDV-2 dsRNAs. Initially, this technique was 
developed and optimised for dsRNA templates (Maan et al., 2007), which permitted 
the amplification of the large and uncharacterised dsRNA virus genome (Shapiro et 
al., 2005). Amplification and sequencing of cDNAs from dsRNA were earlier reported 
in  several studies, such as the single prime amplification technique (SPAT) initially 
described by Lambden et al (Lambden et al., 1992) and then modified by Attoui et al 
(Attoui et al., 2000). However, mispriming was the significant disadvantage of SPAT 
in comparison to FLAC2, which was solved by the design of modified C9 anchor 
primer allowing the synthesis of full-length cDNA by RT-PCR. Prior to cDNA 
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synthesis, the excess of C9 primer was removed by excising the 10 dsRNA 
segments from 0.8% agarose gel. This was an essential step to avoid mispriming or 
any non-specific amplification, permitting the production of full-length single-strand 
cDNAs in the absence of free primer molecules.  
A notable variation in the efficiency of the production and amplification of EHDV-2 
cDNAs of some segments was identified. For instance, it was difficult to amplify 
EHDV-2 (S1, S2 and S3) due to their large size. Furthermore, it was difficult to 
separate some segments due to their close migration pattern on o.8% agarose gel, 
such as; S2 and S3 or S4 and S5 or S7, S8 and S9. To overcome this problem, 
lower percentage of agarose gel was used (0.7% and 0.6%), and electrophoresised 
for longer time that permitted a suitable separation of the targeted segments. 
However, as this method failed to separate three small segments, a pool of them 
were used for RT-PCR. Consistently, the possibility of preparing cDNA of BTV 
segment 2 and 3 from a combination containing both segments, was earlier 
confirmed (Maan et al., 2007). In this work, the yield from S1, S2 and S3 was found 
to be low which was improved by using high annealing temperature of 60°C – 62°C 
for each of the large three segments. Ultimately, all of the 10 genomic RNAs were 
effectively converted into cDNA and amplified with no non-specific products.  
To determine the full-length sequence of the 10 amplified EHDV-2 genome, each 
segment was successfully cloned into pUC19. This was not a straightforward 
approach, particularly, for S1 and S2 due to their large size. Additionally, since the 
resulted PCR amplification of S7, S8 and S9 were from the same pool, several 
colonies were tested by PCR using M13 (F and R) primers, to determine the 
presence of each segment. In due course, successful cloning of the 10 segments 
into pUC19 was achieved; and confirmed by sequencing.  
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To investigate the possibility of recovering EHDV-2 infectious virus from a complete 
set of T7 transcripts, the T7 plasmid clones were efficiently constructed. The T7 
primers for the 10 EHDV-2 segments were designed as described previously by 
Boyce et al (Boyce et al., 2008). Capped T7 transcripts were successfully 
synthesised from the linearised T7 plasmid clones. The transcripts specificity was 
analysed by 1% denaturing agarose gel electrophoresis, which showed exactly the 
same estimated sizes of mRNA strands corresponding to that of EHDV-2 genome 
segments.  
To recover progeny virus with genome segments generating from the 10 T7 
transcripts, BSR cell monolayers were transfected twice with 0.15 µg to 0.25 µg of 
each segment. Following the second transfection, no plaques were observed at 72 
(hpt), but a noticeable difference in cell morphology was documented in the 
transfected BSR monolayers with both amounts of T7 transcripts in comparison to 
the uninfected cells. Such findings indicated that certain mutations including 
deletions and stop codons along the full-length sequence of specific segment/s might 
be exist. Unfortunately, it was not possible to do further investigations due to time 
limitations.  
In conclusion, an approach was presented in this study to establish RG system for 
EHDV-2, which was not reported earlier. The successful recovery of EHDV-2 
infectious virus, entirely from cores transcripts, was achieved using sufficient amount 
of ssRNAs. Furthermore, the full-length sequence of each of the 10 dsRNA 
segments was generated and compared with published data. Successful synthesis 
of the 10 T7 transcripts of EHDV-2 was achieved from the T7 plasmid-derived 
clones. However, the recovery of infectious EHDV-2 from the complete set of 10 T7 
transcripts was not possible.  
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7.1. Overall discussion and conclusions  
7.1.1. The development of VLPs and heterologous VLPs of EHDV serotypes  
Historically, EHDV was considered a disease of deer particularly in North America 
(Shope et al., 1960). However, this premise has changed following the outbreaks 
occurred in the USA and European boarding countries, wherein agricultural cattle 
were the main host (Breard et al., 2004). This was due the emerging pathogenic 
strains from reassortant viruses of EHDV-2, EHDV-6 and EHDV-7, which were more 
fatal for domestic animals (Omori et al., 1969, Campbell and St George, 1986, Yadin 
et al., 2008, Temizel et al., 2009). Genetic characterisation of EHDV-6 highlighted 
this issue indicating that the outer capsid structural proteins VP2 and VP5 were 
those of EHDV-6, while the remaining structural and non-structural proteins were 
derived from EHDV-2 (Allison et al., 2010).  
To control the invasion of EHD, vaccination is the optimal solution. The necessity for 
the development of an effective vaccine has economically increased with recent 
overlapping outbreaks. However, no vaccine is currently available against EHDV 
apart from the live-attenuated vaccine utilised in Japan for EHDV-2 (IBAV) (Aradaib 
et al., 2009). Therefore, the production of VLPs as vaccine candidates for EHDV has 
been considered a promising approach. Several reports have shown that VLPs are 
highly immunogenic, effective and a safe subunit vaccine, for example the HPV 
vaccine (Koutsky et al., 2002, Harper et al., 2004, Harper et al., 2006), as well as 
DIVA compliant. This is because although VLPs mimic the structure of authentic 
native virions, they lack the viral genome and therefore do not express non-structural 
proteins.  
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High level expression and correct folding of the target recombinant proteins are the 
key elements in the production of the VLPs. In this study, a baculovirus expression 
vector system was utilized due to its versatility and its ability to meet the described 
criteria of high level expression of correctly folded proteins for large proteins >100 
kDa in size. This was exemplified by validation experiments of single expression of 
EHDV VLP protein constituents. No earlier reports were available regarding the 
single synthesis of the outer and inner capsid proteins of EHDV-1, EHDV-2 and 
EHDV-7 except for EHDV-1 VP3 (Le Blois et al., 1991). Therefore, as an initial step 
for synthesising VLPs and heterologous VLPs of EHDV-1, -2 and 7 serotypes, it was 
necessary to individually express the structural proteins VP2, VP5, VP7 and VP3, of 
the three serotypes.  
In this study, the utility of baculovirus expression system had confirmed its suitability 
for the generation of EHDV VLPs. Baculovirus system allowed expression of 
correctly folded large capsid proteins, in particular, VP2 and VP3 of EHDV-1, -2 and 
7. Additionally, the expressed recombinant protein VP2 of both serotypes; EHDV-1 
and EHDV-2 was shown to be immunogenic, and antibodies raised against the 
targeted two proteins were highly specific. Achieving such results would not be 
possible in other expression systems. For instance, post-translational modifications 
and correctly folded recombinant protein do not occur in bacterial or yeast 
expression systems (Baneyx, 1999, Mattanovich et al., 2012). However, when 
mammalian cells can provide these, they are expensive for large scale production 
(Wurm, 2004).  
Earlier literature reported the use of baculovirus multiple gene expression system for 
simultaneous expression of the structural recombinant proteins within the same 
insect cell (Noad et al., 2009). Therefore, the possibility of generating heterologous 
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protein complexes using this system is potentially high. Here, this approach was 
utilised to generate VLP of EHDV-1, which was reported to cause highly fatal 
disease in wild-tailed deer, in which morbidity and mortality rates were of concern of 
wildlife managers. Prior to the formation of EHDV-1 VLPs, the recombinant 
Bacmid1629:EHDV1.S7.S3 was successfully generated by inserting EHDV-1 (S7 and 
S3) at egt and 39k loci into baculovirus genome. The EHDV-1 CLPs were effectively 
produced in Sf21 insect monolayers and a high level of synthesised recombinant 
proteins in accurate molecular ratios was detected by 10% SDS-PAGE. Using EM, 
the assembly of the inner capsid proteins VP7 and VP3 of EHDV-1 into CLPs was 
confirmed, indicating correct interactions when compared with EHDV-2 purified core 
particles. Successfully, specific antibodies against EHDV-1 CLPs were raised in 
Rabbits and determined to be highly specific when examined by western blotting.  
Based on the above findings, the possibility of generating EHDV-1 VLPs composed 
of the three capsid proteins VP3, VP7 and VP5 was investigated in Sf21 insect cells. 
This aim was addressed by efficacious construction of the recombinant pRN296-
EHDV1.VP5 followed by a successful integration in to Bacmid1629:EHDV1.S5 at odv-
e56 locus. The expression of each protein was determined by SDS-PAGE after the 
successful formation of the recombinant baculovirus Bacmid1629:EHDV1.S5.S7.S3 in 
Sf21 insect cells. Since the above produced VLP was lacking the most variable 
protein VP2 forming the outermost layer, the construct pAcYM1-EHDV1.VP2 was 
utilised to recover the recombinant baculovirus Bacmid1629:EHDV1.S5.S7.S3 by 
cotransfection of the insect monolayers. After several rounds of amplification, the 
purified infected cell lysate showed optimal ratios of the expressed EHDV-1 four 
recombinant proteins; VP2, VP5, VP7 and VP3 by 10% SDS-PAGE gel. When the 
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assembly of these proteins into VLPs were examined by EM, micrographs displayed 
similar morphological structure to the control double-capsid BTV particles.  
In order to initially assess the immunogenicity and vaccine potential of the produced 
EHDV-1 VLPs a neutralisation assay was performed. VLPs were prepared, purified 
and polyclonal antisera were raised in Rabbits. The authenticity of the developed 
antisera was tested by western blotting. As a result, significant interactions were 
detected for each of the four recombinant proteins; VP2, VP5, VP7 and VP3 of 
EHDV-1. Successfully, EHDV-1 virus was neutralised at 1:64 dilution in cell culture 
using the antisera produced against EHDV-1 VLPs. In addition, cross neutralising 
was detected against EHDV-2 and EHDV-7 serotypes at low level. These data are 
consistent with that of orbiviruses demonstrating that VP2 proteins dictate the host 
antigenic response but still share some cross neutralising epitopes, due to the 
presence of conserved regions along VP2 full-length sequence of different 
serotypes.  
The successful construction of EHDV-1 VLPs was encouraging to test the probability 
of rapid development of the heterologous VLPs of EHDV-1 and EHDV-2 serotypes. 
This was performed by exchanging the outer capsid proteins (VP2 and VP5) of 
EHDV-2 onto the conserved CLPs (VP3 and VP7) proteins of EHDV-1, given the 
neutralisation data this VLP should elicit a neutralising immune response to EHDV-2 
VP2. Due to time constraints this possibility was initially tested utilising coinfection of 
cells with two viruses, the CLPs virus of EHDV-1 and a newly constructed (VP2 and 
VP5) virus of EHDV-2. In addition, a triple infection was tested with the CLP virus of 
EHDV-1 and two viruses each singly expressing VP2 and VP5 of EHDV-2, 
respectively. The triple infection yielded no expression of the outer capsid layer 
EHDV-2 VP2 and very low expression of the inner shell protein EHDV-2 VP5, while 
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both of EHDV-1 (VP3 and VP7) were expressed at high level. However, the dual 
expression of each protein was observed as an intense protein band to the 
estimated sizes of EHDV-2 [VP2 (114 kDa) and VP5 (59 kDa)] and EHDV-1 [VP3 
(103 kDa) and VP7 (39 kDa)]. Further confirmation of the recombinant EHDV-2 VP2 
was identified on the nitrocellulose membrane using the earlier developed antibodies 
against this protein. These results were consistent with the published findings 
showing that multiple infections (triple and quadruple) of the insect cells are not 
suitable for the generation of all targeted proteins, since not every cell in the cell 
culture will be infected simultaneously at the same ratio (Belyaev and Roy, 1993). 
An attempt was carried out to generate EHDV-7 heterologous VLP using EHDV-1 
CLPs as background. The recombinant pAcYM1-EHDV7.S5 was efficiently 
constructed and integrated at odv-e56 locus into baculovirus genome. This work was 
not taken further due to time restrictions.  
 
7.1.2. The Recovery of EHDV-2 from RNAs transcripts 
 
In conjunction to VLP technology the availability of RG system allows an alternative 
approach to develop rationally attenuated vaccines, in this work an attempt was 
made to do so by this methodology for the EHDV-2 Alberta/Canada strain. Prior to 
the establishment of a plasmid-based RG, similar to BTV (Boyce et al., 2008), the 
utility of recovering infectious EHDV-2 virus from core transcripts was tested. To this 
end EHDV-2 cores were prepared from virus culture, and utilised for in vitro 
transcription. Ten core transcripts were efficiently synthesised the correct molar ratio 
as detected on denaturing agarose gel electrophoresis.  
Using micrograms (1.0 µg) of EHDV-2 ssRNAs, their infectivity was determined in 
BSR cells showing 100% CPE three days after double transfection. Further, the 
replication of EHDV-2 genome from transfected cells was confirmed by 
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electrophoresis on agarose gel showing similar dsRNAs segmented genome profile 
to that extracted from infected cells. Moreover, a complete CPE was clearly 
observed in the BSR monolayers incubated with the transfected culture medium. The 
morphology of cells infected by recovered virus was similar to that noticed in BSR 
cells infected with EHDV-2. It is noteworthy that this is the first report indicating the 
successful recovery of infectious EHDV-2 from the core transcripts.  
For vaccine production, it is necessary to generate virus entirely from T7 transcripts, 
to allow understanding the infection of the virus on the molecular level, permitting 
viral genome manipulation, which can be exploited in many research domains. To 
address this aim, the 10 RNA segments were amplified, cloned into pUC19 and then 
sequence validated and from which T7 transcription vectors were constructed.  T7 
Transcripts of each segment were synthesised in vitro with the same expected sizes 
of mRNAs without any signs of degradation as visualised on denaturing agarose gel. 
Utilising the successful protocol of previous reports for BTV, BSR cells were 
transfected twice in an attempt to recover infectious EHDV-2 virus (Matsuo et al., 
2010, Matsuo and Roy, 2009). After 72 hours of incubation, no CPE was 
documented in the transfected cells although morphological differences were 
visualised comparing to the uninfected cells. To confirm the above findings, the 
experiment was three times repeated indicating that specific mutations might be 
presented along the full-length sequence in specific segment/s of the viral genome. 
This problem could be addressed by sequencing full-length of EHDV-2 10 segments 
and comparing the results with published data. As well as, an attempt to recover the 
infectious virus using different concentrations of the entire 10 T7 transcripts should 
be taken into consideration.   
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7.1.3. Conclusions  
Based on the use of baculovirus as multiple gene expression system, the application 
of this sytem to produce immunogens for EHDV was addressed in this work.  
Successful generation of stable EHDV-1 CLPs, EHDV-1 VLPs was achieved which 
allow for the production of heterologous VLPs of EHDV-2 using EHDV-1 CLPs as 
foundation. The assembly of the recombinant expressed proteins were examined 
and confirmed by EM to be similar to EHDV core and virion structural particles. The 
specificity of the raised antisera was tested for VP2 of EHDV-1 and EHDV-2, EHDV-
1 CLPs and EHDV-1 VLPs. Furthermore, the biological activity for EHDV-1 VLPs 
antisera was successfully proved by neutralisation assay against EHDV-1, and 
cross-neutralising activities were detected for EHDV-2 and EHDV-6 serotypes. 
Overall, this work lays the pathway to produce VLP and heterologous VLP vaccine 
for EHDV serotypes to allow emergent disease control.  
Alternative approach to develop EHDV-2 vaccine using RG system was performed. 
In order to validate the RG principles of BTV for EHDV, the successful recovery of 
the infectious virus EHDV-2 from the core transcripts was achieved. To recover 
EHDV-2 entirely from the 10 T7 transcripts, the T7 plasmid clones were constructed 
for the 10 segments and transcribed in vitro. However, unfortunately, it was not 
possible to recover EHDV-2 entirely from the 10 T7 transcripts indicating that studies 
focusing on detecting full-length sequence of each of the 10 segments should be 
undertaken. Then, optimising the specific concentration of the 10 T7 transcripts are 
needed for the recovery of the infectious virus.  
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7.2. Limitations and future work 
This thesis had demonstrated the potential of efficiently developing EHDV-1 VLP and 
heterologous VLPs of EHDV-2 using EHDV-1 CLPs as scaffold. In addition, 
alternative approach to generate a rationally designed vaccine for EHDV-2 using RG 
system was assessed. However, the opportunities for extending the scope of this 
project, were hampered by time constrains. Nevertheless, the reagents generated in 
this study will be valuable for two different type of vaccine development in future and 
also will provide tools for basic understanding of EHDV replication and infection.  
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